# 2025年12月12日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 代谢的酸性调控：酸性环境既挑战肿瘤细胞又支撑其代谢存活

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379545)
**期刊：** Cancer research
**PMID：** 41379545
**DOI：** 10.1158/0008-5472.CAN-25-5633

### 第一部分 原文与翻译

**英文原标题：** The sour regulation of metabolism: acidity challenges tumor cells while fueling their metabolic survival.

> **英文摘要：**
> The tumor microenvironment imposes diverse metabolic challenges to cancer cells. Overcoming these challenges is essential for survival, proliferation, and dissemination. However, how cancer cells cope with the harsh environment and how the different coexisting stresses affect the tumor in vivo is unknown. Recently, Groessl, Kalis and colleagues published their findings in Science showing that acidosis outweighs all other stresses and plays a major role in the adaptation to them. Mechanistically, acidosis inhibits the ERK-DRP1 pathway, resulting in mitochondria elongation, which triggers a metabolic shift from glycolysis to oxidative phosphorylation. These findings highlight the plasticity of cancer cell mitochondria and refute the previous belief that cancer mitochondria are inherently dysfunctional. Indeed, inhibition of mitochondrial fusion or oxidative phosphorylation in acidic tumors is sufficient to promote cell death. Thus, enhancing respiration under acidosis comes to light as an essential metabolic adaptation to cancer survival and proliferation and targeting how cancer cells adapt to acidosis emerges as a new avenue for therapy.

> **中文摘要：**
> 肿瘤微环境对癌细胞施加了多种代谢挑战。克服这些挑战对于癌细胞的生存、增殖和扩散至关重要。然而，癌细胞如何应对这种恶劣环境，以及共存的多种应激因素在体内如何影响肿瘤，仍不清楚。最近，Groessl、Kalis及其同事在《Science》杂志发表研究发现，酸中毒在多种应激中占据主导地位，并在癌细胞的适应过程中起关键作用。从机制上看，酸中毒抑制ERK-DRP1通路，导致线粒体延长，从而引发代谢从糖酵解向氧化磷酸化的转变。这些发现突显了癌细胞线粒体的可塑性，并驳斥了以往认为癌细胞线粒体天生功能缺陷的观点。实际上，在酸性肿瘤中抑制线粒体融合或氧化磷酸化足以诱导细胞死亡。因此，在酸性条件下增强呼吸被视为癌细胞生存和增殖的重要代谢适应，而靶向癌细胞适应酸中毒的机制则成为新的治疗方向。

### 第二部分 AI 大师评价

该研究从代谢调控角度揭示了酸性微环境对肿瘤细胞生存策略的核心影响。作者指出，酸中毒通过抑制ERK-DRP1通路并诱导线粒体形态与代谢重编程，使肿瘤细胞得以在不利条件下维持能量需求。工作创新地推翻了“肿瘤线粒体功能受损”的传统认知，强调线粒体可塑性对肿瘤适应的重要性。其发现为开发针对酸性代谢适应的新型抗癌治疗提供了潜在思路，但在临床转化中仍需验证其安全性与广谱有效性。

---

## 2. 组蛋白甲基转移酶 KMT2D 是去势抵抗性前列腺癌中细胞谱系可塑性与治疗反应的重要介导因子

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379538)
**期刊：** Cancer research
**PMID：** 41379538
**DOI：** 10.1158/0008-5472.CAN-25-2053

### 第一部分 原文与翻译

**英文原标题：** The Histone Methyltransferase KMT2D is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration Resistant Prostate Cancer.

> **英文摘要：**
> Castration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.

> **中文摘要：**
> 去势抵抗性前列腺癌（CRPC）在很大程度上依赖雄激素受体（AR）进行生长，并常因 PTEN 缺失而表现出高活性的 PI3K 信号通路。抗 AR 治疗的药物压力可诱导肿瘤细胞发生向 AR 非依赖性表型的跨分化。近期，AR 非依赖性 CRPC 的不同亚型被重新定义，其中干细胞样（SCL）亚型成为最常见的类型之一。阐明调控这些不同 CRPC 细胞状态维持的表观遗传机制，可能为开发有效的联合治疗策略铺平道路。在本研究中，我们发现组蛋白甲基转移酶 KMT2D 在建立染色质可及性方面发挥关键作用，这种可及性对于 AR 及 FOXA1 等转录因子（TFs）的结合至关重要，从而维持 AR 依赖性 CRPC 细胞系、患者来源类器官及患者样本中的 AR 转录活性。出人意料的是，KMT2D 还维持了 AR 低表达的 CRPC-SCL 亚型的细胞特征，并调控 AP-1 家族转录因子（如 FOSL1）的活性，后者是该亚型的核心调控因子。单细胞转录组学及染色质分析进一步强调，KMT2D 通过 AP-1 和 FOXA1 维持混合谱系的细胞状态。联合抑制 PI3K/AKT 通路与 KMT2D 可显著降低 CRPC-AR 与 CRPC-SCL 亚型中前列腺癌细胞及患者来源类器官的增殖。综上，这些结果揭示 KMT2D 是亚型特异性 CRPC 中调控表观遗传景观的重要介质，参与肿瘤生长与治疗反应的关键过程。

### 第二部分 AI 大师评价

该研究聚焦于表观遗传调控因子 KMT2D 在去势抵抗性前列腺癌不同亚型中的功能作用。通过整合细胞系、类器官及单细胞多组学分析，作者揭示 KMT2D 既促进 AR 依赖性转录网络，又维持干细胞样亚型的混合谱系状态。研究发现 KMT2D 可与 FOXA1、AP-1 等关键转录因子协同调控染色质活性，其抑制与 PI3K/AKT 通路联合干预表现出协同抗肿瘤效应。该工作创新性地将 KMT2D 定义为亚型特异性 CRPC 的核心表观调控节点，为精准分型治疗提供了潜在靶点，但未来仍需临床验证其可行性与安全性。

---

## 3. 癌症患者的中风——时间就是大脑

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379475)
**期刊：** JAMA oncology
**PMID：** 41379475
**DOI：** 10.1001/jamaoncol.2025.5234

### 第一部分 原文与翻译

**英文原标题：** Stroke in Patients With Cancer-Time Is Brain.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文章关注癌症患者罹患中风这一紧急且复杂的临床问题。标题强调“时间就是大脑”的理念，提示快速诊断与治疗在此类患者中的重要性。尽管摘要缺失，但可推测该研究旨在探讨癌症相关中风的发生机制、诊疗效率或预后特征。此类工作对于优化肿瘤患者的神经系统管理具有重要的实践意义，但若能提供更多具体数据及干预策略将更具临床指导价值。

---

## 4. 《黑色素瘤综述》—回复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379471)
**期刊：** JAMA
**PMID：** 41379471
**DOI：** 10.1001/jama.2025.20510

### 第一部分 原文与翻译

**英文原标题：** A Review of Melanoma-Reply.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文是一篇针对“黑色素瘤综述”的作者回复或学术通信，旨在就前期发表的综述或意见进行澄清、补充或回应。文章未提供摘要，因此推测其内容以学术讨论为主，可能集中在方法或结论的再解释上。此类回复类文章在推动学术辩证、提高研究透明度方面具有价值，但自身并不提供新的实验数据或系统性分析。

---

## 5. 绝经前后女性化疗内分泌联合治疗与单纯内分泌治疗相关认知障碍的比较：RxPONDER随机临床试验的二次分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379459)
**期刊：** JAMA oncology
**PMID：** 41379459
**DOI：** 10.1001/jamaoncol.2025.5220

### 第一部分 原文与翻译

**英文原标题：** Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.

> **英文摘要：**
> IMPORTANCE: Breast cancer treatment is associated with cancer-related cognitive impairment (CRCI). However, the association of endocrine therapy (ET) vs chemotherapy plus endocrine therapy (CET) with CRCI is poorly understood.
> 
> OBJECTIVE: To compare patient-reported CRCI between women with breast cancer treated with ET vs CET and to consider whether menopausal status may be associated.
> 
> DESIGN, SETTINGS, AND PARTICIPANTS: This was a prespecified secondary analysis of RxPONDER (SWOG S1007), a multinational phase 3 randomized clinical trial of more than 5000 women with hormone receptor-positive ERBB2-negative (formerly HER2-negative) breast cancer with 1 to 3 involved lymph nodes and Oncotype DX (21-gene recurrence score) of 25 or less. Participants were enrolled from February 2011 to September 2017, with results first reported in December 2020. Participants were randomly assigned to CET or ET, with ongoing follow-up. This secondary analysis assessed cognitive function using the Patient-Reported Outcomes Measurement Information System Perceived Cognitive Function Concerns (PCF) questionnaire at baseline, 6, 12, and 36 months. Data were analyzed from July 2022 to August 2025.
> 
> INTERVENTION: Random assignment to CET or ET.
> 
> MAIN OUTCOMES AND MEASURES: Mean PCF standardized (T) scores by menopausal status over time using generalized estimating equations analysis for continuous outcomes.
> 
> RESULTS: Of the 568 patients who completed the baseline questionnaire and were included in the analysis, 139 (24%) were premenopausal (median [range] age, 47.8 [28.0-56.3] years) and 429 (76%) were postmenopausal (median [range] age, 62.3 [37.3-87.6] years). Among the 274 (48%) who received CET and the 294 (52%) who received ET alone, CET was determined to have a greater negative association with patient-reported CRCI in both the pre- and postmenopausal participants during the 36-month follow-up. In the ET alone group, PCF scores for premenopausal participants decreased from baseline to 6 and 12 months (53.53, 51.51, and 51.72, respectively) but recovered to baseline (54.36) at 36 months. For postmenopausal participants, mean PCF scores were essentially stable (51.72, 51.13, 51.11, and 51.70, respectively); however, in the CET group, PCF scores for both pre- and postmenopausal participants decreased from baseline to 6 and 12 months (premenopausal, 52.84, 49.27, 48.04; postmenopausal, 50.65, 48.39, 47.13, respectively) and did not return to baseline at 36 months (premenopausal, 49.25; postmenopausal, 48.44). The difference in longitudinal mean PCF scores over time between CET and ET groups was -3.02 (95% CI, -5.33 to -0.72; P = .01) for premenopausal and -2.37 (95% CI, -3.92 to -0.82; P = .003) for postmenopausal participants.
> 
> CONCLUSIONS AND RELEVANCE: This secondary analysis of the RxPONDER found that CET had a greater negative association with patient-reported CRCI compared to ET alone in both pre- and postmenopausal participants over a 36-month follow-up period. Interventions to prevent or treat CRCI are needed to improve the long-term quality of life of these patients treated with chemotherapy.
> 
> TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01272037.

> **中文摘要：**
> 重要性：乳腺癌治疗与癌症相关的认知障碍（CRCI）有关。然而，内分泌治疗（ET）与化疗联合内分泌治疗（CET）在CRCI方面的关联尚不清楚。
> 
> 研究目的：比较接受ET或CET治疗的乳腺癌女性患者报告的CRCI差异，并探讨绝经状态是否相关。
> 
> 研究设计、环境及参与者：本研究是RxPONDER（SWOG S1007）预先设定的二次分析，RxPONDER为一项多国Ⅲ期随机临床试验，共纳入5000余名激素受体阳性、ERBB2阴性（原HER2阴性）乳腺癌女性患者，淋巴结受累1至3枚，且Oncotype DX（21基因复发评分）≤25。研究参与者入组时间为2011年2月至2017年9月，初步结果于2020年12月首次报告。所有参与者被随机分配至CET或ET组，并持续随访。本次二次分析通过患者报告结局测量信息系统（PROMIS）感知认知功能问题（PCF）问卷，在基线、6、12及36个月时评估认知功能。数据分析时间为2022年7月至2025年8月。
> 
> 干预措施：随机分配至CET或ET治疗组。
> 
> 主要结局与测量指标：采用广义估计方程方法分析不同绝经状态下各时间点PCF标准化（T）评分的平均值变化。
> 
> 结果：568名完成基线问卷的患者纳入分析，其中139人（24%）为绝经前（中位［范围］年龄47.8［28.0–56.3］岁），429人（76%）为绝经后（中位［范围］年龄62.3［37.3–87.6］岁）。其中274人（48%）接受CET治疗，294人（52%）接受ET单药治疗。在36个月随访期间，CET与患者报告的CRCI呈更强的负相关，绝经前后女性均表现一致。ET单药组中，绝经前女性PCF评分从基线到6和12个月分别下降（53.53、51.51、51.72），但在36个月恢复至接近基线（54.36）；绝经后女性PCF评分基本稳定（51.72、51.13、51.11、51.70）。然而，在CET组中，绝经前后患者PCF评分均于基线至6和12个月显著下降（绝经前：52.84、49.27、48.04；绝经后：50.65、48.39、47.13），且至36个月未恢复基线水平（绝经前49.25，绝经后48.44）。在随访期间，CET组与ET组的平均PCF评分差异为：绝经前-3.02（95% CI，-5.33至-0.72；P＝0.01），绝经后-2.37（95% CI，-3.92至-0.82；P＝0.003）。
> 
> 结论与意义：RxPONDER试验的二次分析显示，在长达36个月随访中，CET较ET单药在绝经前后女性患者中均与更严重的CRCI相关。亟需干预措施预防或治疗CRCI，以改善接受化疗患者的长期生活质量。
> 
> 试验注册号：ClinicalTrials.gov标识符NCT01272037。

### 第二部分 AI 大师评价

本研究作为RxPONDER试验的预设二次分析，系统比较了化疗联合内分泌治疗与单纯内分泌治疗对绝经前后乳腺癌女性认知功能的长期影响。结果显示，接受联合治疗者在36个月内的患者报告认知功能持续下降，而单纯内分泌治疗组的认知功能可部分恢复，提示化疗是诱发癌症相关认知障碍的重要因素。研究方法学严谨，基于大样本随机试验数据，增强了结果的可信度。但评估工具依赖患者自评，缺乏客观神经认知测试，未来研究应结合生物标志物与干预策略以进一步验证结果并优化治疗方案。

---

## 6. 踏入边境地带

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379455)
**期刊：** JAMA
**PMID：** 41379455
**DOI：** 10.1001/jama.2025.20836

### 第一部分 原文与翻译

**英文原标题：** Into the Borderland.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

这篇发表于《JAMA》的文章题为《踏入边境地带》，根据标题推测很可能围绕医学科学或人文医学领域的探索性议题进行思考。虽然缺乏具体摘要信息，但该标题暗示作者可能探讨医学实践与伦理、科学与社会、或生物学与心理学的交界区域。文章或许旨在引发对医学边界和跨学科融合的再思考。由于缺乏研究详情，其创新点和实践意义仍需进一步查阅正文确认。

---

## 7. 揭示乳腺癌相关认知功能损害的复杂性——不同治疗方式与绝经状态的影响

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379440)
**期刊：** JAMA oncology
**PMID：** 41379440
**DOI：** 10.1001/jamaoncol.2025.5088

### 第一部分 原文与翻译

**英文原标题：** Unraveling the Complexity of Cancer-Related Cognitive Impairment in Breast Cancer-Effect of Differing Treatments and Menopausal Status.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究旨在探讨乳腺癌患者癌症相关认知功能损害（CRCI）的复杂机制，重点分析不同治疗方案及绝经状态对认知功能的影响。题目显示作者可能采用比较性设计，以区分化疗、内分泌治疗等因素的差异性作用。研究关注个体生理状态与治疗交互作用的认知后果，体现出对精准肿瘤学与神经认知科学交叉领域的重视。若无摘要限制具体方法细节的呈现，其创新点或在于多维度整合生理与治疗变量，为临床认知干预策略提供了新的研究方向。

---

## 8. 利用根治性放射治疗避免鼻切除术以保留鼻腔癌患者器官功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379436)
**期刊：** JAMA oncology
**PMID：** 41379436
**DOI：** 10.1001/jamaoncol.2025.5241

### 第一部分 原文与翻译

**英文原标题：** Organ Preservation for Nasal Cavity Cancers Using Definitive Radiotherapy for Avoiding Rhinectomy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究聚焦于鼻腔癌的器官保留策略，探讨通过根治性放射治疗在避免鼻切除术情况下实现肿瘤控制的可行性。标题暗示研究可能评估放疗在局部控制率、生存率及生活质量方面的效果。该方向在头颈部肿瘤学中具有重要的临床意义，尤其对改善患者外观与心理负担具有潜在价值。尽管缺乏摘要细节，但此类研究的挑战在于样本有限及疗效随时间变化需进一步验证。

---

## 9. 黑色素瘤综述

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379434)
**期刊：** JAMA
**PMID：** 41379434
**DOI：** 10.1001/jama.2025.20514

### 第一部分 原文与翻译

**英文原标题：** A Review of Melanoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本文为一篇关于黑色素瘤的综述，可能主要总结了该疾病的流行病学特征、病理机制、临床诊断及最新治疗策略。由于未提供摘要，无法具体判断研究细节，但综述类文章通常整合现有证据，为临床和研究者提供系统性的知识框架。该文可能在总结前沿进展或提出未来研究方向方面具有一定价值，但其原创性相对有限。

---

## 10. 抗LAG-3抗体LBL-007联合替雷利珠单抗及化疗作为晚期鼻咽癌一线治疗的多中心Ⅱ期研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41378996)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41378996
**DOI：** 10.1158/1078-0432.CCR-25-2054

### 第一部分 原文与翻译

**英文原标题：** Anti-LAG-3 Antibody LBL-007 Plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial.

> **英文摘要：**
> PURPOSE: Prior studies reported synergistic antitumor activity by dual inhibition of lymphocyte activation gene-3 (LAG-3) and PD-1. This study investigated activity, safety and biomarker of LAG-3/PD-1 co-blockade plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).
> 
> PATIENTS AND METHODS: Previously untreated RM-NPC patients received LBL-007 (anti-LAG-3), tislelizumab (anti-PD-1), and gemcitabine-cisplatin for 4 to 6 cycles, followed by maintenance therapy with LBL-007 and tislelizumab. Primary endpoint was objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), duration of response (DoR), time to response (TTR), disease control rate (DCR), overall survival (OS) and safety. Biomarker analysis included LAG-3 and PD-L1 expression.
> 
> RESULTS: Forty-two patients were enrolled from 15 centers in China. With a median follow-up of 19.0 months, ORR was 83.3% (95% CI, 68.6%-93.0%), and DCR was 97.6% (95% CI, 87.4%-99.9%). Median PFS reached 15.8 months (95% CI, 9.9-not estimable); 12-month PFS rate was 55.1% (95% CI, 41.7%-72.9%). Median DoR was 14.6 months (95% CI, 10.3-not estimable); median OS was not reached. Grade 3 or higher treatment-related adverse events occurred in 37 patients (98.1%). No new safety signals were identified. In biomarker analysis, patients with dual-positive LAG-3/PD-L1 expression demonstrated more favorable outcomes than those lacking either biomarker, including 12-month PFS rate of 65.0% versus 40.2%, and median PFS of 16.0 versus 10.3 months.
> 
> CONCLUSIONS: LBL-007 plus tislelizumab and chemotherapy shows promising clinical benefits and manageable toxicity as first-line therapy for RM-NPC. Dual-positive LAG-3/PD-L1 expression was associated with improved outcomes, supporting further exploration of this biomarker-defined subpopulation in randomized trials.

> **中文摘要：**
> 研究目的：先前的研究报告显示，同时抑制淋巴细胞活化基因3（LAG-3）和程序性死亡蛋白1（PD-1）具有协同抗肿瘤活性。本研究探讨了LAG-3/PD-1联合阻断并联合化疗作为复发或转移性鼻咽癌（RM-NPC）一线治疗的疗效、安全性及生物标志物特征。
> 
> 患者与方法：未接受过系统治疗的RM-NPC患者接受抗LAG-3抗体LBL-007、抗PD-1抗体替雷利珠单抗以及吉西他滨/顺铂方案治疗，共4至6个周期，随后进行LBL-007与替雷利珠单抗的维持治疗。主要终点为客观缓解率（ORR）；次要终点包括无进展生存期（PFS）、缓解持续时间（DoR）、缓解时间（TTR）、疾病控制率（DCR）、总生存期（OS）及安全性。生物标志物分析包括LAG-3与PD-L1的表达。
> 
> 结果：共有来自中国15家中心的42例患者入组。中位随访时间为19.0个月，ORR为83.3%（95% CI，68.6%–93.0%），DCR为97.6%（95% CI，87.4%–99.9%）。中位PFS为15.8个月（95% CI，9.9–无法估计）；12个月PFS率为55.1%（95% CI，41.7%–72.9%）。中位DoR为14.6个月（95% CI，10.3–无法估计）；中位OS尚未达到。37例患者（98.1%）出现≥3级治疗相关不良事件，未观察到新的安全性信号。在生物标志物分析中，同时LAG-3/PD-L1阳性的患者较缺乏任一标志物者疗效更佳，12个月PFS率分别为65.0%与40.2%，中位PFS分别为16.0个月与10.3个月。
> 
> 结论：LBL-007联合替雷利珠单抗及化疗作为RM-NPC一线治疗表现出良好的临床获益与可控的毒性。双阳性LAG-3/PD-L1表达与改善的疗效相关，支持在随机对照试验中进一步探索该生物标志物定义的亚群。

### 第二部分 AI 大师评价

该研究通过Ⅱ期多中心临床试验证实，LAG-3与PD-1双重阻断联合化疗可为复发或转移性鼻咽癌患者提供显著疗效与可接受的安全性。结果显示总体缓解率高、无进展生存期延长，提示免疫协同机制在鼻咽癌治疗中的潜在临床价值。值得关注的是，LAG-3/PD-L1双阳性患者的预后更佳，为未来个体化免疫治疗提供了生物标志物依据。然而，样本量有限及缺乏对照组仍需在后续随机试验中进一步验证。

---

## 11. GOG281/LOGS 研究的分子特征分析与肿瘤生物标志物研究：曲美替尼用于复发/持续性低级别浆液性卵巢癌的阳性晚期试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41378992)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41378992
**DOI：** 10.1158/1078-0432.CCR-25-3042

### 第一部分 原文与翻译

**英文原标题：** Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer.

> **英文摘要：**
> PURPOSE: Low-grade serous ovarian carcinoma(LGSOC) is a distinct form of ovarian cancer characterised by younger patient age and relative chemoresistance. The GOG281/LOGS trial(NCT02101788) investigated the efficacy of the MEK inhibitor trametinib compared to physician's choice standard of care(SOC) in LGSOC patients with persistent/recurrent disease. The study demonstrated significantly improved progression-free survival(PFS) in the trametinib-treated arm.
> 
> EXPERIMENTAL DESIGN: 260 patients with recurrent/persistent LGSOC were enrolled and randomised in GOG281. We performed molecular analysis of 170 patients with available tumour specimens, comprising whole exome sequencing and phospho-ERK immunohistochemistry, to identify biomarkers of clinical benefit from trametinib. The demographics of the translational cohort(n=170) were comparable to the total trial cohort.
> 
> RESULTS: High tumour pERK expression (greater than the median histoscore of 140) was associated with significantly prolonged PFS with trametinib treatment versus SOC (median 20.1 vs 5.6 months, log-rank P<0.0001; test for interaction P=0.023). Tumours harbouring canonical RAS-RAF-MAPK mutations (KRAS/BRAF/NRAS: 44/134, 32.8% of cases) had a higher response rate to trametinib (50.0% vs 8.3%; Barnard's P=0.0004; test for interaction P=0.054), but KRAS/BRAF/NRAS status was not predictive of prolonged PFS (test for interaction P=0.719). KRAS amplification (n=5 without KRAS/NRAS/BRAF mutation) and mutation of MAPK-associated genes (n=25 without KRAS/NRAS/BRAF mutation or KRAS copy-number gain) expanded the number of cases with identifiable MAPK defects to 55.2%, but consideration of these events did not improve the discrimination of trametinib responders. Chr1p loss(49% cases) was associated with lower pERK expression(P=0.021).
> 
> CONCLUSION: This exploratory analysis suggests pERK expression and mutation of KRAS/BRAF/NRAS are candidate biomarkers of improved PFS and response to trametinib, respectively.

> **中文摘要：**
> 研究目的：低级别浆液性卵巢癌（LGSOC）是一种独特的卵巢癌亚型，其特征为患者年龄较轻且对化疗相对耐受。GOG281/LOGS 临床试验（NCT02101788）评估了 MEK 抑制剂曲美替尼相较医生选择的标准治疗（SOC）在持续/复发性 LGSOC 患者中的疗效。研究显示，曲美替尼治疗组较 SOC 组的无进展生存期（PFS）显著延长。
> 
> 实验设计：在 GOG281 研究中，共入组并随机分配了 260 例持续/复发性 LGSOC 患者。我们对其中 170 例有可用肿瘤标本的患者进行了分子分析，包括全外显子测序与磷酸化 ERK（pERK）免疫组化染色，以寻找与曲美替尼临床获益相关的生物标志物。转化研究队列（n=170）的人口学特征与整体试验队列相近。
> 
> 研究结果：肿瘤 pERK 表达水平高（组织学评分中位数 140 以上）与曲美替尼治疗下显著延长的 PFS 相关，相较于 SOC 组（中位 PFS：20.1 个月 vs 5.6 个月；log-rank P<0.0001；交互检验 P=0.023）。具有典型 RAS-RAF-MAPK 通路突变（KRAS/BRAF/NRAS：44/134，32.8%）的肿瘤对曲美替尼的反应率更高（50.0% vs 8.3%；Barnard 检验 P=0.0004；交互检验 P=0.054），但 KRAS/BRAF/NRAS 状态并非延长 PFS 的预测因子（交互检验 P=0.719）。KRAS 扩增（n=5，无 KRAS/NRAS/BRAF 突变）以及 MAPK 相关基因突变（n=25，无 KRAS/NRAS/BRAF 突变及 KRAS 拷贝数增益）将可辨识 MAPK 缺陷的病例比例扩大至 55.2%，但考虑这些事件未能进一步提高曲美替尼应答者的区分能力。1p 染色体缺失（49% 病例）与较低的 pERK 表达相关（P=0.021）。
> 
> 结论：该探索性分析提示，pERK 表达水平及 KRAS/BRAF/NRAS 突变分别为曲美替尼改善 PFS 和药物应答的候选生物标志物。

### 第二部分 AI 大师评价

本研究聚焦于低级别浆液性卵巢癌中 MEK 抑制剂曲美替尼的分子生物标志物探索。通过对 GOG281/LOGS 随机对照试验中 170 例患者样本进行全外显子测序及 pERK 检测，研究发现高 pERK 表达与曲美替尼治疗获益显著相关，提示 MAPK 通路活化水平可能是疗效预测因素。KRAS/BRAF/NRAS 突变与更高的反应率相关，但不一定延长无进展生存。研究创新性在于首次系统分析曲美替尼敏感性与 MAPK 通路分子改变的关系，但受样本量及探索性设计限制，仍需进一步验证。

---

## 12. 纳武利尤单抗与伊匹单抗在罕见癌脑转移中的疗效与中枢神经系统毒性：多中心篮式试验（NCI/SWOG S1609）分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41378983)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41378983
**DOI：** 10.1158/1078-0432.CCR-25-2900

### 第一部分 原文与翻译

**英文原标题：** Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multi-Center Basket Trial Analysis (NCI/SWOG S1609).

> **英文摘要：**
> PURPOSE: To evaluate the efficacy and safety of dual immune checkpoint inhibitors (ICI) in patients with brain metastases (BM) from rare cancers.
> 
> PATIENTS AND METHODS: Patients with and without BM received nivolumab (240 mg every two weeks) and ipilimumab (1 mg/kg every six weeks) (NCI/SWOG S1609 DART trial, NCT02834013) across >1,000 sites. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method; hazard ratios (HR) with 95% confidence intervals (CI) were derived from Cox models. Systemic ORR was assessed by RECIST v1.1, and adverse events were graded using CTCAE v5.0. Intracranial outcomes were assessed in a subset of patients with BM to evaluate best intracranial response.
> 
> RESULTS: Among 727 patients, the systemic ORR was 11.5% in those without BM (n=707) and 10% in those with BM (n=20) (p=0.76). PFS and OS were similar between groups (PFS: HR=1.29, 95% CI 0.81-2.07, p=0.28; OS: HR=1.36, 95% CI 0.81-2.27, p=0.24). Intracranial response was evaluable in 12 patients with BM (60%). No intracranial complete or partial responses were observed, and six patients (50%) achieved intracranial stable disease as their best intracranial response. Grade ≥3 CNS toxicities occurred in 3% of patients without BM and 5% of those with BM (p=0.43).
> 
> CONCLUSIONS: Dual-ICI therapy showed comparable efficacy and safety in patients with and without BM.

> **中文摘要：**
> 研究目的：评估双重免疫检查点抑制剂（ICI）在罕见癌脑转移（BM）患者中的疗效和安全性。
> 
> 患者与方法：在超过1000个试验中心中，入组具有或不具有脑转移的患者，均接受纳武利尤单抗（每两周240 mg）联合伊匹单抗（每六周1 mg/kg）治疗（NCI/SWOG S1609 DART试验，NCT02834013）。无进展生存期（PFS）和总生存期（OS）采用Kaplan-Meier法估计；危险比（HR）及其95%置信区间（CI）由Cox模型计算。系统性客观缓解率（ORR）依据RECIST v1.1评估，不良事件依据CTCAE v5.0分级。在脑转移患者亚组中评估颅内结局，以测定最佳颅内反应。
> 
> 结果：在727名患者中，无脑转移者（n=707）的系统性ORR为11.5%，有脑转移者（n=20）为10%（p=0.76）。两组的PFS和OS相似（PFS：HR=1.29，95% CI 0.81–2.07，p=0.28；OS：HR=1.36，95% CI 0.81–2.27，p=0.24）。有脑转移的患者中有12例（60%）可评估颅内反应。未观察到颅内完全或部分缓解，6例患者（50%）的最佳颅内反应为颅内疾病稳定。≥3级中枢神经系统毒性在无脑转移患者中发生率为3%，在有脑转移者中为5%（p=0.43）。
> 
> 结论：双重ICI治疗在有无脑转移的患者中显示出相似的疗效和安全性。

### 第二部分 AI 大师评价

本研究在多中心篮式试验框架下，系统评估了纳武利尤单抗联合伊匹单抗对罕见癌脑转移患者的疗效与中枢神经系统安全性。结果显示，与无脑转移患者相比，脑转移组的总体缓解率及生存结局相近，未见明显疗效差异。颅内缓解率有限，仅有部分患者达疾病稳定状态，提示免疫治疗对该亚群疗效受限。研究设计广泛且方法严谨，但样本量较小可能限制了统计学检验的充分性。总体而言，该研究为罕见癌脑转移的免疫治疗提供了重要的真实世界证据。

---

## 13. 保留或不保留脾血管的脾脏保留远端胰切除术的长期结局：双中心经验研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41373100)
**期刊：** Annals of surgery
**PMID：** 41373100
**DOI：** 10.1097/SLA.0000000000006992

### 第一部分 原文与翻译

**英文原标题：** Long-term Outcomes of Spleen-preserving Distal Pancreatectomy With or Without Preservation of Splenic Vessels: A Bi-institutional Experience.

> **英文摘要：**
> OBJECTIVE: To compare the short- and long-term outcomes of the Warshaw (splenic vessel resection) and Kimura (splenic vessel preservation) techniques in spleen-preserving distal pancreatectomy (SPDP).
> 
> SUMMARY BACKGROUND DATA: SPDP is an alternative to splenectomy that preserves immune function. Both Warshaw and Kimura are used, but comparative data on their long-term safety and indications are limited.
> 
> METHODS: Retrospective bi-institutional analysis of 297 patients undergoing SPDP at Massachusetts General Hospital and Cedars-Sinai Medical Center (2002-2020). Clinicopathologic, operative, and radiologic outcomes were compared.
> 
> RESULTS: Of 297 patients, 245 (82.5%) underwent Warshaw and 52 (17.5%) Kimura. Warshaw was more commonly performed for larger tumors (2.5 cm vs. 1.5 cm, P<0.001), proximal lesions (specimen 8.2 cm vs. 5.7 cm, P<0.001), and malignant or complex disease, Kimura was more commonly performed minimally invasively (MIS) (73.1% vs. 44.1%, P<0.001) and was associated with shorter operative time. Higher ASA class, larger tumor size, pancreatic ductal adenocarcinoma, and the Warshaw technique independently predicted longer operative time in MIS cases, suggesting a preferential adoption of the Warshaw technique for technically more challenging tumor dissections. Short-term morbidity, readmission, and mortality rates were comparable. With a median follow-up of 85.8 months splenic hypoperfusion (30.4% vs. 12.2%, P=0.010), and perigastric varices (19.6% vs. 7.3%, P=0.056) were more frequent after Warshaw, although most were clinically silent, and the need for secondary splenectomy was rare (1.2%).
> 
> CONCLUSIONS: Both techniques are safe and effective for SPDP. Warshaw is preferred for proximal, malignant, or complex lesions, while Kimura may minimize long-term splenic sequelae in small, distal, benign tumors. An anatomy- and disease-driven approach remains essential to optimize outcomes.

> **中文摘要：**
> 目的：比较在脾脏保留远端胰切除术（SPDP）中采用 Warshaw（脾血管切除）与 Kimura（脾血管保留）技术的短期及长期结局。
> 
> 背景资料摘要：SPDP 是脾切除的替代术式，可保留机体免疫功能。Warshaw 与 Kimura 两种技术均被广泛采用，但它们在长期安全性及适应证方面的比较数据有限。
> 
> 方法：对马萨诸塞总医院及西达赛奈医疗中心 2002 至 2020 年期间行 SPDP 的 297 例患者进行回顾性双中心分析。比较其临床病理、手术及影像学结局。
> 
> 结果：297 例患者中，245 例（82.5%）接受 Warshaw 技术，52 例（17.5%）接受 Kimura 技术。Warshaw 技术更常用于肿瘤较大（2.5 cm vs. 1.5 cm，P<0.001）、病灶位于近端（切除标本 8.2 cm vs. 5.7 cm，P<0.001），以及恶性或复杂病变；而 Kimura 技术更常以微创方式实施（73.1% vs. 44.1%，P<0.001），且手术时间更短。ASA 分级较高、肿瘤较大、胰腺导管腺癌及 Warshaw 技术是微创手术中手术时间延长的独立预测因素，提示 Warshaw 技术在技术上更具挑战的肿瘤切除中更常被选择。短期发病率、再入院率及死亡率两组相似。中位随访 85.8 个月后，Warshaw 组脾脏低灌注（30.4% vs. 12.2%，P=0.010）及胃周静脉曲张（19.6% vs. 7.3%，P=0.056）更为常见，但多数无临床症状，继发脾切除的发生率罕见（1.2%）。
> 
> 结论：两种技术在 SPDP 中均安全有效。Warshaw 技术更适用于近端、恶性或复杂病变，而 Kimura 技术可在小的、远端、良性肿瘤中减少长期脾脏并发症。基于解剖及疾病特点的个体化选择对于优化手术结局仍至关重要。

### 第二部分 AI 大师评价

该研究系统比较了 Warshaw 与 Kimura 两种脾脏保留远端胰切除术技术在近二十年内的短期与长期结局，是目前较大规模的双中心研究。结果显示，两种技术总体安全有效，但 Warshaw 术式更适用于近端或复杂病灶，而 Kimura 术式有助于降低长期脾脏并发症。研究突出了基于解剖及疾病特征选择手术方式的重要性。其创新性在于提供了较高质量的长期随访数据，但作为回顾性研究仍存在选择偏倚的局限。

---

## 14. 线粒体在RNA修饰与代谢重编程交汇处的作用：对细胞死亡、肿瘤微环境及免疫治疗的启示

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41373022)
**期刊：** Journal of hematology & oncology
**PMID：** 41373022
**DOI：** 10.1186/s13045-025-01762-7

### 第一部分 原文与翻译

**英文原标题：** Mitochondria at the intersections of RNA modifications and metabolism reprogramming implications in cell death, tumor microenvironment, and immunotherapy.

> **英文摘要：**
> Mitochondria, the powerhouse of the cell, orchestrate a plethora of critical functions, including energy production, metabolic regulation, programmed cell death, and signal transduction. Their pivotal role in the pathogenesis of numerous diseases underscores their significance. Among the various regulatory mechanisms, RNA modifications emerge as a dominant posttranscriptional modulator of gene expression, increasingly recognized for their profound impact on mitochondrial functions. Groundbreaking discoveries have unveiled compelling links between RNA modifications and oxidative phosphorylation, regulated cell death-particularly cuproptosis-and antitumor immunity, underscoring RNA modifications' vital role and untapped potential in mitochondrial biology, cancers and aging-related diseases. In this Review, we comprehensively catalog the primary RNA modifications modifiers and their small-molecule inhibitors that influence mitochondrial functions. We explore the latest research delineating RNA modifications' involvement in mitochondria-related glucose metabolism, regulated cell death, and mitochondrial dynamics, presenting an intricate regulatory network. Furthermore, we investigate the intriguing intersection of RNA modifications and mitochondria-related antitumor immunity, highlighting prospective therapeutic targets to enhance immunotherapy outcomes. This review not only accentuates the critical importance of RNA modifications in mitochondrial function but also paves the way for novel therapeutic strategies in disease treatment.

> **中文摘要：**
> 线粒体作为细胞的能量工厂，协调着能量生成、代谢调控、程序性细胞死亡及信号转导等多种关键功能。它们在多种疾病发病机制中的核心作用凸显了其重要性。在多种调控机制中，RNA修饰作为一种主要的转录后基因表达调节因子，因其对线粒体功能的深刻影响而日益受到重视。开创性的研究揭示了RNA修饰与氧化磷酸化、受调控的细胞死亡——特别是铜死亡（cuproptosis）——以及抗肿瘤免疫之间的紧密联系，强调了RNA修饰在线粒体生物学、肿瘤及衰老相关疾病中的关键作用和潜在价值。在本综述中，我们系统总结了影响线粒体功能的主要RNA修饰调控因子及其小分子抑制剂。我们探讨了最新研究中RNA修饰在与线粒体相关的葡萄糖代谢、受调控细胞死亡及线粒体动力学中的作用，揭示了一个复杂的调控网络。此外，我们进一步研究了RNA修饰与线粒体相关抗肿瘤免疫的相互作用，突出其作为增强免疫治疗疗效的潜在治疗靶点。本综述不仅强调了RNA修饰在线粒体功能中的关键重要性，也为疾病治疗的新型治疗策略铺平了道路。

### 第二部分 AI 大师评价

本文系统探讨了RNA修饰与线粒体功能、代谢重编程及抗肿瘤免疫的交叉调控关系。作者综述了主要RNA修饰调控因子及其小分子抑制剂，并梳理其在葡萄糖代谢、细胞死亡及线粒体动力学中的作用机制。文章创新性地揭示了RNA修饰与线粒体相关免疫调控的潜在联系，为开发针对线粒体功能失衡相关疾病的免疫治疗新策略提供了方向。总体而言，该综述具有较强的整合性与前瞻性，但在机制验证及临床转化层面仍需进一步研究。

---

## 15. 免疫细胞衰老驱动黑色素瘤对免疫治疗的应答。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372921)
**期刊：** Molecular cancer
**PMID：** 41372921
**DOI：** 10.1186/s12943-025-02517-1

### 第一部分 原文与翻译

**英文原标题：** Immune cell senescence drives responsiveness to immunotherapy in melanoma.

> **英文摘要：**
> BACKGROUND: Immunotherapy has significantly improved cancer treatment. However, it is not effective in all cancer patients, rendering the need to further delineate the differences among responders and non-responders at the molecular and cellular level. Unresponsiveness to immunotherapy has been attributed to dysfunctional immune cell states such as T-cell exhaustion and anergy, whereas the contribution of cellular senescence remains elusive. Herein, we have investigated the role of immune cell senescence in the response to checkpoint inhibitors in melanomas where these immunotherapies are applied as a first line treatment.
> 
> METHODS: Two senescence detecting complementary approaches were utilized in a case control study we conducted. First, we implemented a senescence molecular signature we developed, termed "SeneVick", retrospectively in a single cell RNA-seq dataset from melanoma patients who received immunotherapy. Prior to this analysis, the signature was extensively validated in a variety of cell/tissue contexts, senescence types and species. Second, cellular senescence was assessed via an established experimental algorithmic approach in circulating immune cells of an analogous melanoma clinical cohort.
> 
> RESULTS: Melanoma patients who did not respond to immunotherapy exhibited increased cellular senescence in the CD8 + T-cell, CD4 + T-cell, B-cell (CD19 + /CD20 +) and NK cell compartments compared to responders. This phenomenon was independent of patients' clinical features (age, sex, melanoma type, stage) and not an outcome of immunotherapy, in contrast to conventional anti-cancer treatments. Interestingly, alterations of cell-to-cell interactions among the immune sub-populations in non-responders compared to responders were identified, supporting, along with cytotoxicity assays, that senescent immune cells display immunosuppressive properties driving defective immune responses and treatment failure.
> 
> CONCLUSION: Overall, our findings provide evidence that cellular senescence within the immune cell compartment of the tumor micro-environment is a potent determinant of the response to immunotherapy and pave the way for strategies targeting it as promising approaches to improve the outcome of such interventions.

> **中文摘要：**
> 背景：免疫治疗显著改善了癌症的治疗效果。然而，它并非对所有癌症患者都有效，因此有必要在分子和细胞水平上进一步阐明应答者与无应答者之间的差异。免疫治疗无反应与免疫细胞功能障碍状态有关，如T细胞耗竭和无能，但细胞衰老的贡献仍不明确。在本研究中，我们探讨了免疫细胞衰老在黑色素瘤检查点抑制剂应答中的作用，这些免疫疗法被用作一线治疗。
> 
> 方法：我们在一项病例对照研究中采用了两种互为补充的衰老检测方法。首先，我们将自建的衰老分子特征签名“ SeneVick ”应用于接受免疫治疗的黑色素瘤患者的单细胞RNA测序数据集中进行回顾性分析。在此之前，该特征签名已在多种细胞/组织环境、衰老类型和物种中得到了广泛验证。其次，我们在一个类似的黑色素瘤临床队列中，通过既定的实验算法方法评估了外周循环免疫细胞的细胞衰老水平。
> 
> 结果：与应答者相比，免疫治疗无应答的黑色素瘤患者在CD8⁺ T细胞、CD4⁺ T细胞、B细胞（CD19⁺/CD20⁺）以及NK细胞群体中表现出更高的细胞衰老水平。这一现象与患者的临床特征（年龄、性别、黑色素瘤类型、分期）无关，且不同于常规抗癌治疗，不是免疫治疗造成的结果。有趣的是，在无应答者与应答者之间的免疫亚群细胞间相互作用发生了变化。结合细胞毒活性实验结果，这些发现表明，衰老的免疫细胞具有免疫抑制特性，从而导致免疫反应缺陷和治疗失败。
> 
> 结论：总体而言，我们的研究表明，肿瘤微环境中免疫细胞群体的细胞衰老是决定免疫治疗应答的重要因素，并为针对衰老细胞的治疗策略提供了新的思路，可能成为改善免疫治疗效果的有前景途径。

### 第二部分 AI 大师评价

本研究揭示了免疫细胞衰老在黑色素瘤免疫治疗应答中的关键调控作用。研究者结合单细胞转录组和外周免疫细胞实验分析，发现无应答患者中多种免疫亚型细胞的衰老水平升高，并与免疫功能抑制相关。该工作创新性地将衰老生物学引入免疫治疗耐药机制研究，为改善治疗效果提供了潜在干预靶点。但研究样本规模和机制验证仍需后续强化，以巩固其临床推广价值。

---

## 16. 通过靶向胰腺癌相关糖基调控CAR-T细胞功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372740)
**期刊：** Nature communications
**PMID：** 41372740
**DOI：** 10.1038/s41467-025-66102-2

### 第一部分 原文与翻译

**英文原标题：** Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer.

> **英文摘要：**
> Chimeric antigen receptor (CAR) T cell therapy has transformed cancer treatment but its efficacy remains limited in solid tumors due to antigen heterogeneity, an immunosuppressive microenvironment, and the glycocalyx barrier. The glycocalyx, composed of dense glycoproteins such as MUC1, is markedly expanded in cancers, where it impedes immune cell access and antigen engagement, thereby reducing efficacy. In most adenocarcinomas, Tn antigen, comprising N-acetylgalactosamine linked to serine or threonine, is overexpressed. Tn-MUC1, a truncated form of MUC1 decorated with Tn antigen, is frequently overexpressed in pancreatic cancer. Here, we incorporate a non-signaling glyco-bridge binder recognizing Tn-MUC1 into mesothelin-directed CAR-T cells. This bridge enhances tumor recognition and cytotoxicity by increasing avidity and facilitating CAR activation in a density- and affinity-dependent manner. To broaden its applicability, we design a tandem Helix pomatia agglutinin (HPA) lectin-based bridge that recognizes Tn antigens across cancer types. CAR-T cells with the HPA-bridge exhibit superior cytotoxicity in pancreatic cancer models.

> **中文摘要：**
> 嵌合抗原受体（CAR）T细胞疗法已改变癌症治疗格局，但由于抗原异质性、免疫抑制性微环境以及糖萼屏障的存在，其在实体瘤中的疗效仍然有限。糖萼由密集的糖蛋白（如MUC1）组成，在癌症中显著增厚，阻碍免疫细胞的接触与抗原结合，从而降低治疗效果。在大多数腺癌中，Tn抗原（由连接于丝氨酸或苏氨酸的N-乙酰半乳糖胺组成）呈过度表达状态。Tn-MUC1是一种带有Tn抗原修饰的MUC1截短形式，在胰腺癌中常呈高表达。本研究将一种可识别Tn-MUC1的非信号型糖桥结合分子引入靶向间皮素的CAR-T细胞中。该桥通过提高亲和力并以密度和亲和依赖的方式促进CAR激活，从而增强肿瘤识别与细胞毒性。为拓展其适用性，研究者设计了一种串联的基于Helix pomatia凝集素（HPA）的桥，可识别多种癌症类型中的Tn抗原。携带HPA桥的CAR-T细胞在胰腺癌模型中表现出更强的细胞毒活性。

### 第二部分 AI 大师评价

该研究旨在通过靶向胰腺癌相关糖基Tn-MUC1来优化CAR-T细胞的抗肿瘤效应。研究团队设计并引入一种非信号型糖桥分子，以增强CAR-T细胞对肿瘤的识别与攻击能力，并进一步开发了基于HPA凝集素的泛癌糖桥结构。结果显示，这种结构提高了细胞亲和力和抗肿瘤细胞毒性，为克服实体瘤抗原异质性和糖萼屏障提供了新思路。该策略具有一定创新性，但仍需进一步验证其体内安全性与可控制性。

---

## 17. 针对猴痘病毒 A28 蛋白的抗体可实现强效中和作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372735)
**期刊：** Nature communications
**PMID：** 41372735
**DOI：** 10.1038/s41467-025-66344-0

### 第一部分 原文与翻译

**英文原标题：** Potent neutralization by antibodies targeting the MPXV A28 protein.

> **英文摘要：**
> Monkeypox virus (MPXV) is the most pathogenic Poxvirus in circulation, yet key viral antigens remain immunologically unexplored. We isolate and characterize a panel of monoclonal antibodies (mAbs) targeting MPXV A28 (OPG153), an important membranal protein present on mature MPXV virions. From male convalescent individuals, we isolate anti-A28 mAbs alongside additional mAbs targeting the A35 and H3 proteins. Anti-A28 mAbs potently neutralize MPXV and Vaccinia virus (VACV) through complement-dependent mechanisms involving C1q and C3 deposition. High-resolution crystal structures of two anti-A28 mAbs, 10M2146 and 8M2110, in complex with VACV A26 reveal two distinct and highly conserved proximal epitopes within the N-terminal domain. Passive transfer of 8M2110 modestly attenuates disease in infected female mice. Moreover, immunization with A28 elicits antigen-specific B cells and robust neutralizing antibody responses and provides protection against lethal VACV challenge. These findings identify MPXV A28 as a promising central target for the induction of neutralizing antibodies and antiviral interventions.

> **中文摘要：**
> 猴痘病毒（MPXV）是目前流行的最具致病性的痘病毒，但其关键病毒抗原在免疫学上仍未得到充分研究。我们分离并鉴定出一组针对 MPXV A28（OPG153）的单克隆抗体（mAbs），A28 是存在于成熟 MPXV 病毒颗粒表面的重要膜蛋白。我们从男性康复者体内分离出抗 A28 的单抗，同时还获得了针对 A35 和 H3 蛋白的其他单抗。抗 A28 单抗能够通过依赖补体的机制（涉及 C1q 和 C3 沉积）强效中和 MPXV 和痘苗病毒（VACV）。两种抗 A28 单抗 10M2146 和 8M2110 与 VACV A26 复合物的高分辨率晶体结构显示，在其 N 端结构域内存在两个不同且高度保守的近端表位。被动转移 8M2110 可轻度减轻感染雌性小鼠的疾病程度。此外，用 A28 蛋白免疫可诱导抗原特异性的 B 细胞及强效的中和抗体反应，并能对致死性 VACV 攻击产生保护作用。这些发现表明，MPXV A28 是诱导中和抗体和开发抗病毒干预措施的一个具有前景的核心靶点。

### 第二部分 AI 大师评价

本研究聚焦于猴痘病毒 A28 蛋白这一此前未充分探索的抗原，通过分离鉴定多株单克隆抗体揭示其强大的中和潜力。研究结合结构生物学和动物模型实验，明确了抗体的作用机制及保护效果，为痘病毒免疫防护提供新靶点。其创新点在于首次系统阐明 A28 蛋白的免疫学特性与中和位点。然而，动物模型保护效应较为有限，未来可进一步优化抗体效能和疫苗策略。

---

## 18. 更正：维奈托克联合 FLAG-IDA 诱导及巩固治疗在新诊断及复发/难治性急性髓系白血病中的长期结果。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372600)
**期刊：** Leukemia
**PMID：** 41372600
**DOI：** 10.1038/s41375-025-02827-9

### 第一部分 原文与翻译

**英文原标题：** Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本条目为一篇更正通知，涉及将维奈托克与 FLAG-IDA 联合用于新诊断及复发/难治性急性髓系白血病的长期疗效研究。该文章主要用于修正文献内容或数据，不提供新的科学结果。其核心意义在于保证研究记录的准确性与可追溯性，显示出期刊对研究质量控制的严谨性。

---

## 19. 令编辑抓狂的那些事：术语滥用、不必要的缩写、错误使用小数及其他问题

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372599)
**期刊：** Leukemia
**PMID：** 41372599
**DOI：** 10.1038/s41375-025-02838-6

### 第一部分 原文与翻译

**英文原标题：** Things that drive Editors crazy: jargon, unnecessary abbreviations, abusing decimals and a few more.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文以编辑视角讨论学术论文写作中的常见问题，包括过度使用专业术语、不必要的缩写、以及小数格式滥用等写作细节。其目的在于提醒科研作者改进论文表达的清晰度与规范性。尽管该文似属意见性稿件而非实证研究，但对医学期刊写作质量的提升具有现实指导意义。

---

## 20. 脂质降低治疗与未定潜能克隆性造血中克隆动态关联的分析：来自英国老龄化纵向研究的见解

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372598)
**期刊：** Leukemia
**PMID：** 41372598
**DOI：** 10.1038/s41375-025-02822-0

### 第一部分 原文与翻译

**英文原标题：** Analysis of the association of lipid-lowering therapy on clonal dynamics in clonal haematopoiesis of indeterminate potential: insights from the English Longitudinal Study of Ageing.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究探讨了脂质降低治疗（如他汀类药物）与未定潜能克隆性造血（CHIP）中克隆动态变化之间的关系，利用英国老龄化纵向研究（ELSA）的队列数据进行分析。尽管原文未提供摘要，但从标题可推测研究重点在于心血管代谢干预对血液干细胞克隆演化的影响。此类研究有助于阐明代谢治疗与造血系统老化或癌变风险之间的潜在联系。其创新性在于跨越代谢与克隆性造血领域的整合分析，但仍可能受限于观察性研究设计及因果推断不足。

---

## 21. 在急性髓系白血病中，以定量下限作为基于流式细胞术的可测残余病灶评估低水平界值的预后意义。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372597)
**期刊：** Leukemia
**PMID：** 41372597
**DOI：** 10.1038/s41375-025-02825-x

### 第一部分 原文与翻译

**英文原标题：** Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于急性髓系白血病（AML）中可测残余病灶（MRD）的量化评估，探讨将定量下限作为流式细胞术检测的低水平阈值对于预后判定的意义。该工作可能通过优化MRD检测敏感度和临界定义，提高预后分层的精准度。其创新点在于引入“定量下限”概念作为临界标准，为MRD结果解释提供新的分析框架。然而，研究细节尚待披露，验证性数据及对临床决策的实际影响仍需进一步探讨。

---

## 22. 贯穿癌症诊疗全程的液体活检

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372534)
**期刊：** Nature medicine
**PMID：** 41372534
**DOI：** 10.1038/s41591-025-04093-9

### 第一部分 原文与翻译

**英文原标题：** Liquid biopsies across the cancer care continuum.

> **英文摘要：**
> Liquid biopsies have the potential to transform precision oncology by enabling the sensitive and timely detection of cancer across various clinical settings. Minimally invasive analyses of circulating cell-free DNA (cfDNA) have emerged as cutting-edge approaches for cancer detection, characterization and monitoring. Early efforts focused on mutation-based targeted sequencing, whereas newer methods use whole-genome and epigenome sequencing combined with artificial intelligence to broaden the range of alterations that can be assessed in cfDNA. Despite these advances, substantial technical and clinical challenges prevent widespread adoption. Key areas for improvement include achieving clinically meaningful detection sensitivities, enhancing assay accessibility and prospectively evaluating the clinical sensitivity of circulating tumor DNA burden in early and metastatic settings, to support the integration of liquid biopsies into therapeutic decision-making. Here we discuss technologies and analytical methodologies in cfDNA detection, together with their clinical validity and utility. We highlight opportunities to address key challenges and to support the implementation of liquid biopsies throughout the cancer care continuum.

> **中文摘要：**
> 液体活检有潜力通过在多种临床情境下实现对癌症的高灵敏度和及时检测，从而变革精准肿瘤学。对于循环无细胞 DNA（cfDNA）的微创分析已成为癌症检测、特征界定及监测的前沿方法。早期研究主要聚焦于基于突变的靶向测序，而新的方法则结合全基因组和表观基因组测序与人工智能技术，以拓展在 cfDNA 中可检测的分子改变范围。尽管取得了进展，但重大的技术与临床挑战仍限制了其广泛应用。需要改进的关键方面包括实现具临床意义的检测灵敏度、提升检测手段的可及性，以及在早期与转移性癌症中前瞻性评估循环肿瘤 DNA 负荷的临床敏感性，以支持液体活检在治疗决策中的整合。本文讨论了 cfDNA 检测的技术与分析方法，以及其临床有效性和实用性。作者强调了解决关键挑战及推动液体活检在癌症全程管理中应用的机遇。

### 第二部分 AI 大师评价

本文系统综述了液体活检技术在癌症检测与治疗管理中的最新进展，特别聚焦于 cfDNA 的多维度分析方法。文章指出，液体活检正从突变检测扩展至整合全基因组与表观遗传学特征，并利用人工智能提升灵敏度与特异性。该研究的创新之处在于提出推动液体活检在临床转化中普及的关键技术路线与验证框架。然而，目前检测灵敏度、标准化及临床验证的不足仍是主要限制。整体而言，本文为液体活检融入精准肿瘤学提供了重要的理论与策略方向。

---

## 23. 跨膜蛋白——上皮细胞膜蛋白1在胰腺导管腺癌发病机制中的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372485)
**期刊：** Oncogene
**PMID：** 41372485
**DOI：** 10.1038/s41388-025-03633-4

### 第一部分 原文与翻译

**英文原标题：** Role of a transmembrane protein, epithelial membrane protein 1, in the pathogenesis of pancreatic ductal adenocarcinoma.

> **英文摘要：**
> Pancreatic ductal adenocarcinoma (PDAC) has two subtypes: the "classical/progenitor" type and "basal-like/squamous" type, the latter of which has poor clinical outcomes with no effective treatment strategies. We aimed to elucidate the role of epithelial membrane protein 1 (EMP1) in PDAC and its potential as a therapeutic target, particularly in aggressive disease such as "basal-like/squamous" type of PDAC. We examined the association of EMP1 expression using patient-derived organoids (PDOs) of human PDAC, K-RAS, Trp 53, and Pdx1-Cre recombinase mice, human PDAC cell lines, and publicly available clinical datasets. The functional roles of EMP1 were evaluated in vitro and in vivo through its knockout and stable overexpression. EMP1 knockout reduced proliferation, metastasis, and drug resistance, whereas overexpression enhanced malignant features. Transcriptomic analysis revealed that EMP1 promotes epithelial-mesenchymal transition (EMT), extracellular matrix remodeling, and the K-RAS signaling pathway. EMP1 expression is inversely implicated in the oxidative phosphorylation pathway, which is characteristic of the "classical/progenitor" type. Furthermore, integrated analysis revealed an association between EMP1 expression and ERK phosphorylation. EMP1 plays a crucial role in the pathogenesis of PDAC, as it contributes to the proliferative and metastatic characteristics of PDAC. This study suggests that EMP1 may be a potential therapeutic target gene for aggressive disease.

> **中文摘要：**
> 胰腺导管腺癌（PDAC）可分为两种亚型：“经典/祖细胞型”和“基底样/鳞状型”，其中后者预后不良，缺乏有效的治疗策略。本研究旨在阐明上皮细胞膜蛋白1（EMP1）在PDAC中的作用及其作为治疗靶点的潜力，尤其是在“基底样/鳞状型”等侵袭性疾病中。研究者利用来源于患者的PDAC类器官（PDOs）、K-RAS、Trp53 与 Pdx1-Cre重组酶小鼠模型、人PDAC细胞系及公开临床数据集，分析了EMP1的表达关联。通过在体内外进行EMP1的敲除与稳定过表达实验评估其功能作用。结果显示，EMP1敲除可抑制细胞增殖、转移及耐药性，而EMP1过表达则增强恶性特征。转录组分析表明，EMP1可促进上皮-间质转化（EMT）、细胞外基质重构及K-RAS信号通路的活化。EMP1的表达与氧化磷酸化途径呈负相关，而该途径是“经典/祖细胞型”PDAC的特征。此外，整合分析发现EMP1表达与ERK磷酸化存在相关性。综上，EMP1在PDAC的发病机制中发挥关键作用，有助于其增殖与转移特性。本研究提示EMP1可能是侵袭性PDAC的潜在治疗靶基因。

### 第二部分 AI 大师评价

本研究系统揭示了上皮细胞膜蛋白1（EMP1）在胰腺导管腺癌中的促肿瘤作用，通过多层次模型（类器官、小鼠、细胞系及公共数据集）验证其与肿瘤增殖、转移及耐药性密切相关。机制上，EMP1驱动EMT、基质重塑及K-RAS通路活化，并与ERK磷酸化正相关。研究创新性地提出EMP1在侵袭性PDAC中可能作为新的治疗靶点，但临床验证及靶向可行性仍需进一步研究。

---

## 24. 癌症神经科学领域的关键进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372481)
**期刊：** Nature cancer
**PMID：** 41372481
**DOI：** 10.1038/s43018-025-01082-2

### 第一部分 原文与翻译

**英文原标题：** Key developments in the cancer neuroscience field.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本篇发表于《Nature Cancer》的综述性文章显然旨在梳理和总结癌症神经科学这一新兴交叉领域的关键研究进展。尽管目前未提供摘要，但从标题推测，文章可能讨论了肿瘤微环境中的神经元与免疫、代谢及转移过程之间的相互作用，以及这些发现对癌症治疗策略带来的启发。该研究方向兼具创新性与复杂性，标志着科学界正逐步从传统的分子肿瘤学迈向以神经调控为核心的新视角。然而，其潜在局限在于机制研究尚处探索阶段，临床转化仍需大量验证。

---

## 25. 重塑在学术医学中开启有意义职业生涯的叙事视角

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372480)
**期刊：** Nature cancer
**PMID：** 41372480
**DOI：** 10.1038/s43018-025-01076-0

### 第一部分 原文与翻译

**英文原标题：** Flipping the narrative on launching a rewarding career in academic medicine.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本文作为一篇刊登于《Nature Cancer》的评论性或观点性文章，旨在探讨如何在学术医学领域中重新定义并构建有意义、可持续且令人满意的职业路径。标题暗示作者希望突破传统关于学术生涯起始的刻板印象，或提出新的指导理念。尽管缺乏摘要限制了对具体内容的深入理解，但其主题显然关注学术生态和职业发展的平衡，对医学教育及人才培养具有启发意义。

---

## 26. 拓展肺癌的靶向治疗策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372479)
**期刊：** Nature cancer
**PMID：** 41372479
**DOI：** 10.1038/s43018-025-01083-1

### 第一部分 原文与翻译

**英文原标题：** Expanding targeted therapy for lung cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 摘要暂无提供。

### 第二部分 AI 大师评价

该研究标题表明其聚焦于肺癌靶向治疗领域的拓展与优化，可能涵盖新靶点发现、耐药机制研究或药物组合策略。尽管缺乏摘要，推测本文旨在推动精准医学在肺癌患者中的进一步应用，为个体化治疗提供新的方向。其创新性在于可能突破现有靶向治疗的局限性；然而，缺乏摘要使得具体方法与数据支撑尚待查证。

---

## 27. 2025世代

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372478)
**期刊：** Nature cancer
**PMID：** 41372478
**DOI：** 10.1038/s43018-025-01086-y

### 第一部分 原文与翻译

**英文原标题：** The 2025 generation.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文发表于《Nature Cancer》，标题“2025世代”暗示其聚焦于未来一年癌症研究的趋势或全新一代研究方向。虽然暂无摘要信息，但根据刊物特征推测，文章可能综述了癌症基础研究与临床实践在2025年面临的关键创新与挑战。其价值在于提供学科方向性洞见，但因缺乏全文内容，暂难评估其具体研究方法与结果。

---

## 28. RAS 靶向治疗的演变格局

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372477)
**期刊：** Nature cancer
**PMID：** 41372477
**DOI：** 10.1038/s43018-025-01077-z

### 第一部分 原文与翻译

**英文原标题：** The evolving landscape of RAS-targeted therapies.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要提供。

### 第二部分 AI 大师评价

本研究综述了 RAS 靶向治疗领域的最新进展，探讨了从直接抑制 RAS 蛋白到干扰其下游信号通路的多种策略。文章重点突出了新兴的小分子抑制剂和结合 RAS 突变特征的精准治疗方法。该综述展示了 RAS 药物研发由长期‘不可成药’到逐步实现突破的演变历程，同时指出仍需解决的耐药与特异性挑战，对未来肿瘤精准治疗具有重要参考价值。

---

## 29. 回顾2025年

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372476)
**期刊：** Nature cancer
**PMID：** 41372476
**DOI：** 10.1038/s43018-025-01091-1

### 第一部分 原文与翻译

**英文原标题：** A look back at 2025.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本文作为刊载于《Nature Cancer》的年度回顾性文章，旨在总结2025年癌症研究领域的重要进展与趋势。尽管缺乏具体摘要，但从标题来看，作者可能回顾了过去一年在肿瘤学基础研究、临床治疗和转化医学方面的重要里程碑。此类综述通常具有高度学术概览价值，有助于梳理科研方向与未来策略。其局限在于未提供详细实验数据或研究结论，主要偏向于宏观性总结。

---

## 30. 利用新冠mRNA疫苗增强癌症免疫治疗效果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372475)
**期刊：** Nature cancer
**PMID：** 41372475
**DOI：** 10.1038/s43018-025-01088-w

### 第一部分 原文与翻译

**英文原标题：** Boosting cancer immunotherapy with COVID-19 mRNA vaccines.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 摘要暂无可用内容。

### 第二部分 AI 大师评价

本研究标题暗示作者探索了新冠mRNA疫苗在癌症免疫治疗中的增强作用，可能涉及疫苗诱导免疫激活或免疫记忆机制的再利用。该研究的设想具有创新性，因为它跨越了传染病疫苗与肿瘤免疫疗法的边界。若实验或临床验证成功，可能为个体化肿瘤治疗提供新的辅助策略。然而，具体机制、适用性及安全性仍需进一步系统研究。

---

## 31. 2025年癌症药物的批准与挫折

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372474)
**期刊：** Nature cancer
**PMID：** 41372474
**DOI：** 10.1038/s43018-025-01080-4

### 第一部分 原文与翻译

**英文原标题：** Cancer drug approvals and setbacks in 2025.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文献发表于《Nature Cancer》，重点综述2025年癌症药物研发领域的批准进展与受挫案例。尽管目前未提供摘要，但根据标题可推测其旨在总结新药监管趋势、市场批准动态及研究失败的原因。这类年度评述有助于全面认识癌症治疗药物开发的进步与挑战，为未来研发方向提供策略性指导。其创新点在于将监管与临床试验成果系统归纳，但仍可能受限于公开数据的时效性与完整性。

---

## 32. 肿瘤学中的基础模型在基准测试中表现优异，但在临床应用中尚显不足。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372473)
**期刊：** Nature cancer
**PMID：** 41372473
**DOI：** 10.1038/s43018-025-01071-5

### 第一部分 原文与翻译

**英文原标题：** Foundation models in oncology win benchmarks but miss the clinic.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文章讨论了大型基础模型在肿瘤学领域的研究与应用现状，指出其在标准化评测中的优异表现，但在临床落地方面仍存在显著差距。作者可能意在反思当前人工智能模型从实验室到临床转化的瓶颈问题。文章具有较强的现实针对性和科技前瞻性，但由于缺乏摘要与具体方法描述，外部读者难以全面了解其实证内容与证据深度。

---

## 33. 癌症免疫治疗中抗生素相关肠道菌群失调：从前临床洞见到改变实践的证据

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372472)
**期刊：** Nature cancer
**PMID：** 41372472
**DOI：** 10.1038/s43018-025-01055-5

### 第一部分 原文与翻译

**英文原标题：** Antibiotic-related dysbiosis in cancer immunotherapy: from preclinical insights to practice-changing evidence.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于抗生素使用引起的肠道微生态失调对癌症免疫治疗疗效的影响，旨在整合从实验模型到临床实践的关键证据，探讨微生物组与免疫水平之间的互动机制。此类综述具有重要的指导意义，有助于优化免疫治疗中的抗生素管理策略。尽管缺乏摘要细节，但从标题来看，研究可能涵盖转化医学视角，强调从机制研究到临床应用的桥接。其潜在局限在于不同癌种及治疗方案间的异质性仍需进一步量化验证。

---

## 34. 欧洲癌症研究亟需重新提起紧迫感

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372471)
**期刊：** Nature cancer
**PMID：** 41372471
**DOI：** 10.1038/s43018-025-01062-6

### 第一部分 原文与翻译

**英文原标题：** European cancer research requires renewed urgency.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可供参考。

### 第二部分 AI 大师评价

本篇文章以评论性视角强调欧洲癌症研究现阶段面临的紧迫局势，呼吁科研界与政策层面加快行动步伐。尽管未提供具体研究数据或方法，但标题传达出一种对科研资源协调与创新策略重整的急迫需求。该文可能意在推动欧洲在全球癌症研究体系中的协调进展与竞争力。整体上，它是一篇具有政策倡议与战略反思意义的评论性文章。

---

## 35. 癌症治疗后正常组织中的体细胞进化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372419)
**期刊：** Nature
**PMID：** 41372419
**DOI：** 10.1038/s41586-025-09792-4

### 第一部分 原文与翻译

**英文原标题：** Somatic evolution following cancer treatment in normal tissue.

> **英文摘要：**
> The extent to which exogenous sources, including cancer treatment, contribute to somatic evolution in normal tissue remains unclear. Here we used high-depth duplex sequencing (more than 30,000× coverage) to analyse 168 cancer-free samples representing 16 organs from 22 patients with metastatic cancer enroled in the PEACE research autopsy study. In every sample, we identified somatic mutations (range 305-2,854 mutations) at low variant allele frequencies (median 0.0000323). We extracted 16 distinct single-base substitution mutational signatures, reflecting processes that have moulded the genomes of normal cells. We identified alcohol-induced mutation acquisition in liver, smoking-induced mutagenesis in lung and cardiac tissue, and multiple treatment-induced processes, which correlated with therapy type and duration. Exogenous sources, including treatment, underpinned, on average, more than 40% of mutations in liver but less than 10% of mutations in brain samples. Finally, we observed tissue-specific selection, with positive selection in tissues such as lung (PTEN and PIK3CA), liver (NF2L2) and spleen (BRAF and NOTCH2), and limited selection in others, such as brain and cardiac tissue. More than 25% of driver mutations in normal tissue exposed to systemic anti-cancer therapy, including in TP53, could be attributed to treatment. Immunotherapy, although not associated with increased mutagenesis, was linked to driver mutations in PPM1D and TP53, illustrating how non-mutagenic treatment can sculpt somatic evolution. Our study reveals the rich tapestry of mutational processes and driver mutations in normal tissue, and the profound effect of lifetime exposures, including cancer treatment, on somatic evolution.

> **中文摘要：**
> 目前尚不清楚外源性因素（包括癌症治疗）在正常组织体细胞进化中所起的作用程度。在本研究中，我们采用高深度双链测序（覆盖度超过30,000×），分析了22例转移性癌症患者的PEACE研究尸检项目中来自16个器官的共168份无癌样本。在每个样本中，我们都检测到体细胞突变（范围305至2,854个突变），其变异等位基因频率较低（中位数为0.0000323）。我们提取出16种不同的单碱基替换突变特征，反映出塑造正常细胞基因组的多种过程。我们在肝组织中发现了酒精诱导的突变获得，在肺和心脏组织中发现了吸烟诱导的致突变，以及多种治疗诱发的突变过程，这些过程与治疗类型和持续时间相关。平均而言，包括治疗在内的外源性来源可解释肝脏中超过40%的突变，但在脑组织样本中占比不足10%。此外，我们观察到组织特异性的选择作用，例如肺组织（PTEN和PIK3CA）、肝组织（NF2L2）和脾脏组织（BRAF和NOTCH2）具有正性选择，而脑和心脏组织中选择作用有限。在经受系统性抗癌治疗的正常组织中，超过25%的驱动突变（包括TP53）可归因于治疗。免疫治疗虽然未与突变负担增加相关，但与PPM1D和TP53驱动突变的产生有关，表明非致突变性治疗也能影响体细胞进化。本研究揭示了正常组织中复杂多样的突变过程和驱动基因突变，并展示了包括癌症治疗在内的终身暴露如何对体细胞进化产生深远影响。

### 第二部分 AI 大师评价

该研究旨在揭示癌症治疗及其他外源性因素对正常组织体细胞进化的影响。研究者利用超高深度双链测序技术，对多器官的无癌组织样本进行系统性突变特征分析，发现治疗类型与突变过程和选择压力高度相关。结果指出，外源性因素在某些器官中占据主要突变来源，并揭示不同组织的正性选择差异。该工作在描绘正常组织体细胞进化全景方面具有重要创新性，但其样本规模和因果推断仍存在一定局限。

---

## 36. 从调控因子到生物程序再到性状的基因效应因果建模

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372418)
**期刊：** Nature
**PMID：** 41372418
**DOI：** 10.1038/s41586-025-09866-3

### 第一部分 原文与翻译

**英文原标题：** Causal modelling of gene effects from regulators to programs to traits.

> **英文摘要：**
> Genetic association studies provide a unique tool for identifying candidate causal links from genes to human traits and diseases. However, it is challenging to determine the biological mechanisms underlying most associations, and we lack genome-scale approaches for inferring causal mechanistic pathways from genes to cellular functions to traits. Here we propose approaches to bridge this gap by combining quantitative estimates of gene-trait relationships from loss-of-function burden tests with gene-regulatory connections inferred from Perturb-seq experiments in relevant cell types. By combining these two forms of data, we aim to build causal graphs in which the directional associations of genes with a trait can be explained by their regulatory effects on biological programs or direct effects on the trait. As a proof of concept, we constructed a causal graph of the gene-regulatory hierarchy that jointly controls three partially co-regulated blood traits. We propose that perturbation studies in trait-relevant cell types, coupled with gene-level effect sizes for traits, can bridge the gap between genetic association and biological mechanism.

> **中文摘要：**
> 遗传关联研究为识别从基因到人类性状和疾病的潜在因果联系提供了一种独特的工具。然而，确定大多数关联背后的生物学机制仍具挑战性，我们缺乏可在全基因组尺度上从基因到细胞功能再到性状推断因果机制通路的方法。在此，我们提出一种方法，通过将基因与性状关系的定量估计（来源于功能缺失负担检测）与从相关细胞类型的 Perturb-seq 实验中推断的基因调控连接相结合，以弥合这一空白。通过整合这两类数据，我们旨在构建因果图，使基因与性状的方向性关联可由其对生物程序的调控效应或对性状的直接效应加以解释。作为概念验证，我们构建了一个基因调控层级的因果图，该图共同控制三个部分共调控的血液性状。我们提出，在与性状相关的细胞类型中进行扰动研究，并结合基因层面的性状效应大小，可以弥合遗传关联与生物机制之间的差距。

### 第二部分 AI 大师评价

该研究旨在建立从基因调控到性状的因果建模框架，结合功能缺失负担分析与 Perturb-seq 数据，以推断基因到生物程序乃至性状的机制性路径。作者通过构建血液性状相关的因果图验证了该方法的可行性，展示了跨尺度整合数据推理生物因果关系的潜力。该工作创新性地连接了遗传关联与功能机制研究，为复杂性状的系统性理解奠定基础，但其应用仍受限于扰动实验数据的覆盖度和模型的普适性。

---

## 37. cDC1 上的促红细胞生成素受体决定免疫耐受性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372415)
**期刊：** Nature
**PMID：** 41372415
**DOI：** 10.1038/s41586-025-09824-z

### 第一部分 原文与翻译

**英文原标题：** Erythropoietin receptor on cDC1s dictates immune tolerance.

> **英文摘要：**
> Type 1 conventional dendritic cells (cDC1s) are unique in their efferocytosis and cross-presenting abilities, resulting in antigen-specific T cell immunity or tolerance. However, the mechanisms that underlie cDC1 tolerogenic function remain largely unknown. Here we show that the erythropoietin receptor (EPOR) acts as a critical switch that determines the tolerogenic function of cDC1s and the threshold of antigen-specific T cell responses. In total lymphoid irradiation-induced allograft tolerance, cDC1s upregulate EPOR expression, and conditional knockout of EPOR in cDC1s diminishes antigen-specific induction and expansion of FOXP3 regulatory T (T) cells, resulting in allograft rejection. Mechanistically, EPOR promotes efferocytosis-induced tolerogenic maturation of splenic cDC1s towards late-stage CCR7 cDC1s characterized by increased expression of the integrin β8 gene (Itgb8), and conditional knockout of Itgb8 in cDC1s impairs tolerance induced by total lymphoid irradiation plus anti-thymocyte serum. Migratory cDC1s in peripheral lymph nodes preferentially express EPOR, and their FOXP3 T cell-inducing capacity is enhanced by erythropoietin. Reciprocally, loss of EPOR enables immunogenic maturation of peripheral lymph node migratory and splenic CCR7 cDC1s by upregulating genes involved in MHC class II- and class I-mediated antigen presentation, cross-presentation and costimulation. EPOR deficiency in cDC1s reduces tumour growth by enhancing anti-tumour T cell immunity, particularly increasing the generation of precursor exhausted tumour antigen-specific CD8 T cells in tumour-draining lymph nodes and supporting their maintenance within tumours, while concurrently reducing intratumoural T cells. Targeting EPOR on cDC1s to induce or inhibit T cell immune tolerance could have potential for treating a variety of diseases.

> **中文摘要：**
> 1 型常规树突状细胞（cDC1）在其清除凋亡细胞（efferocytosis）及交叉呈递能力方面具有独特性，可引发抗原特异性的 T 细胞免疫或耐受反应。然而，驱动 cDC1 免疫耐受功能的机制尚不清楚。本研究表明，促红细胞生成素受体（EPOR）充当关键开关，决定 cDC1 的耐受相关功能及抗原特异性 T 细胞反应的阈值。在全淋巴照射诱导的异体移植物耐受模型中，cDC1 上调 EPOR 表达，而 cDC1 特异性敲除 EPOR 会削弱抗原特异性 FOXP3 调节性 T（Treg）细胞的诱导与扩增，导致移植物排斥。从机制上看，EPOR 促进脾脏 cDC1 在清除凋亡细胞后的耐受性成熟，向晚期 CCR7⁺ cDC1 过渡，这一亚型以整合素 β8 基因（Itgb8）表达上调为特征；而在 cDC1 中条件性敲除 Itgb8 会削弱由全淋巴照射结合抗胸腺细胞血清诱导的免疫耐受。外周淋巴结中的迁移性 cDC1 优先表达 EPOR，其诱导 FOXP3⁺ T 细胞的能力可被促红细胞生成素增强。相反，EPOR 缺失使外周淋巴结迁移性及脾脏 CCR7⁺ cDC1 发生免疫原性成熟，表现为上调与 MHC II 类与 I 类介导的抗原呈递、交叉呈递及共刺激相关的基因。cDC1 中 EPOR 缺失通过增强抗肿瘤 T 细胞免疫而抑制肿瘤生长，显著促进肿瘤引流淋巴结中肿瘤抗原特异性前体耗竭性 CD8⁺ T 细胞的生成，并有助于其在肿瘤内的维持，同时降低肿瘤内 T 细胞浸润。靶向 cDC1 上的 EPOR 以诱导或抑制 T 细胞免疫耐受，可能为多种疾病的治疗提供潜在途径。

### 第二部分 AI 大师评价

该研究揭示促红细胞生成素受体（EPOR）是调控 cDC1 细胞免疫耐受功能的关键分子。通过小鼠异体移植与肿瘤模型，研究团队发现 EPOR 可决定 cDC1 的耐受性或免疫原性命运，影响调节性 T 细胞的诱导与抗肿瘤免疫效应。在机制层面，EPOR 通过 Itgb8 介导的耐受性成熟通路调控细胞状态转变。研究创新性地将造血调控因子与树突状细胞免疫功能联系，为免疫耐受及肿瘤免疫治疗提供了新靶点。局限性在于仍需进一步验证该通路在人体免疫调控中的普遍性及安全性。

---

## 38. 禁食通过激活糖皮质激素增强乳腺癌治疗效果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372410)
**期刊：** Nature
**PMID：** 41372410
**DOI：** 10.1038/s41586-025-09869-0

### 第一部分 原文与翻译

**英文原标题：** Fasting boosts breast cancer therapy efficacy via glucocorticoid activation.

> **英文摘要：**
> The majority of breast cancers are driven by oestrogen receptor-α (ERα) activation, and endocrine therapy represents the mainstay treatment for these patients. However, resistance is common and tumours often progress after years of endocrine suppression. Periodic fasting enhances the efficacy of standard endocrine therapy and delays acquired drug resistance, although the underlying mechanisms remain unclear. Here we show that fasting induces extensive epigenetic reprogramming in ERα-positive breast cancer xenografts when combined with endocrine therapy, with large-scale activation of glucocorticoid receptor (GR) and progesterone receptor signalling and concomitant reduction in the activity of activator protein-1 (AP-1) family members. GR-driven gene programmes are selectively activated in in vivo models of ERα-positive breast cancer during fasting, and GR knockout hinders the anti-tumour effects of fasting combined with tamoxifen. Exogenous administration of GR ligands recapitulates fasting-enhanced anti-oestrogen action, thus promoting tumour regression. Patients undergoing a cyclic fasting-mimicking diet exhibited increased blood progesterone and cortisol concentrations. Additionally, tumours collected after the fasting-mimicking diet showed an inverse correlation of GR activation with proliferation markers, providing clinical confirmation of our observations in animal models. Our results indicate that GR activation has a pivotal role in the ability of fasting to enhance endocrine therapy activity in breast cancer and suggest that corticosteroid administration should be evaluated as an adjuvant to endocrine therapy in this setting.

> **中文摘要：**
> 大多数乳腺癌是由雌激素受体-α（ERα）的激活所驱动，内分泌治疗是这类患者的主要治疗手段。然而，耐药性常见，且肿瘤在多年内分泌抑制后常出现进展。周期性禁食可增强标准内分泌治疗的疗效并延缓获得性耐药的产生，但其潜在机制仍不清楚。本研究显示，当禁食与内分泌治疗联合应用时，可在ERα阳性乳腺癌异种移植瘤中诱导广泛的表观遗传重编程，伴随大规模的糖皮质激素受体（GR）和孕激素受体信号激活，以及活化蛋白-1（AP-1）家族成员活性的同步下降。在体内的ERα阳性乳腺癌模型中，禁食期间GR驱动的基因程序被选择性激活，而敲除GR会削弱禁食联合他莫昔芬的抗肿瘤作用。外源性给予GR配体可重现禁食增强的抗雌激素效应，从而促进肿瘤退缩。接受周期性模拟禁食饮食的患者表现出血清孕激素和皮质醇浓度升高。此外，从接受模拟禁食饮食的患者肿瘤样本中观察到GR激活与增殖标志物呈负相关，验证了动物模型中的发现。研究结果表明，GR激活在禁食增强乳腺癌内分泌治疗活性中起关键作用，并提示应评估糖皮质激素给药作为内分泌治疗辅助方案的可行性。

### 第二部分 AI 大师评价

该研究探索禁食对乳腺癌内分泌治疗疗效的影响，揭示了糖皮质激素受体在其中发挥核心作用。作者通过动物模型和临床样本结合的多层验证，证明禁食可诱导表观遗传重塑并增强内分泌治疗的抗肿瘤效应。研究创新性地阐明了代谢状态与激素信号轴之间的联系，提出糖皮质激素作为潜在辅助治疗的新思路。其局限性在于机制的临床转化仍需进一步研究。

---

## 39. 人类肠道 M 细胞类似树突状细胞并可呈递谷蛋白抗原

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372409)
**期刊：** Nature
**PMID：** 41372409
**DOI：** 10.1038/s41586-025-09829-8

### 第一部分 原文与翻译

**英文原标题：** Human gut M cells resemble dendritic cells and present gluten antigen.

> **英文摘要：**
> Microfold (M) cells are rare intestinal epithelial cells that reside in the follicle-associated epithelium of Peyer's patches. M cells transport luminal antigens to submucosal antigen-presenting cells. These insights primarily derive from transmission electron microscopy and studies using genetically modified mice. Here we establish an intestinal organoid model to study human M cells and reconstruct the differentiation trajectory of M cells through transcriptome profiling. The results indicate that as well as facilitating luminal antigen transport, human M cells also directly present antigens via the class II major histocompatibility complex (MHC-II). Notably, the related enterocytes only express MHC-II in chronic inflammatory states and do not express typical dendritic cell markers. Human M cells physiologically express a gene profile that resembles that of dendritic cells. Similar to dendritic cells, M cell development is induced by RANKL and CSF2 and requires the transcription factors SPIB and RUNX2. HLA-DQ2.5 M cells process and present gluten antigen as demonstrated in organoid-T cell co-culture assays. These findings suggest that M cells may have a central role in coeliac disease.

> **中文摘要：**
> 微褶皱（M）细胞是罕见的肠上皮细胞，位于派尔集合淋巴小结的滤泡相关上皮中。M 细胞将腔内抗原转运至黏膜下的抗原呈递细胞。这些认识主要来源于透射电子显微镜观察以及使用基因修饰小鼠的研究。在本研究中，我们建立了一种肠类器官模型用于研究人类 M 细胞，并通过转录组测序重建了 M 细胞的分化轨迹。结果显示，除了促进腔内抗原转运外，人类 M 细胞还可通过 II 类主要组织相容性复合体（MHC-II）直接进行抗原呈递。值得注意的是，相关的肠上皮细胞仅在慢性炎症状态下表达 MHC-II，且不表达典型的树突状细胞标志物。人类 M 细胞在生理条件下表现出类似树突状细胞的基因表达特征。与树突状细胞相似，M 细胞的发育受 RANKL 和 CSF2 诱导，并依赖转录因子 SPIB 和 RUNX2。HLA-DQ2.5 型 M 细胞在类器官—T 细胞共培养实验中被证实可加工并呈递谷蛋白抗原。这些发现提示，M 细胞可能在乳糜泻的发生中发挥核心作用。

### 第二部分 AI 大师评价

本研究通过建立人类肠道类器官模型，对 M 细胞的分化轨迹与功能进行了系统分析。研究发现 M 细胞不仅承担抗原转运功能，还具备通过 MHC-II 分子直接呈递抗原的能力，且其基因表达谱类似树突状细胞。该发现拓展了人类肠道免疫细胞功能的认知，并为阐明乳糜泻等免疫相关肠病的发病机制提供了新思路。然而，该模型仍需进一步验证其在体内环境中的代表性与功能一致性。

---

## 40. 细胞质细菌受体 ALPK1 激动剂可诱导抗肿瘤免疫。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372408)
**期刊：** Nature
**PMID：** 41372408
**DOI：** 10.1038/s41586-025-09828-9

### 第一部分 原文与翻译

**英文原标题：** Agonists for cytosolic bacterial receptor ALPK1 induce antitumour immunity.

> **英文摘要：**
> Targeting innate immunity holds promise in cancer immunotherapy, particularly in improving checkpoint inhibitors. However, the use of agonists of the promising innate receptors TLRs and STING is facing challenges. Here we examined the antitumour function of the α-kinase 1 (ALPK1) receptor for bacterial ADP-heptose (ADP-Hep). Treatment of mice with ADP-Hep induced multiple proinflammatory factors including CXCL10 and CCL2, and stimulated Alpk1-dependent antitumour immunity. Mice bearing a gain-of-function ALPK1(T237M) disease variant also rejected grafted tumours. Using medicinal chemistry, we identified a more potent analogue, UDSP-Hep. In contrast to ADP-Hep, UDSP-Hep distinguished Alpk1 polymorphism, which correlates with mouse susceptibility to bacteria-associated colitis. UDSP-Hep exhibited a stronger Alpk1-mediated antitumour effect and synergized with checkpoint inhibitors. The effect required CD8 T cells, dendritic cells (DCs) and macrophages, and was sensitive to antibodies that block CXCL10 or CCL2 function. ALPK1 agonists activated DCs for cross-presentation, promoting tumour-specific T cell expansion in the tumour-draining lymph nodes. ALPK1 has wider expression than STING in non-immune cells with a distinct inflammatory signature. UDSP-Hep is differentiated from STING agonists in stimulating tumour-cell antigen presentation, macrophage-DC cross-priming and protective memory T cell differentiation, and it does not induce T cell apoptosis. Our study elucidates the antitumour effect of ALPK1 agonism and suggests the potential of ALPK1 agonists in cancer immunotherapy.

> **中文摘要：**
> 靶向天然免疫在癌症免疫治疗中具有潜力，尤其是在提高检查点抑制剂疗效方面。然而，针对有前景的天然受体（如 TLRs 和 STING）的激动剂使用仍面临挑战。本研究探讨了细菌 ADP-庚糖（ADP-Hep）受体 α-激酶 1（ALPK1）的抗肿瘤功能。以 ADP-Hep 处理小鼠可诱导多种促炎因子（包括 CXCL10 和 CCL2）的表达，并激活依赖 Alpk1 的抗肿瘤免疫。携带获得功能型突变 ALPK1(T237M) 的小鼠同样能排斥移植性肿瘤。通过药物化学，我们鉴定出一种更强效的类似物 UDSP-Hep。与 ADP-Hep 相比，UDSP-Hep 能区分 Alpk1 的多态性，该多态性与小鼠对细菌相关性结肠炎的易感性相关。UDSP-Hep 展示出更强的 Alpk1 介导的抗肿瘤作用，并与检查点抑制剂有协同效应。该效应依赖于 CD8 T 细胞、树突状细胞（DCs）和巨噬细胞，并对阻断 CXCL10 或 CCL2 功能的抗体敏感。ALPK1 激动剂可激活用于交叉呈递的 DCs，促进肿瘤引流淋巴结中肿瘤特异性 T 细胞的扩增。与 STING 相比，ALPK1 在非免疫细胞中具有更广泛的表达及独特的炎症特征。UDSP-Hep 在刺激肿瘤细胞抗原呈递、巨噬细胞-DC 交叉启动和保护性记忆 T 细胞分化方面区别于 STING 激动剂，且不会诱导 T 细胞凋亡。本研究阐明了 ALPK1 激动作用的抗肿瘤效应，并提示 ALPK1 激动剂在癌症免疫治疗中的潜在应用价值。

### 第二部分 AI 大师评价

该研究聚焦于通过激活细胞质受体 ALPK1 途径来增强抗肿瘤免疫的新策略。作者发现细菌来源的 ADP-Hep 及其优化衍生物 UDSP-Hep 能显著诱导多种促炎因子，激活 DC 介导的交叉呈递，并促进 CD8 T 细胞依赖的抗肿瘤反应。相比传统 STING 激动剂，UDSP-Hep 在抗原呈递和记忆 T 细胞分化上具有优势，且不诱导 T 细胞凋亡。该工作揭示了 ALPK1 激动剂作为一种新型免疫治疗靶点的潜力，但还需进一步验证其在人体免疫系统中的安全性与疗效。

---

## 41. 揭示LINE-1在肺腺癌演化中的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372401)
**期刊：** Nature
**PMID：** 41372401
**DOI：** 10.1038/s41586-025-09825-y

### 第一部分 原文与翻译

**英文原标题：** Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma.

> **英文摘要：**
> Understanding lung cancer evolution can identify tools for intercepting its growth. Here, in a landscape analysis of 1,024 lung adenocarcinomas (LUADs) with deep whole-genome sequencing integrated with multiomic data, we identified 542 LUADs with a diverse clonal architecture. In this group, we observed divergent evolutionary trajectories based on tobacco smoking exposure, ancestry and sex. LUAD from smokers showed an abundance of tobacco-related C:G>A:T driver mutations in KRAS and short subclonal diversification. LUAD in people who have never smoked (hereafter, never-smokers) showed early occurrence of copy-number alterations and EGFR mutations associated with SBS5 and SBS40a mutational signatures. Tumours containing EGFR mutations exhibited long latency, particularly in female individuals of European-ancestry. Tumours from Asian never-smokers showed a short clonal evolution. Importantly, we found that the mutational signature ID2 is a marker of a previously unrecognized mechanism for LUAD evolution. Tumours with ID2 showed short latency and high long interspersed nuclear element-1 (LINE-1, hereafter L1) retrotransposon activity linked to L1 promoter demethylation. These tumours exhibited an aggressive phenotype with genomic instability, elevated hypoxia scores, low neoantigen burden, metastasis propensity and poor overall survival. Reactivated L1-retrotransposition-induced mutagenesis probably contributes to the mutational signature ID2, including through the regulation of the transcriptional factor ZNF695, a member of the KZFP family. The complex nature of LUAD evolution creates both challenges and opportunities for screening and treatment plans.

> **中文摘要：**
> 理解肺癌的演化过程有助于确定遏制其生长的工具。在对1024例肺腺癌（LUAD）进行深度全基因组测序并整合多组学数据的全景分析中，我们识别出542例具有多样克隆结构的LUAD。在该组中，我们观察到基于烟草暴露、祖源和性别的不同演化轨迹。吸烟者的LUAD表现出KRAS基因中富含与烟草相关的C:G>A:T驱动突变以及较短的亚克隆多样化过程。而从未吸烟者（以下简称“从未吸烟者”）的LUAD则表现出早期拷贝数改变和与SBS5及SBS40a突变特征相关的EGFR突变。携带EGFR突变的肿瘤显示出较长的潜伏期，尤其是在具有欧洲血统的女性个体中。亚洲从未吸烟者的肿瘤则呈现较短的克隆演化。重要的是，我们发现突变特征ID2是LUAD演化中一种此前未被识别的机制的标志。携带ID2的肿瘤表现出短潜伏期和高水平的长散在核元件-1（LINE-1，以下简称L1）逆转座子活性，与L1启动子去甲基化相关。这些肿瘤具有侵袭性表型，包括基因组不稳定、高缺氧评分、低新抗原负荷、易转移倾向及总体生存不良。被再激活的L1逆转座子介导的突变可能促成突变特征ID2的形成，其中包括通过调控KZFP家族成员转录因子ZNF695实现的机制。LUAD复杂的演化特性为筛查和治疗方案带来了挑战与机遇。

### 第二部分 AI 大师评价

本研究通过大规模肺腺癌全基因组测序与多组学整合分析，揭示了不同吸烟状态、性别及祖源背景下肺腺癌演化的差异性。作者发现突变特征ID2可作为一种新型的肺腺癌演化机制标志，并与LINE-1逆转座子活化和启动子去甲基化密切相关。研究指出L1活化型肿瘤具有侵袭性强、预后差等特点，提示其在治疗和监测中具有潜在意义。该工作创新性地将转座子活动与肿瘤演化机制相联系，但仍需进一步功能验证以明确因果关系。

---

## 42. MLH1异常胞质定位定义了一类促发乳腺癌复发的细胞群体

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372237)
**期刊：** Nature communications
**PMID：** 41372237
**DOI：** 10.1038/s41467-025-67257-8

### 第一部分 原文与翻译

**英文原标题：** Aberrant cytoplasmic localization of MLH1 characterizes a cell population that seeds breast cancer recurrence.

> **英文摘要：**
> Estrogen receptor-positive breast cancer remains a leading cause of cancer-related death in women, with mortality largely driven by late recurrence of treatment-resistant disease. Loss of MLH1 promotes resistance to estrogen-targeting therapies by uncoupling cell cycle progression from estrogen regulation. Here, we show that even when MLH1 is abundantly expressed, aberrant cytoplasmic localization in a subset of tumor cells drives endocrine therapy resistance by enabling estrogen-independent growth. This resistance arises from failure to undergo robust cell cycle arrest in response to endocrine therapy, creating acute dependency on CDK4/6 activity. Consequently, CDK4/6 inhibitors induce strong regression in cells with cytoplasmic MLH1 compared to cells with nuclear MLH1. As cytoplasmic localization occurs in ~11% of ER+ patients, it represents a contributor to MLH1 dysregulation. Incorporating cytoplasmic MLH1 localization into diagnostics could guide the use of CDK4/6 inhibitors in this hard-to-treat subset.

> **中文摘要：**
> 雌激素受体阳性乳腺癌仍然是女性癌症相关死亡的主要原因之一，其死亡率主要由治疗耐药疾病的晚期复发所驱动。MLH1的缺失通过使细胞周期进程与雌激素调控脱耦而促进对靶向雌激素治疗的耐药。在本研究中，我们发现即使MLH1丰度较高，其在部分肿瘤细胞中的异常胞质定位也能通过促进雌激素非依赖性生长而驱动内分泌治疗耐药。这种耐药性源自细胞未能在内分泌治疗反应中经历有效的细胞周期阻滞，从而形成对CDK4/6活性的急性依赖。结果显示，与具有核内MLH1的细胞相比，CDK4/6抑制剂在具有胞质MLH1的细胞中可诱导显著的肿瘤退缩。由于胞质定位约发生在约11%的ER阳性患者中，它构成MLH1失调的重要因素。将MLH1胞质定位纳入诊断流程，可能有助于指导在这一难治亚群中使用CDK4/6抑制剂。

### 第二部分 AI 大师评价

本研究聚焦于雌激素受体阳性乳腺癌中MLH1亚细胞定位异常与复发的关系。研究团队发现，即便MLH1表达水平充足，其异常定位至胞质的细胞亚群仍导致内分泌治疗耐药，并形成对CDK4/6活性的依赖。该发现揭示了复发性乳腺癌中的新的分子机制，并提示CDK4/6抑制剂可能在特定MLH1胞质定位患者中具有治疗潜力。研究的创新之处在于将MLH1定位异常与临床药物反应直接关联，然而仍需进一步临床验证以确立其预测与指导治疗的应用价值。

---

## 43. 将临床安全药物重新用于调控 CRISPR 基因组编辑中 DNA 修复通路选择和合成致死性研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372233)
**期刊：** Nature communications
**PMID：** 41372233
**DOI：** 10.1038/s41467-025-67243-0

### 第一部分 原文与翻译

**英文原标题：** Repurposing clinically safe drugs for DNA repair pathway choice in CRISPR genome editing and synthetic lethality.

> **英文摘要：**
> We evaluate the effect of most FDA-approved drugs (>7,000 conditions) on double-strand DNA break repair pathways by analyzing mutational outcomes in human induced pluripotent stem cells. We identify drugs that can be repurposed as inhibitors and enhancers of repair outcomes attributed to non-homologous and microhomology-mediated end joining (NHEJ, MMEJ), and homology-directed repair (HDR). We also identify functions of the proteins estrogen receptor 2 (ESR2) and aldehyde oxidase 1 (AOX1), affecting several key DNA repair proteins, such as ATM and 53BP1. Silencing of ESR2 can have a synergistic effect on increasing HDR when combined with NHEJ inhibition (mean 4.6-fold increase). We further identify drugs that induce synthetic lethality when NHEJ or HDR is blocked and may therefore be candidates for precision medicine. We anticipate that the ability to modulate the DNA repair outcomes with clinically safe drugs will help disease modeling, gene therapy, chimeric antigen receptor immunotherapy, and cancer treatment.

> **中文摘要：**
> 我们通过分析人诱导多能干细胞中的突变结果，评估了大多数获得 FDA 批准的药物（涉及超过7,000种疾病）对 DNA 双链断裂修复通路的影响。我们鉴定出可重新利用为修复结果抑制剂或增强剂的药物，这些修复结果包括非同源末端连接（NHEJ）、微同源介导末端连接（MMEJ）以及同源重组修复（HDR）。我们还发现了雌激素受体2（ESR2）和醛氧化酶1（AOX1）两种蛋白的功能，它们影响多种关键的 DNA 修复蛋白，如 ATM 和 53BP1。当 ESR2 被沉默并与 NHEJ 抑制联合使用时，可产生协同效应，使 HDR 水平平均提高 4.6 倍。我们进一步鉴定出在 NHEJ 或 HDR 被阻断时可诱导合成致死的药物，这些药物因此可能成为精确医学的候选者。我们预期，利用临床安全药物调控 DNA 修复结果的能力，将有助于疾病建模、基因治疗、嵌合抗原受体免疫疗法以及癌症治疗。

### 第二部分 AI 大师评价

本研究系统性评估了 FDA 批准药物对 DNA 双链断裂修复通路的影响，揭示了可重新利用的药物在调控 NHEJ、MMEJ 和 HDR 等修复机制中的作用。研究发掘了 ESR2 和 AOX1 在 DNA 修复调控中的新功能，并通过联合抑制产生显著的 HDR 增强效果。该工作还识别出可在特定修复通路受阻时诱导合成致死的药物，为精准医疗提供了新思路。研究的创新性在于将药物再利用与基因编辑修复通路调控相结合，但其转化应用仍需更多体内验证。

---

## 44. 脂质氧自由基防御通路的识别及其表观遗传调控机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372219)
**期刊：** Nature communications
**PMID：** 41372219
**DOI：** 10.1038/s41467-025-67304-4

### 第一部分 原文与翻译

**英文原标题：** Identification of a lipid oxygen radical defense pathway and its epigenetic control.

> **英文摘要：**
> Membrane phospholipids are vulnerable to oxidative radicals, and uncontrolled lipid peroxidation affects cell viability. Cells have evolved quality control and defense mechanisms, of which the genetic regulation is not fully understood. Here, we identify what we have coined the Lipid Oxygen Radical Defense (LORD) pathway. It is epigenetically repressed by a complex comprising the KRAB-zinc finger protein ZNF354A, the scaffold protein KAP1/TRIM28, the histone methyltransferase SETDB1, and the transcriptional activator ATF2. Upon lipid peroxide accumulation, p38- and JNK-dependent phosphorylation of ATF2, KAP1/TRIM28, and ZNF354A leads to disassembly of the repressive complex, releasing ZNF354A from specific DNA loci and activating a network of protective genes, including NRF2 targets. The pathway affects the cellular sensitivity to oxidative stress and ferroptosis, revealing a previously uncharacterized layer of epigenetic control in lipid quality control and damage repair. This positions the LORD pathway as a promising therapeutic target for diseases linked to chronic inflammation, neurodegeneration and cancer.

> **中文摘要：**
> 膜磷脂易受氧化自由基的损伤，而不受控的脂质过氧化会影响细胞活力。细胞已经进化出质量控制和防御机制，但其遗传调控机制尚未被完全理解。在本研究中，我们鉴定出一种被称为脂质氧自由基防御（LORD）通路的新机制。该通路受到一个由KRAB-锌指蛋白ZNF354A、支架蛋白KAP1/TRIM28、组蛋白甲基转移酶SETDB1及转录激活因子ATF2组成的复合物的表观遗传性抑制。当脂质过氧化物积累时，ATF2、KAP1/TRIM28和ZNF354A在p38和JNK依赖性磷酸化的作用下，导致该抑制复合物的解体，从而使ZNF354A从特定DNA位点解离，并激活包括NRF2靶基因在内的保护性基因网络。该通路影响细胞对氧化应激和铁死亡的敏感性，揭示了脂质质量控制和损伤修复中先前未表征的表观遗传调控层。此发现将LORD通路定位为与慢性炎症、神经退行性疾病及癌症相关疾病的潜在治疗靶点。

### 第二部分 AI 大师评价

该研究识别并命名了脂质氧自由基防御（LORD）通路，揭示其受特定蛋白复合物的表观遗传性抑制。通过解析脂质过氧化积累后p38和JNK信号调控复合物解体的机制，作者揭开了脂质氧化应激响应的新层次。结果强调LORD通路在调节氧化应激、铁死亡及相关疾病中的关键作用，为理解脂质稳态的表观遗传调控提供了新视角。研究创新性强，但仍需进一步验证其在疾病模型和临床转化中的功能。

---

## 45. 脑干结构的遗传构成

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372214)
**期刊：** Nature communications
**PMID：** 41372214
**DOI：** 10.1038/s41467-025-67221-6

### 第一部分 原文与翻译

**英文原标题：** The genetic architecture of brainstem structures.

> **英文摘要：**
> The brainstem houses numerous nuclei and tracts that serve vital functions. Genome-wide associations with brainstem substructure volumes have been explored in European individuals, yet other ancestries remain under-represented. Here, we conduct cross-ancestry genome-wide association meta-analyses in 103,098 individuals for brainstem and 78,062 individuals for eight substructure volumes, including 7094 Chinese Han individuals. We identify 713 locus-trait associations with brainstem and substructure volumes at P < 5.56 ×10, comprising 569 new associations. Two associations show different effect sizes, while 496 associations have similar effect sizes between ancestries. We prioritize 186 genes associated with brainstem volumetric traits. We find both shared and distinct genetic loci, genes, and pathways for midbrain, pons, and medulla volumes, along with the shared genetic architectures related to disease phenotypes and physiological functions. The results provide new insights into the genetic architectures of brainstem and substructure volumes and their genetic associations with brainstem physiologies and pathologies.

> **中文摘要：**
> 脑干包含众多具有重要功能的神经核团和神经束。此前的全基因组关联研究主要在欧洲人群中探索了脑干各亚结构体积的遗传相关性，而其他祖源群体的研究仍然不足。本研究在来自103,098名个体的脑干以及78,062名个体（其中包括7094名中国汉族个体）的八个亚结构体积数据上，进行了跨祖源的全基因组关联Meta分析。研究共鉴定出713个与脑干及其亚结构体积相关的位点-性状关联（P < 5.56 ×10），其中包括569个新的关联。两处关联在不同祖源间显示出效应量差异，而496处关联在不同祖源间的效应量相似。研究共优先筛选出186个与脑干体积相关的基因。结果发现中脑、脑桥及延髓体积存在共性与特异的遗传位点、基因及通路，同时揭示了与疾病表型及生理功能相关的共享遗传构架。这些发现为理解脑干及其下属亚结构体积的遗传基础及其在生理与病理中的遗传关联提供了新的见解。

### 第二部分 AI 大师评价

该研究旨在系统解析脑干及其亚结构体积的遗传构架，采用跨祖源的全基因组关联Meta分析，样本量庞大，纳入中国汉族个体，弥补了以往研究的种群局限。研究发现了大量新的位点-性状关联，揭示中脑、脑桥、延髓之间既有共享又有差异的遗传机制，并识别出关键基因及通路。其创新性在于具备全球多祖源视角，为脑干相关疾病的遗传学探究提供了重要基础。可能的局限包括非欧洲样本人群样本量仍相对较小及功能验证尚待深入。

---

## 46. 揭示成人人体球囊的异质性及其损伤反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372202)
**期刊：** Nature communications
**PMID：** 41372202
**DOI：** 10.1038/s41467-025-66358-8

### 第一部分 原文与翻译

**英文原标题：** Revealing heterogeneity and damage response in the adult human utricle.

> **英文摘要：**
> The human utricle is a vestibular organ essential for balance, a function that declines with age. With the aging population projected to double to 2 billion by 2050 and no pharmaceutical or biological treatments available, balance disorders represent a significant unmet medical need. The utricle is composed of sensory and non-sensory cells, which are closely related. Non-sensory cells have limited capacity to regenerate sensory cells and, therefore, are a relevant therapeutic target. In this work, we profile the cellular and transcriptional landscape of the adult human utricle and its early response to ototoxic damage using bulk and single-cell RNA-sequencing of patient-derived samples. We identify six transcriptionally distinct non-sensory cell types, including a previously uncharacterized supporting cell-like population, demonstrating utricular heterogeneity. Following aminoglycoside-induced damage, we detect early transcriptional changes consistent with a capacity to respond to ototoxic damage within 24 hours and potentially initiate a regenerative response via an early-responding cell population, providing a foundation for regenerative strategies for balance recovery.

> **中文摘要：**
> 人体球囊是维持平衡所必需的前庭器官，其功能会随年龄增长而下降。预计到2050年，老龄人口将增至20亿，而目前尚无药物或生物学治疗手段，因此平衡障碍构成了显著未满足的医疗需求。球囊由感觉细胞和非感觉细胞组成，这两类细胞关系密切。非感觉细胞具有有限的再生感觉细胞的能力，因此是一个具有潜在临床意义的治疗靶点。在本研究中，我们利用源自患者的样本，通过整体及单细胞RNA测序技术，描绘了成人球囊的细胞与转录图谱及其对耳毒性损伤的早期反应。我们识别出六种转录学上有明显差异的非感觉细胞类型，其中包括一种此前未被描述的类似支持细胞的群体，揭示了球囊的异质性。在氨基糖苷类药物诱导损伤后，我们检测到在24小时内出现的早期转录变化，与对耳毒性损伤产生反应的能力相一致，并可能通过一类早期反应细胞群体启动再生反应，为平衡功能恢复的再生策略奠定基础。

### 第二部分 AI 大师评价

本研究揭示了成人人体球囊在细胞组成和分子层面的高度异质性，并首次展示其在耳毒性损伤后24小时内的早期转录应答。通过结合整体与单细胞RNA测序，作者识别了六种不同的非感觉细胞类型及一种未被表征的支持细胞样亚群，丰富了对平衡器官细胞生物学的理解。该研究为探索平衡功能再生策略提供了基础，但其局限在于样本来源受限及功能验证尚待进一步实验支持。

---

## 47. PTEN 调控迷走神经-胰岛素信号以优化自主神经输出，从而决定外周炎症与代谢稳态。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372197)
**期刊：** Nature communications
**PMID：** 41372197
**DOI：** 10.1038/s41467-025-67192-8

### 第一部分 原文与翻译

**英文原标题：** PTEN regulates vagal-insulin signaling to optimize autonomic output determining peripheral inflammatory and metabolic homeostasis.

> **英文摘要：**
> The vagus nerve (VN) is a major component of the parasympathetic nervous system that regulates glucose and energy homeostasis. However, the specific molecular signaling pathways within the VN that regulates this homeostasis remain unclear. Here, we show that vagal neuron-specific deletion of phosphatase and tensin homolog (Pten), the endogenous negative regulator of PI3K, led to increased vagal output. Intriguingly, dopaminergic signaling genes were upregulated, correlating with elevated sympathetic nerve density and increased norepinephrine levels in adipose tissue of vagal Pten-deficient mice. These mice were also protected against high-fat diet-induced obesity, insulin resistance, and systemic inflammation. To investigate insulin-specific PI3K signaling within the VN, we generated mice with vagal neuron-specific insulin receptor deletion that resulted in exacerbation of metabolic defects, which was rescued by concomitant Pten deletion. In summary, we show that insulin-PI3K-PTEN axis within vagal neurons is essential in optimizing the autonomic output that determines peripheral inflammatory and metabolic homeostasis.

> **中文摘要：**
> 迷走神经（VN）是副交感神经系统的重要组成部分，负责调节葡萄糖和能量稳态。然而，VN 内部调控此稳态的特定分子信号通路仍不清楚。在本研究中，我们发现，对磷酸酶及张力蛋白同源物（Pten）这一内源性 PI3K 负调控因子进行迷走神经元特异性缺失，可导致迷走神经输出增加。有趣的是，多巴胺能信号相关基因上调，这与迷走 Pten 缺失小鼠中交感神经密度升高及脂肪组织中去甲肾上腺素水平增加相对应。这些小鼠还表现出对高脂饮食诱导的肥胖、胰岛素抵抗及全身炎症的保护作用。为探究 VN 内胰岛素特异性 PI3K 信号，我们构建了迷走神经元特异性胰岛素受体缺失小鼠，结果出现代谢缺陷加重的现象，但联合删除 Pten 后可恢复这些缺陷。总而言之，我们的结果表明，迷走神经元中的胰岛素-PI3K-PTEN 轴对于优化自主神经输出、维持外周炎症和代谢稳态至关重要。

### 第二部分 AI 大师评价

本研究揭示了 PTEN 在迷走神经元内通过调控胰岛素-PI3K 信号通路来平衡自主神经输出的关键作用，从而维持外周炎症及代谢稳态。研究采用神经元特异性基因敲除小鼠模型，系统评估了 PI3K-PTEN 信号轴对代谢、炎症及交感-副交感神经协调的影响。结果显示，Pten 缺失增强了迷走输出并改善了高脂饮食相关代谢异常。创新之处在于首次建立了胰岛素信号与迷走神经调控代谢稳态的直接分子联系，但其在人体及慢性代谢疾病中的可转化性仍有待进一步验证。

---

## 48. CK2 激酶介导的 PA28γ 磷酸化促进头颈鳞状细胞癌的形成与进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372189)
**期刊：** Nature communications
**PMID：** 41372189
**DOI：** 10.1038/s41467-025-67131-7

### 第一部分 原文与翻译

**英文原标题：** Phosphorylation of PA28γ by CK2 kinase facilitates HNSCC tumor formation and progression.

> **英文摘要：**
> Proteasome activator 28 subunit gamma (PA28γ) attracts considerable attention for its ability to regulate multiple molecules involved in tumor progression. However, its intrinsic activation and functional regulatory mechanisms in the regulation of tumor growth remain incompletely understood. Here, using head and neck squamous cell carcinoma (HNSCC) as a model, we identify phosphorylation at the T23 site of PA28γ, a modification that is highly expressed across pan-cancer types and associated with poor prognosis. Notably, phosphorylation-deficient PA28γ-T23 mutant mice exhibit resistance to carcinogen-induced HNSCC tumors, whereas the phosphomimetic PA28γ-T23 mutant promotes tumor formation and progression. We subsequently explore the underlying mechanism and find that casein kinase 2 (CK2) mediates PA28γ-T23 phosphorylation, which regulates the abundance of growth-related E4F transcription factor 1 (E4F1) through the PA28γ-proteasome pathway. These findings highlight PA28γ-T23 phosphorylation as a crucial pro-oncogenic signal and an unfavorable prognostic indicator across various cancers and underscore its potential as a target for early cancer intervention and treatment.

> **中文摘要：**
> 蛋白酶体激活因子28γ亚基（PA28γ）因其调控多种参与肿瘤进展的分子而备受关注。然而，其内在的激活及功能调控机制在肿瘤生长中的作用仍未被完全阐明。在此，研究者以头颈鳞状细胞癌（HNSCC）为模型，鉴定出 PA28γ 在 T23 位点的磷酸化修饰，该修饰在多种癌症类型中高表达，并与不良预后相关。值得注意的是，缺乏磷酸化的 PA28γ-T23 突变小鼠对致癌物诱导的 HNSCC 肿瘤表现出抗性，而模拟磷酸化的 PA28γ-T23 突变体则促进肿瘤的形成与进展。进一步的机制研究发现，酪蛋白激酶 2（CK2）介导 PA28γ-T23 的磷酸化，并通过 PA28γ-蛋白酶体通路调控与细胞生长相关的 E4F 转录因子 1（E4F1）的丰度。这些结果揭示了 PA28γ-T23 磷酸化是一个关键的促癌信号及不良预后指标，并强调其作为早期癌症干预和治疗潜在靶点的重要性。

### 第二部分 AI 大师评价

本研究聚焦于 PA28γ 的功能磷酸化修饰机制，揭示 CK2 介导的 T23 位点磷酸化在头颈鳞状细胞癌中的致癌作用。作者通过遗传模型验证磷酸化缺失与模拟突变在肿瘤形成上的对比效应，并进一步解析其通过 PA28γ-蛋白酶体通路调控 E4F1 水平的分子机制。该研究创新性地将 PA28γ 磷酸化确立为跨癌种的促肿瘤信号和预后标志。虽然机制阐释较为深入，但对临床转化潜力及不同癌种中具体调控差异的探讨仍需进一步研究。

---

## 49. MSA α‑突触核蛋白聚集体的种子扩增保持其来源于脑组织聚集体的生物学与结构特性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372188)
**期刊：** Nature communications
**PMID：** 41372188
**DOI：** 10.1038/s41467-025-66146-4

### 第一部分 原文与翻译

**英文原标题：** Seed amplification of MSA alpha-synuclein aggregates preserves the biological and structural properties of brain-derived aggregates.

> **英文摘要：**
> Parkinson's disease (PD), Dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), are characterized by the misfolding and aggregation of alpha-synuclein (αSyn). Compelling evidence showed that αSyn aggregates exist as distinct conformational strains in different synucleinopathies. Recently, we reported that the αSyn Seed Amplification Assay (αSyn-SAA) can amplify and distinguish αSyn strains from PD and MSA. In this study, we investigate whether MSA-seeded, SAA-amplified αSyn fibrils retain the biological and structural properties of the αSyn seeds present in MSA brains. We study the biological activities of both brain-derived and SAA-amplified αSyn aggregates using an αSyn "biosensor" cell model and a synucleinopathy transmission mouse model. Our in vitro and in vivo findings reveal that the SAA-amplified αSyn fibrils preserve the biological properties of the brain-derived MSA strain. Detailed analyses of the in vivo studies demonstrate that both brain-derived and SAA-generated αSyn aggregates induce a similar disease, with comparable incubation periods, neuropathological damages and clinical manifestations. High-resolution cryo-EM analysis of SAA-amplified αSyn fibrils demonstrates that their conformation at the protofilament level closely resembles one of the αSyn filaments previously identified in MSA patient brains. Our findings suggest that SAA can amplify disease-specific misfolded αSyn conformation while preserving its main biological properties.

> **中文摘要：**
> 帕金森病（PD）、路易体痴呆（DLB）和多系统萎缩（MSA）的特征是α‑突触核蛋白（αSyn）的错误折叠与聚集。大量证据表明，αSyn聚集物在不同的突触核蛋白病中以不同的构象株态存在。我们最近报道，αSyn种子扩增分析（αSyn‑SAA）能够扩增并区分来自PD和MSA的αSyn株型。在本研究中，我们探讨由MSA种子驱动、经SAA扩增的αSyn纤维是否保留了MSA脑中αSyn种子的生物学和结构特性。我们利用αSyn“生物传感器”细胞模型和突触核蛋白病传递小鼠模型，研究脑源性与SAA扩增的αSyn聚集物的生物学活性。我们的体外与体内结果显示，SAA扩增的αSyn纤维保留了脑源性MSA株的生物学特性。对体内研究的详细分析表明，无论脑源性还是SAA生成的αSyn聚集物，均可诱发类似的疾病，表现为相近的潜伏期、神经病理损伤以及临床表现。高分辨率冷冻电镜分析显示，SAA扩增的αSyn纤维在原丝水平的构象与此前在MSA患者脑中鉴定的某一αSyn丝状体高度相似。我们的研究结果提示，SAA技术在扩增疾病特异性错误折叠的αSyn构象时，能够保持其主要生物学特性。

### 第二部分 AI 大师评价

本研究旨在验证αSyn种子扩增分析（SAA）是否能够保留多系统萎缩（MSA）相关αSyn聚集体的疾病特异性特征。作者通过细胞模型和动物模型，比较脑源性与SAA扩增的αSyn聚集物的生物学活性，并结合冷冻电镜进行结构解析。结果表明，SAA扩增的纤维能够维持原始MSA株的病理学与构象特征，进一步支持SAA可作为研究αSyn病理株的可靠工具。该研究在疾病模型一致性验证及结构层面具有创新性，但仍需探讨其在不同个体和疾病阶段的适用性。

---

## 50. SLFN11 抑制 RFWD3–PRIMPOL DNA 损伤耐受通路，以限制复制应激下的间隙 DNA 合成。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372167)
**期刊：** Nature communications
**PMID：** 41372167
**DOI：** 10.1038/s41467-025-66068-1

### 第一部分 原文与翻译

**英文原标题：** SLFN11 counteracts the RFWD3-PRIMPOL DNA damage tolerance axis to restrain gapped DNA synthesis in response to replication stress.

> **英文摘要：**
> Schlafen family member 11 (SLFN11) expression sensitizes cells to a spectrum of DNA-damaging chemotherapies. Previous studies have shown that SLFN11 is recruited to stalled replication forks in response to replication stress; however, the role of SLFN11 at stressed replication forks remains unclear. Using single-molecule DNA fiber analysis and super-resolution microscopy to interrogate the dynamics of individual replication forks, we show that SLFN11 acts upon stalled replication forks to suppress efficient fork restart. In the absence of SLFN11 expression, fork restart proceeds through a pathway involving the ubiquitin ligase RFWD3 and the DNA primase-polymerase PRIMPOL to facilitate gapped DNA synthesis, thereby ensuring that cells do not accumulate replication-associated DNA damage. SLFN11 antagonizes this pathway by disrupting recruitment of RFWD3 and PRIMPOL to stalled forks in a manner dependent on a functional ATPase domain and persistent fork localization, but not on tRNA hydrolysis or ssDNA binding. Collectively, our results provide a mechanistic basis for how SLFN11 can counteract DNA damage tolerance by suppressing the RFWD3-PRIMPOL fork restart pathway.

> **中文摘要：**
> Schlafen 家族成员 11（SLFN11）的表达可使细胞对多种 DNA 损伤类化疗药物更为敏感。先前研究表明，SLFN11 会在复制应激时被招募至停滞的复制叉，但其在应激复制叉中的具体作用尚不清楚。通过单分子 DNA 纤维分析与超分辨显微成像技术，对单个复制叉的动态进行研究，我们发现 SLFN11 作用于停滞的复制叉，以抑制复制叉的高效重启。在缺乏 SLFN11 表达的情况下，复制叉重启通过泛素连接酶 RFWD3 与 DNA 引发酶–聚合酶 PRIMPOL 参与的通路进行，从而促进间隙 DNA 合成，确保细胞不会积累与复制相关的 DNA 损伤。SLFN11 通过干扰 RFWD3 和 PRIMPOL 向停滞复制叉的募集来拮抗此通路，这一过程依赖于其具有功能性的 ATP 酶结构域及在复制叉上的持续定位，但与 tRNA 水解或单链 DNA 结合无关。综合来看，我们的研究揭示了 SLFN11 通过抑制 RFWD3–PRIMPOL 复制叉重启通路来抵消 DNA 损伤耐受的分子机制基础。

### 第二部分 AI 大师评价

该研究旨在揭示 SLFN11 在复制应激下的复制叉调控机制。作者利用单分子 DNA 纤维实验与超分辨显微技术，发现 SLFN11 能抑制复制叉重启，进而干扰 RFWD3–PRIMPOL 介导的 DNA 间隙合成通路。研究创新性地阐明了 SLFN11 抑制 DNA 损伤耐受的分子机制，为理解其在化疗敏感性中的作用提供了坚实依据。但仍需进一步研究以明确其在不同细胞类型及应激环境中的调控普适性。

---

## 51. 体内DNA甲基化的编辑

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372159)
**期刊：** Nature communications
**PMID：** 41372159
**DOI：** 10.1038/s41467-025-67222-5

### 第一部分 原文与翻译

**英文原标题：** Editing DNA methylation in vivo.

> **英文摘要：**
> DNA methylation is a crucial epigenetic mechanism that regulates gene expression. Precise editing of DNA methylation has emerged as a promising tool for dissecting its biological function. However, challenges in delivery have limited most applications of DNA methylation editing to in vitro systems. Here, we develop two transgenic mouse lines harboring an inducible dCas9-DNMT3A or dCas9-TET1 editor to enable tissue-specific DNA methylation editing in vivo. We demonstrate that targeted methylation of the Psck9 promoter in the liver of dCas9-DNMT3A mice results in decreased Pcsk9 expression and a subsequent reduction in serum low-density lipoprotein cholesterol level. Targeted demethylation of the Mecp2 promoter in dCas9-TET1 mice reactivates Mecp2 expression from the inactive X chromosome and rescues neuronal nuclear size in Mecp2 mice. Genome-wide sequencing analyses reveal minimal transcriptional off-targets, demonstrating the specificity of the system. These results demonstrate the feasibility and versatility of methylation editing, to functionally interrogate DNA methylation in vivo.

> **中文摘要：**
> DNA甲基化是一种调控基因表达的重要表观遗传机制。对DNA甲基化进行精确编辑已成为解析其生物学功能的有前景工具。然而，递送方式的挑战使得DNA甲基化编辑的大多数应用局限于体外系统。本研究建立了两种转基因小鼠系，分别携带可诱导的dCas9-DNMT3A或dCas9-TET1编辑器，从而实现体内特异组织的DNA甲基化编辑。我们证明，在dCas9-DNMT3A小鼠肝脏中靶向甲基化Psck9启动子可降低Pcsk9的表达，并进一步减少血清低密度脂蛋白胆固醇水平。在dCas9-TET1小鼠中靶向去甲基化Mecp2启动子可重新激活来自失活X染色体的Mecp2表达，并恢复Mecp2小鼠神经元核的大小。全基因组测序分析显示转录水平的非靶向效应极少，证明了该系统的特异性。这些结果表明甲基化编辑在体内功能解析中的可行性和多样性。

### 第二部分 AI 大师评价

本研究旨在开发可在体内实现组织特异性DNA甲基化编辑的系统。研究者通过构建可诱导的dCas9-DNMT3A和dCas9-TET1转基因小鼠，实现了DNA甲基化与去甲基化的精准控制。模型验证显示，该系统能有效调节目标基因表达并改善相关表型，且具有较高特异性。研究在体内表观遗传学干预技术上具有重要创新，为探究DNA甲基化的功能提供了有力工具，但未来仍需优化递送效率与长期安全性。

---

## 52. T细胞识别两种免疫优势性SARS-CoV-2核衣壳表位的克隆受限性与多样性的结构学洞见

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372155)
**期刊：** Nature communications
**PMID：** 41372155
**DOI：** 10.1038/s41467-025-66322-6

### 第一部分 原文与翻译

**英文原标题：** Structural insights into clonal restriction and diversity in T cell recognition of two immunodominant SARS-CoV-2 nucleocapsid epitopes.

> **英文摘要：**
> T cells play a crucial role in clearing SARS-CoV-2 and in forming long-term memory responses to that coronavirus. The highly immunogenic nucleocapsid (N) protein of SARS-CoV-2 is much more conserved than the spike (S) protein across variants of concern, making it an attractive vaccine target for activating cytotoxic CD8 T cells. Of particular interest are the immunodominant N epitopes LLL and SPR. Whereas LLL elicits a clonally restricted T cell response, the response to SPR is highly diverse. To understand the basis for this difference, here we determine structures of T cell receptors (TCRs) bound to LLL-HLA-A2 and SPR-HLA-B7, revealing the structural underpinnings of highly restricted Vα gene usage by LLL-specific TCRs, as well as multiple structural solutions to recognizing SPR and thereby generating a clonally diverse T cell response to that epitope. These structures also provide frameworks for understanding T cell recognition of SARS-CoV-2 variants and other coronaviruses. Finally, we compare the X-ray structures of TCR-LLL-HLA-A2 and TCR-SPR-HLA-B7 complexes with models predicted by multiple versions of AlphaFold, highlighting some success while showing room for improvement. Overall, our findings expand understanding of coronavirus T cell recognition, informing vaccine design and advances in computational modeling approaches.

> **中文摘要：**
> T细胞在清除SARS-CoV-2及形成针对该冠状病毒的长期记忆应答中起关键作用。SARS-CoV-2的高度免疫原性核衣壳（N）蛋白在各类关注变异株中相比刺突（S）蛋白保守性更高，使其成为激活细胞毒性CD8 T细胞的理想疫苗靶点。特别值得关注的是免疫优势性N表位LLL和SPR。LLL诱导的T细胞应答表现出克隆受限性，而SPR诱导的应答则高度多样。为理解这种差异的基础，本研究解析了LLL-HLA-A2和SPR-HLA-B7复合物结合的T细胞受体（TCR）结构，揭示了LLL特异性TCR对Vα基因高度受限性使用的结构基础，以及识别SPR所采用的多种结构解决方案，从而产生对该表位的克隆多样性T细胞应答。这些结构还为理解T细胞识别SARS-CoV-2变异株及其他冠状病毒提供了结构框架。最后，我们将TCR-LLL-HLA-A2与TCR-SPR-HLA-B7复合物的X射线结构与不同版本AlphaFold预测的模型进行比较，既凸显该算法的部分成功，也指出仍有改进空间。总体而言，我们的研究拓展了对冠状病毒T细胞识别机制的理解，为疫苗设计与计算建模方法的发展提供了启示。

### 第二部分 AI 大师评价

本研究旨在通过解析TCR与SARS-CoV-2核衣壳两种免疫优势表位复合物的结构，揭示T细胞识别的克隆受限性与多样性机制。作者通过高分辨率结构学手段揭示了LLL表位特异性TCR对Vα基因受限的结构基础，并展示了SPR表位存在多种结构识别模式。研究结果为理解T细胞应答的多样化提供了分子层面证据，同时也为冠状病毒疫苗设计与AI结构预测模型的改进提供了重要参考。其创新性在于结合结构生物学与人工智能模型验证，但受限于样本数与复合物类型的范围。

---

## 53. PIK3CA/AKT通路驱动横纹肌肉瘤的治疗耐药性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372143)
**期刊：** Nature communications
**PMID：** 41372143
**DOI：** 10.1038/s41467-025-66632-9

### 第一部分 原文与翻译

**英文原标题：** The PIK3CA/AKT pathway drives therapy resistance in rhabdomyosarcoma.

> **英文摘要：**
> Olaparib and temozolomide (OT) combination therapy is in clinical trial evaluation for rhabdomyosarcoma (RMS). Unfortunately, OT resistance has been reported in other cancers. Using preclinical mouse xenograft experiments, we show that OT effectively suppresses RMS growth, yet over half of RMS tumors develop resistance associated with transcriptomic changes that occur in the absence of recurrent genomic mutation. Importantly, most resistant RMS models upregulate the PIK3CA/AKT pathway, activating NRF2 phosphorylation and subsequent transcriptional expression of multidrug resistance ABC transporters. PIK3CA inhibitor alpelisib re-sensitizes resistant cells to OT by suppressing expression of ABC transporters. The combination of OT + alpelisib also kills RMS cells which are resistant to standard-of-care combination chemotherapy and was effective in preclinical xenograft mouse models at curbing tumor growth. Our work defines a common resistance pathway in RMS and has credentialled PIK3CA/AKT inhibition as a preclinical strategy to kill therapy resistant RMS.

> **中文摘要：**
> Olaparib与替莫唑胺（OT）的联合治疗正在针对横纹肌肉瘤（RMS）进行临床试验评估。不幸的是，在其他癌症中已有OT耐药性的报道。通过前临床小鼠异种移植实验，我们发现OT能够有效抑制RMS的生长，但超过一半的RMS肿瘤会在缺乏反复基因组突变的情况下出现与转录组变化相关的耐药性。重要的是，大多数耐药性RMS模型上调了PIK3CA/AKT通路，激活NRF2的磷酸化并继而诱导多药耐药性ABC转运蛋白的转录表达。PIK3CA抑制剂alpelisib通过抑制ABC转运蛋白的表达，使耐药细胞重新对OT产生敏感性。OT与alpelisib的联合治疗还能杀伤对标准化联合化疗耐药的RMS细胞，并在前临床小鼠异种移植模型中有效抑制肿瘤生长。我们的研究阐明了RMS中的一条共同耐药通路，并将PIK3CA/AKT抑制确立为一种用于消除耐药RMS的前临床策略。

### 第二部分 AI 大师评价

该研究旨在揭示横纹肌肉瘤中治疗耐药的分子机制。研究者通过前临床异种移植模型发现，OT治疗有效但易诱导无突变的转录组重编程，主要表现为PIK3CA/AKT通路的激活。进一步表明，PIK3CA抑制剂alpelisib可逆转OT耐药性，并增强对多药耐药细胞的杀伤作用。此研究在机制上提出了NRF2与ABC转运蛋白介导的耐药轴线，创新性地提示联合PIK3CA抑制可能成为应对RMS耐药的新策略，但其临床可行性仍需进一步验证。

---

## 54. RoCK 和 ROI：结合多重选择性转录本富集与特定区域测序的单细胞转录组学

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372142)
**期刊：** Nature communications
**PMID：** 41372142
**DOI：** 10.1038/s41467-025-66248-z

### 第一部分 原文与翻译

**英文原标题：** RoCK and ROI: single-cell transcriptomics with multiplexed enrichment of selected transcripts and region-specific sequencing.

> **英文摘要：**
> Single-cell profiling technologies allow exploring molecular mechanisms that drive development, health, and disease. However, current methods still fall short of profiling single cell transcriptomes comprehensively, with one major challenge being high non-detection rates of specific transcripts and transcript regions. Such information is often crucial to understanding the biology of cells. Here, we introduce RoCK and ROI (Robust Capture of Key transcripts and Regions Of Interest), a scRNA-seq workflow encompassing two techniques. RoCKseq uses targeted capture to enrich for key transcripts, thereby supporting the detection and identification of cell types and complex phenotypes in scRNA-seq experiments. ROIseq directs a subset of reads to a specific region of interest via selective priming. Importantly, RoCK and ROI enables retrieval of specific sequence information without compromising overall single cell transcriptome information. We validate RoCK and ROI across diverse biological systems highlighting the versatility and showing the power of the method to retrieve critical transcriptomic features.

> **中文摘要：**
> 单细胞分析技术使研究人员能够探究驱动发育、健康和疾病的分子机制。然而，现有方法仍难以全面解析单细胞转录组，其中一个主要挑战在于特定转录本及其区域的高漏检率。而这些信息往往对于理解细胞生物学至关重要。在本研究中，我们引入了 RoCK 和 ROI（Robust Capture of Key transcripts and Regions Of Interest），这是一种包含两项技术的单细胞 RNA 测序（scRNA-seq）流程。RoCKseq 采用靶向捕获以富集关键转录本，从而提高在 scRNA-seq 实验中对细胞类型和复杂表型的检测与识别能力。ROIseq 通过选择性引物设计，将部分测序读段定向至特定感兴趣区域。值得注意的是，RoCK 和 ROI 能够在不影响整体单细胞转录组信息的情况下，获取特定序列信息。我们在多种生物系统中验证了 RoCK 和 ROI 的可行性，展示了其方法的多样性及在获取关键转录组特征方面的强大能力。

### 第二部分 AI 大师评价

该研究旨在解决现有单细胞转录组技术中特定转录本检测率低的问题。作者提出的 RoCK 和 ROI 流程通过靶向捕获与区域特异测序结合，实现了在不牺牲全局信息的情况下增强关键转录信息的获取。方法学上融合了多重富集与区域定向策略，证明具有高度灵活性和适用性。此工作在单细胞测序解析深度与特异性方面具有显著创新，但未来实际应用中仍需要在通量与成本平衡之间进一步优化。

---

## 55. 一种复发性致病性BRCA2截短变异揭示了BRCA2-PCAF复合物在调控NF-κB驱动转录中的作用。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372141)
**期刊：** Nature communications
**PMID：** 41372141
**DOI：** 10.1038/s41467-025-67209-2

### 第一部分 原文与翻译

**英文原标题：** A recurrent pathogenic BRCA2 truncating variant reveals a role for BRCA2-PCAF complex in modulating NF-κB-driven transcription.

> **英文摘要：**
> Germline monoallelic truncating mutations in BRCA2, a key mediator of homologous recombination (HR), predispose individuals to breast and ovarian cancer. Tumorigenesis is typically attributed to biallelic inactivation, yet evidence suggests haploinsufficiency can suffice in some contexts. We model two pathogenic BRCA2 truncating variants in heterozygosis in non-tumorigenic breast epithelial cells. One variant is not expressed and confers PARP inhibitor (PARPi) sensitivity and reduced HR, indicating haploinsufficiency. In contrast, the other produces a truncated protein that rewires transcription in cells and tumors. Mechanistically, this truncated product acts as a dominant negative by forming abnormal oligomers with full-length BRCA2 and sequestering the PCAF acetyltransferase. This interaction reduces global histone H4 acetylation and suppresses NF-κB transcriptional activity, ultimately altering epithelial migration. Our findings reveal a BRCA2-PCAF axis that modulates NF-κB signaling, a process co-opted by a recurrent BRCA2 pathogenic variant.

> **中文摘要：**
> BRCA2是同源重组（HR）的关键介导因子，其种系单等位截短突变会使个体易患乳腺癌和卵巢癌。肿瘤发生通常归因于双等位基因失活，但有证据表明，在某些情境下单倍剂量不足即可导致致病效应。我们在非肿瘤性乳腺上皮细胞中以杂合状态模拟了两种致病性BRCA2截短变异。其中一种变异未被表达，表现为对PARP抑制剂（PARPi）敏感并伴随HR能力降低，提示存在单倍剂量不足。而另一种则产生截短蛋白，可在细胞和肿瘤中重塑转录。机制上，该截短产物通过与全长BRCA2形成异常寡聚体并结合PCAF乙酰转移酶而发挥显性负效应。这种相互作用降低了全局组蛋白H4乙酰化水平并抑制NF-κB转录活性，最终改变上皮细胞迁移。我们的研究结果揭示了调控NF-κB信号的BRCA2-PCAF轴，这一过程被一种复发性BRCA2致病性变异所劫持。

### 第二部分 AI 大师评价

本研究聚焦于BRCA2截短变异在转录调控及信号通路中的新功能，揭示了该蛋白通过与PCAF相互作用影响NF-κB依赖的转录活性。研究团队利用非肿瘤性乳腺上皮细胞模型比较了两种致病性截短变异，明确一种引起单倍剂量不足，另一种则引发蛋白互作及表观遗传改变。其发现丰富了对BRCA2功能异常机制及其在癌症发生中作用的新认识。研究创新性地提出了“BRCA2-PCAF-NF-κB轴”这一全新调控通路，但未来仍需在体内模型与临床样本中进一步验证其生物学与临床意义。

---

## 56. 患者来源的结肠上皮类器官揭示儿童溃疡性结肠炎中的脂质相关代谢功能障碍

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372139)
**期刊：** Nature communications
**PMID：** 41372139
**DOI：** 10.1038/s41467-025-65988-2

### 第一部分 原文与翻译

**英文原标题：** Patient-derived colon epithelial organoids reveal lipid-related metabolic dysfunction in pediatric ulcerative colitis.

> **英文摘要：**
> Ulcerative colitis (UC) is associated with epithelial metabolic derangements which exacerbate gut inflammation. Here, we develop colon organoid (colonoid) lines from pediatric patients with endoscopically active UC, inactive UC, and those without intestinal inflammation to interrogate functional metabolic differences in the colon epithelia. We demonstrate that active UC colonoids exhibit hypermetabolic features and cellular stress, specifically during differentiation. Hypermetabolism in active UC colonoids is driven, in part, by increased proton leak, and excess lipid accumulation. Active UC colonoids exhibit heightened activation of the master lipid regulator PPAR-α and its transcriptional pathways. Pharmacological PPAR-α inhibition limits lipid accumulation, induces a metabolic shift towards glucose utilization, suppresses hypermetabolism, and reduces chemokine secretion and cellular stress markers. Collectively, our findings identify lipid-related metabolic dysfunction as a key pathologic feature of the pediatric UC epithelium and highlight the potential of patient-derived colonoids as a preclinical model for evaluating epithelial-targeted therapies addressing this dysfunction.

> **中文摘要：**
> 溃疡性结肠炎（UC）与上皮代谢紊乱相关，而这种紊乱会加剧肠道炎症。在本研究中，我们从内镜下活动性UC、非活动性UC以及无肠道炎症的儿童患者中建立了结肠类器官（colonoid）系，以探究结肠上皮的功能性代谢差异。我们发现，活动性UC来源的类器官表现出高代谢特征和细胞应激，尤其在分化过程中尤为显著。活动性UC类器官的高代谢部分由质子泄漏增加和脂质过度积累所驱动。活动性UC类器官显示出脂质代谢主调因子PPAR-α及其转录通路的增强激活。药理性抑制PPAR-α可限制脂质积累，引导代谢向葡萄糖利用方向转变，抑制高代谢状态，并降低趋化因子分泌及细胞应激标志物。综合来看，我们的研究结果揭示了脂质相关代谢功能障碍是儿童UC上皮的关键病理特征，并突出了患者来源的结肠类器官作为评估针对该功能障碍的上皮靶向治疗的临床前模型的潜力。

### 第二部分 AI 大师评价

本研究利用儿童患者来源的结肠类器官，系统比较了不同炎症状态下上皮代谢的功能差异，明确指出脂质代谢紊乱在儿童溃疡性结肠炎中具有关键病理作用。研究创新性地结合代谢功能分析与药理干预，揭示PPAR-α通路在脂质代谢异常中的核心地位，并通过抑制实验验证其可调性。该工作不仅深化了对UC代谢机制的理解，也为上皮靶向治疗提供了可行的临床前模型。然而，研究仍需进一步验证其在成人患者及长期生理条件下的适用性与可转化性。

---

## 57. 去泛素化酶 USP35 通过调控代谢重编程促进胃癌腹膜播散

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372134)
**期刊：** Cell death & disease
**PMID：** 41372134
**DOI：** 10.1038/s41419-025-08322-4

### 第一部分 原文与翻译

**英文原标题：** De-ubiquitinase USP35 promotes peritoneal dissemination of gastric cancer by regulating metabolic reprogramming.

> **英文摘要：**
> The enhanced adhesion between gastric cancer (GC) cells and peritoneal mesothelial cells (PMCs) is one of the key factors in the formation of the pre-peritoneal-metastasis adaptive microenvironment. USP35 belongs to the ubiquitin-specific protease family and is involved in regulating the occurrence and progression of various diseases. However, whether this gene can regulate the adhesion of GC cells to PMCs has not been clarified. The aim of this study was to identify the mechanism by which USP35 promotes the formation of the pre-peritoneal-metastasis adaptive microenvironment of GC and to find potential therapeutic targets. For the first time, we found that USP35 expression is upregulated in GC tissues, especially in peritoneal metastatic nodules, and is associated with poor prognosis. USP35 expression is the highest in MKN-45P, which is closely related to its high peritoneal metastasis potential. The mechanism of action involves several key steps. Firstly, the gene targets STING through de-ubiquitination and stabilizes its expression. Through this interaction, USP35/STING activates the HIF-1α/FAK pathway, promoting energy metabolism reprogramming and further improving the adhesion ability of GC cells. Secondly, exosome USP35 derived from GC cells has been shown to promote the mesothelial-mesenchymal transformation (MMT) of PMCs, preparing the "soil" for cancer cell adhesion and growth and contributing to the establishment of a pre-peritoneal-metastasis adaptive microenvironment. In summary, USP35 synergistically promotes the establishment of this environment through the dual mechanisms of regulating energy metabolic reprogramming of tumor cells and inducing the MMT of PMCs via the exosome pathway, providing a new theoretical basis for searching for therapeutic targets of gastric cancer with peritoneal dissemination.

> **中文摘要：**
> 胃癌（GC）细胞与腹膜间皮细胞（PMCs）之间黏附增强，是形成腹膜转移前适应性微环境的关键因素之一。USP35 属于特异性去泛素化酶家族，参与多种疾病的发生与进展调控。然而，该基因是否能够调节 GC 细胞与 PMCs 的黏附尚未明确。本研究旨在阐明 USP35 促进 GC 腹膜转移前适应性微环境形成的机制，并寻找潜在治疗靶点。首次发现，USP35 在 GC 组织中表达上调，尤其在腹膜转移结节中显著增高，并与不良预后相关。USP35 在 MKN-45P 细胞系中表达最高，与其高腹膜转移潜能密切相关。其作用机制包括若干关键步骤。首先，USP35 通过去泛素化作用靶向 STING，稳定其表达。通过这一相互作用，USP35/STING 轴激活 HIF-1α/FAK 通路，促进能量代谢重编程，从而增强 GC 细胞的黏附能力。其次，来源于 GC 细胞的外泌体 USP35 可促进 PMCs 的间皮—间质转化（MMT），为癌细胞黏附与生长“准备土壤”，有助于腹膜转移前适应性微环境的建立。综上所述，USP35 通过调控肿瘤细胞能量代谢重编程及经外泌体诱导 PMCs MMT 的双重机制协同促进该微环境的形成，为寻找胃癌腹膜播散的治疗靶点提供了新的理论基础。

### 第二部分 AI 大师评价

该研究系统揭示了去泛素化酶 USP35 在胃癌腹膜播散中的关键作用，发现其通过稳定 STING 并激活 HIF-1α/FAK 代谢通路，增强肿瘤细胞黏附及代谢适应能力。同时，外泌体 USP35 可诱导间皮细胞发生间质化改变，为肿瘤细胞提供有利微环境。此双重机制揭示了肿瘤细胞与宿主微环境的复杂互作，具有较强创新性。未来仍需进一步验证其在临床中的可干预性，以评估 USP35 作为治疗靶点的可行性。

---

## 58. 通过整合活细胞与合成细胞实现混合三维培养体系的自组装

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372132)
**期刊：** Nature communications
**PMID：** 41372132
**DOI：** 10.1038/s41467-025-66789-3

### 第一部分 原文与翻译

**英文原标题：** Self-assembly of hybrid 3D cultures by integrating living and synthetic cells.

> **英文摘要：**
> Self-assembly is a fundamental property of living matter that drives the three-dimensional organization of cell collectives such as tissues and organs. Here, the co-assembly of synthetic and natural cells is leveraged to create hybrid living 3D cancer cultures. We screen a range of synthetic cell models for their ability to form augmented tumoroids with artificial but controllable micro-environments, and show that the balance of inter- and extracellular adhesion and synthetic cell surface tension are key material properties driving integrated co-assembly. We demonstrate that synthetic cells based on droplet-supported lipid bilayers can establish artificial tumor immune microenvironments (ART-TIMEs), mimicking immunogenic signals within tumoroids and eliminating the need to integrate complex living immune cells. Using the ART-TIME approach, we identify a AhR-ARNT-mediated co-signaling mechanism between PD-1 and CD2 as a driver in immune evasion of pancreatic ductal adenocarcinoma. Our study advances the field of hybrid organoid engineering, offers opportunities for the construction and modelling of artificial tumour environments, and marks a step towards the design of functional living/non-living cytomimetic materials.

> **中文摘要：**
> 自组装是生命物质的一种基本特性，驱动细胞群体（如组织与器官）的三维结构组织。在此研究中，作者利用合成细胞与天然细胞的共同组装，构建了混合型三维癌症培养体系。研究团队筛选了一系列合成细胞模型，以评估其在形成具有人工但可控微环境的增强型肿瘤类器官（tumoroid）方面的能力，并揭示了细胞间与细胞外黏附力的平衡以及合成细胞表面张力，是促进整合共组装的关键材料属性。研究进一步表明，基于液滴支持脂质双层的合成细胞可建立人工肿瘤免疫微环境（ART-TIME），在肿瘤类器官中模拟免疫原性信号，从而无需引入复杂的活性免疫细胞。利用 ART-TIME 方法，作者鉴定出一种由 AhR-ARNT 介导的 PD-1 与 CD2 共信号通路机制，该机制促进了胰腺导管腺癌的免疫逃逸。本研究推动了混合类器官工程领域的发展，为人工肿瘤环境的构建与建模提供了新的可能，并迈出了设计功能性活性/非活性仿生细胞材料的重要一步。

### 第二部分 AI 大师评价

本研究旨在通过合成细胞与天然细胞的自组织协同，探索构建具备可控免疫功能的混合三维癌症模型。作者将材料科学与肿瘤微环境工程相结合，创新性地提出了 ART-TIME 平台，可模拟肿瘤免疫信号并规避真实免疫细胞整合的复杂性。研究揭示了影响共组装的关键物理参数，并发现 PD-1/CD2 之间的 AhR-ARNT 通路在胰腺癌免疫逃逸中的作用。该工作为人工肿瘤生态系统及仿生细胞材料的设计提供了新方向，但后续仍需验证其在体内环境中的适用性与稳定性。

---

## 59. 多重血清学揭示新冠疫情后呼吸道病原体的年龄特异性免疫动力学特征

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372127)
**期刊：** Nature communications
**PMID：** 41372127
**DOI：** 10.1038/s41467-025-65957-9

### 第一部分 原文与翻译

**英文原标题：** Multiplex serology reveals age-specific immunodynamics of respiratory pathogens in the wake of the COVID-19 pandemic.

> **英文摘要：**
> The rebound of endemic respiratory viruses following the COVID-19 pandemic was marked by atypical transmission dynamics, with children experiencing increased disease burden and out-of-season epidemics as restrictions relaxed. Here we used serology from a newly developed quantitative multiplex assay to assess the post-pandemic immunity debt. We assessed age-specific antibody dynamics across a broad range of respiratory viruses, including influenza, respiratory syncytial virus, seasonal coronaviruses, and SARS-CoV-2 using serology collected in King County, Washington, US, from 2020-2022 (n = 1508). We found that respiratory virus immunodynamics differed between individuals <5 years of age and older individuals, with young children experiencing larger boosts and quicker waning of antibodies across pathogens. We confirmed that these patterns are upheld in a non-pandemic setting by analyzing influenza serology collected in South Africa between 2016-2018 (n = 1028). We incorporated our serological insights into an influenza transmission model calibrated to epidemiological data from King County and show that consideration of age-specific immunodynamics may be important to anticipate the effects of pandemic perturbations.

> **中文摘要：**
> 在新冠疫情之后，地方性呼吸道病毒的回升表现出非典型的传播动态，随着防控措施放松，儿童经历了更重的疾病负担和非季节性流行。本文利用一种新开发的定量多重血清学检测方法，评估了疫情后免疫负债。研究通过分析采自美国华盛顿州金县2020–2022年（n=1508）的血清样本，评估了包括流感病毒、呼吸道合胞病毒、季节性冠状病毒及SARS-CoV-2在内的多种呼吸道病毒的年龄特异性抗体动态。结果显示，呼吸道病毒的免疫动力学在5岁以下儿童与年长者之间存在差异，幼儿在多种病原体上的抗体提升更强且衰减更快。通过分析南非2016–2018年收集的流感血清学数据（n=1028），研究进一步证实这些模式在非疫情情境下同样存在。最后，研究将这些血清学发现纳入基于金县流行病学数据校准的流感传播模型，结果表明，考虑年龄特异性的免疫动力学对于预测疫情扰动的影响具有重要意义。

### 第二部分 AI 大师评价

该研究旨在解析新冠疫情后人群对呼吸道病毒的免疫恢复动态，尤其关注不同年龄层的免疫差异。作者通过新型定量多重血清学技术，系统测量了多种呼吸道病毒的抗体水平，并发现儿童群体的抗体波动幅度更大，衰减更快。研究还结合不同地区和时期的数据验证了这一规律，并将其嵌入传播模型以预测疫情扰动的后果。该工作创新性地结合血清学与建模方法，为理解“免疫负债”及未来流行病管理提供了科学依据，但可能受限于地区样本代表性及模型假设简化。

---

## 60. 由STAT5激活型致癌基因诱导的白血病抑制素M促进血液恶性肿瘤的疾病进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372120)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41372120
**DOI：** 10.1038/s41392-025-02491-6

### 第一部分 原文与翻译

**英文原标题：** Oncostatin M induced by STAT5-activating oncogenes promotes disease progression in hematologic malignancies.

> **英文摘要：**
> Understanding the interplay between oncogenic mutations and the tumor microenvironment could help improve therapy for hematological malignancies. We found that the STAT5-activating oncogenes JAK2 p.V617F, FLT3-ITD, and BCR::ABL1 induce oncostatin M (OSM), which triggers disease progression and immunosuppression. The OSM receptor was predominantly expressed on nonhematopoietic bone marrow (BM) stromal cells. OSM reprogrammed these cells via STAT3 and induced the secretion of cytokines connected to T-cell exhaustion, including IL-6 and MCP-1. Compared with control mice, OSM-overexpressing mice presented reduced T-cell numbers, increased levels of inhibitory receptors on T cells, and elevated lactic acid production by BM stromal cells. OSM induced the expansion of myeloid cells which suppressed T cells. Conversely, genetic deletion of Osm in a JAK2 p.V617F-driven polycythemia vera mouse model reduced polycythemia, BM fibrosis, inflammatory cytokine levels and the expression of inhibitory markers on T cells. Transcriptomic analyses of T cells from OSM-overexpressing mice revealed enrichment of IL6-JAK-STAT3 and inflammatory signaling pathways. Additionally, pharmacological inhibition of OSM reduced disease activity and cytokine production. These findings establish OSM as a key mediator linking oncogenic STAT5 activation to remodeling of the microenvironment and immune suppression. Targeting OSM signaling therefore represents a promising therapeutic strategy to alleviate disease progression in myeloproliferative neoplasms and related malignancies.

> **中文摘要：**
> 理解致癌突变与肿瘤微环境之间的相互作用，有助于改进血液恶性肿瘤的治疗。我们发现，STAT5激活型致癌基因JAK2 p.V617F、FLT3-ITD和BCR::ABL1可诱导白血病抑制素M（OSM）的产生，进而触发疾病进展和免疫抑制。OSM受体主要表达于骨髓（BM）非造血基质细胞上。OSM通过STAT3重新编程这些细胞，并诱导其分泌与T细胞衰竭相关的细胞因子，包括IL-6和MCP-1。与对照小鼠相比，OSM过表达小鼠表现为T细胞数量减少，T细胞上抑制性受体水平升高，BM基质细胞乳酸生成增加。OSM促进了抑制T细胞功能的髓系细胞扩增。相反，在JAK2 p.V617F驱动的真性红细胞增多症小鼠模型中，Osm的基因敲除可减少红细胞增多、BM纤维化、炎症性细胞因子水平及T细胞上抑制性标志物的表达。来自OSM过表达小鼠T细胞的转录组分析显示，IL6-JAK-STAT3及炎症信号通路显著富集。此外，药理学抑制OSM可降低疾病活性和细胞因子产生。这些发现确立了OSM作为连接致癌性STAT5激活与微环境重塑及免疫抑制的关键介质。因此，靶向OSM信号通路代表着一种有前景的治疗策略，以缓解骨髓增生性肿瘤及相关恶性疾病的进展。

### 第二部分 AI 大师评价

本研究揭示了STAT5激活型致癌基因通过诱导白血病抑制素M（OSM）在血液恶性肿瘤中的关键致病作用。作者结合转录组分析、基因敲除模型和药理干预，系统阐明了OSM驱动的骨髓基质重塑和T细胞抑制机制。结果表明，OSM是连接致癌信号与免疫微环境失衡的核心因子。该研究创新性地提出了靶向OSM信号作为控制骨髓增生性肿瘤进展的潜在治疗策略，但仍需进一步验证其在临床上的安全性与可行性。

---

## 61. 通过调控SATB1增强嵌合抗原受体T细胞的抗肝肿瘤效能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372119)
**期刊：** Cell death & disease
**PMID：** 41372119
**DOI：** 10.1038/s41419-025-08307-3

### 第一部分 原文与翻译

**英文原标题：** Enhanced anti-liver tumor efficacy of chimeric antigen receptor-T cells via SATB1 modulation.

> **英文摘要：**
> Although Chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable success in treating hematopoietic malignancies, its clinical application in solid tumors is profoundly hindered by persistent T-cell exhaustion within the immunosuppressive tumor microenvironment (TME). Here, we identified SATB1-a genome organizer regulating chromatin architecture-as a key suppressor of CAR-T cell exhaustion. In Glypican-3 (GPC3)-targeted CAR-T cells, SATB1 was significantly downregulated in tumor-infiltrating exhausted populations. SATB1 overexpression not only reduced expression of multiple inhibitory receptors (PD-1, CTLA-4, TIM3, and LAG-3) but also promoted a central memory phenotype, enhancing cytokine production and cytotoxicity against hepatocellular carcinoma (HCC) cells in vitro. In vivo, SATB1-engineered CAR-T cells exhibited superior tumor control and promoted survival, accompanied by reduced exhaustion markers in tumor-infiltrating T cells. These functional improvements are consistent with the reported role of SATB1 in modulating T cell exhaustion, positioning it as a multifunctional enhancer of CAR-T cell fitness. Collectively, our study unveils SATB1 as a multifunctional modulator that simultaneously targets exhaustion and memory differentiation, offering a novel strategy to enhance CAR-T efficacy against solid tumors.

> **中文摘要：**
> 尽管嵌合抗原受体（CAR）T细胞疗法在治疗造血系统恶性肿瘤中取得了显著成功，但其在实体瘤中的临床应用受到免疫抑制性肿瘤微环境（TME）中T细胞持续耗竭的严重限制。在本研究中，我们鉴定出SATB1——一种调控染色质结构的基因组组织因子——是CAR-T细胞耗竭的关键抑制因子。在靶向Glypican-3（GPC3）的CAR-T细胞中，SATB1在肿瘤浸润的耗竭性T细胞群体中显著下调。SATB1过表达不仅降低了多种抑制性受体（PD-1、CTLA-4、TIM3和LAG-3）的表达，而且促进了中心记忆型表型的形成，从而增强了其对人肝细胞癌（HCC）细胞的细胞因子产生能力和体外细胞毒活性。在体内实验中，SATB1修饰的CAR-T细胞表现出更优越的肿瘤控制能力并延长了生存时间，同时伴随肿瘤浸润T细胞中耗竭标志物的减少。这些功能改善与已报道的SATB1调节T细胞耗竭的作用一致，使其成为多功能的CAR-T细胞适应性增强因子。总体而言，我们的研究揭示，SATB1是一种可同时调控耗竭和记忆分化的多功能调节因子，为提高CAR-T疗法在实体瘤中的效能提供了一种新策略。

### 第二部分 AI 大师评价

该研究围绕SATB1在CAR-T细胞功能调控中的作用展开，旨在解决实体瘤治疗中CAR-T细胞易于耗竭的问题。通过在GPC3靶向CAR-T细胞中过表达SATB1，研究发现其能降低多种抑制性受体的表达，增强记忆性分化与细胞毒效应，从而在体内外均显著改善抗肝癌活性。结果表明SATB1可作为关键的细胞功能增强节点，为提升CAR-T在固体肿瘤中的疗效提供新方向。该研究创新性地将染色质调控机制与免疫细胞适应力结合，但仍需进一步探索其在临床转化中的安全性与稳定性。

---

## 62. 光动力疗法在卵巢癌细胞中同时诱导类铁死亡和类凋亡的脂质特征。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372113)
**期刊：** Cell death & disease
**PMID：** 41372113
**DOI：** 10.1038/s41419-025-08189-5

### 第一部分 原文与翻译

**英文原标题：** Photodynamic therapy simultaneously induces ferroptosis- and apoptosis-like lipid signatures in ovarian cancer cells.

> **英文摘要：**
> Resistance to apoptosis-inducing chemotherapy is a major factor contributing to treatment failure and poor survival outcomes in high-grade serous ovarian cancer (HGSOC). Ferroptosis, a regulated form of cell death driven by lipid peroxidation, has emerged as a promising effector mechanism because it remains available in HGSOC cells with impaired apoptosis signaling. While most research has focused on pharmacological ferroptosis inducers, there is growing interest in strategies that could trigger lipid autoxidation through externally delivered energy, such as photons. Photodynamic therapy (PDT), which utilizes light and light-activatable photosensitizers to generate reactive molecular species, offers a means of initiating lipid peroxidation with a high degree of precision and minimal systemic toxicities. However, the precise lipid targets of PDT, the influence of varying tumor lipidomic landscapes, and the role of ferroptosis sensitivity on PDT-lipid interactions have yet to be elucidated. In this study, we systematically compare PDT to ferroptosis induced by the inhibition of glutathione peroxidase 4, focusing on lipid redox states and composition in HGSOC cell lines. While PDT was similarly effective in both ferroptosis-sensitive and -resistant cells, its effects on cellular lipidomes differed markedly. PDT robustly induced lipid radical formation in both cell types; however, a dose-dependent accumulation of lipid hydroxides and hydroperoxides was only observed in ferroptosis-sensitive cells rich in unsaturated phospholipids. Further analysis revealed a significant overlap in lipid oxidation targets between PDT and ferroptosis. Notably, in both cell types, and in vivo, PDT upregulated ceramides, a lipid class strongly associated with mitochondrial apoptosis. In summary, PDT exhibited comparable efficacy in both ferroptosis-sensitive and -resistant cells by triggering a combination of lipid peroxidation and ceramide upregulation, suggesting the activation of both ferroptosis and apoptosis pathways. Further studies are needed to explore the role of PDT-induced lipidomic changes in the initiation of various cell death pathways and in overcoming chemoresistance in HGSOC.

> **中文摘要：**
> 对抗诱导凋亡的化疗产生耐药性是导致高级别浆液性卵巢癌（HGSOC）治疗失败和生存率差的主要因素。铁死亡是一种受脂质过氧化驱动的、可调控的细胞死亡形式，由于在凋亡信号受损的HGSOC细胞中仍可被激活，因此成为一种有前景的效应机制。虽然多数研究集中于药理学铁死亡诱导剂，但人们对可通过外源能量（如光子）触发脂质自氧化的策略兴趣日益增加。光动力疗法（PDT）利用光及光激活的光敏剂生成反应性分子物种，能够以高精度并伴随极小的系统毒性诱导脂质过氧化。然而，目前尚不清楚PDT的特定脂质靶点、不同行瘤脂质组构景的影响，以及铁死亡敏感性在PDT-脂质相互作用中的作用。本研究系统比较了PDT与谷胱甘肽过氧化物酶4抑制所诱导的铁死亡，并重点关注HGSOC细胞系中的脂质氧化还原状态及成分。结果显示，PDT在铁死亡敏感和耐受细胞中均具有类似的效力，但其对细胞脂质组的影响却存在显著差异。PDT在两种细胞中均强烈诱导脂质自由基的形成；然而，仅在富含不饱和磷脂的铁死亡敏感细胞中观察到脂质羟化物和过氧化物的剂量依赖性积累。进一步分析表明，PDT与铁死亡在脂质氧化靶点上存在显著的重叠。值得注意的是，在两种细胞类型及体内实验中，PDT均上调了神经酰胺，这是一类与线粒体凋亡密切相关的脂质。综上所述，PDT通过触发脂质过氧化和神经酰胺上调的组合，在铁死亡敏感与耐受细胞中均表现出可比的疗效，提示其可同时激活铁死亡与凋亡通路。未来研究需进一步探讨PDT诱导的脂质组学变化在多种细胞死亡途径启动及克服HGSOC化疗耐药中的作用。

### 第二部分 AI 大师评价

该研究旨在探讨光动力疗法（PDT）对卵巢癌细胞中脂质代谢和细胞死亡类型的双重作用。作者采用系统性的脂质组学比较，揭示PDT可同时触发铁死亡样和凋亡样脂质特征，且作用机制与谷胱甘肽过氧化物酶4抑制诱导的铁死亡部分重叠。研究创新地指出PDT上调神经酰胺并引发线粒体凋亡，为理解光能诱导的脂质氧化反应与细胞死亡路径提供新视角。尽管结果具有启发性，但进一步的机制性与动物模型验证仍有必要。

---

## 63. Kupffer细胞自噬调节原发性胆汁性胆管炎中CD8 T细胞的活化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41371935)
**期刊：** Gut
**PMID：** 41371935
**DOI：** 10.1136/gutjnl-2025-335611

### 第一部分 原文与翻译

**英文原标题：** Autophagy of Kupffer cells modulates CD8 T cell activation in primary biliary cholangitis.

> **英文摘要：**
> BACKGROUND: Kupffer cells and monocyte-derived macrophages (MoMs) are difficult to study in human primary biliary cholangitis (PBC) even though they reflect a dynamic hepatic immune population.
> 
> OBJECTIVE: We aim to investigate the role of hepatic macrophage and its therapeutic potential in human PBC and murine autoimmune cholangitis.
> 
> DESIGN: Phenotypic analysis of hepatic macrophages in patients with PBC and dnTGFβRII mice model was performed by single-cell RNA sequencing, flow cytometry and immunohistochemistry. Depletion of hepatic macrophages and inhibition of MoMs were performed in murine autoimmune cholangitis. -mediated  knockout mice and co-culture experiments were applied to explore the role and mechanism of macrophage autophagy in autoimmune cholangitis. Therapeutic intervention was performed using nanoparticle-capsuled small interfering RNA against .
> 
> RESULTS: Kupffer cells from patients with PBC and dnTGFβRII mice upregulate genes associated with inflammatory responses and exhibit increased autophagy. Further, macrophage-specific knockout of  leads to reduction of inflammation and bile duct damage. We propose that the mechanism of this modulation is secondary to decreased activation of pathogenic CD8 T cells. Indeed, Kupffer cells maintain CD8 T cell tolerance through expression of inducible nitric oxide synthase (iNOS) and generation of NO. Increased autophagy resulted in degradation of iNOS in Kupffer cells and abrogated their suppressive activity against CD8 T cells. Finally, we report that targeted downregulation of Kupffer cell autophagy in vivo using cationic lipid-assisted nanoparticles encapsulating siRNA against  leads to reduction of liver inflammation and bile duct damage.
> 
> CONCLUSION: Macrophage autophagy promotes autoimmune cholangitis and strongly supports this pathway as a potential therapeutic target.

> **中文摘要：**
> 背景：尽管Kupffer细胞和单核细胞来源的巨噬细胞（MoMs）在人体原发性胆汁性胆管炎（PBC）中反映了一个动态的肝脏免疫群体，但研究它们仍然具有较大困难。
> 
> 研究目的：本研究旨在探讨肝巨噬细胞在人体PBC及小鼠自身免疫性胆管炎中的作用及其潜在治疗价值。
> 
> 研究设计：通过单细胞RNA测序、流式细胞术和免疫组化，对PBC患者及dnTGFβRII小鼠模型的肝巨噬细胞进行表型分析。在小鼠自身免疫性胆管炎模型中进行了肝巨噬细胞的消除和MoMs的抑制实验。还利用巨噬细胞特异性敲除模型及共培养实验，探究自噬在巨噬细胞中的功能及机制。治疗性干预通过包裹特异性小干扰RNA（siRNA）的纳米颗粒实现。
> 
> 结果：PBC患者及dnTGFβRII小鼠的Kupffer细胞上调了与炎症反应相关的基因，并表现出增强的自噬活性。进一步的研究显示，巨噬细胞特异性缺失某基因可减少炎症及胆管损伤。我们提出，这种调节机制主要源于致病性CD8 T细胞活化的降低。实际上，Kupffer细胞通过表达诱导型一氧化氮合酶（iNOS）及产生一氧化氮（NO）来维持CD8 T细胞的耐受。自噬增加导致Kupffer细胞中iNOS降解，从而削弱其对CD8 T细胞的抑制作用。最后，我们发现，利用阳离子脂质辅助纳米颗粒包裹的siRNA在体内特异性下调Kupffer细胞自噬，可明显降低肝脏炎症和胆管损伤。
> 
> 结论：巨噬细胞自噬促进自身免疫性胆管炎的发生，提示该通路可能成为潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究揭示Kupffer细胞自噬在原发性胆汁性胆管炎（PBC）发病中的关键作用。研究结合单细胞测序、流式细胞术及基因敲除模型，系统阐明了Kupffer细胞通过iNOS/NO途径维持CD8 T细胞耐受的机制，并指出自噬增强会削弱这一免疫调控功能。研究具有创新性地提出了以Kupffer细胞自噬为靶点的治疗策略，并通过纳米颗粒介导的RNA干预加以验证。其主要亮点在于跨物种的机制验证，但仍需进一步探索自噬调节的上下游信号及临床可转化性。

---

## 64. 通过监测乳腺癌中对检查点抑制的系统性免疫反应揭示宿主反应与耐药机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41371907)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41371907
**DOI：** 10.1136/jitc-2025-012606

### 第一部分 原文与翻译

**英文原标题：** Monitoring systemic immune responses to checkpoint inhibition in breast cancer reveals host responses and mechanisms of resistance.

> **英文摘要：**
> BACKGROUND: Immune checkpoint inhibitors (ICI) have improved survival in various cancers, but their success in breast cancer, specifically triple-negative breast cancer, remains limited, benefiting less than 10% of patients.
> 
> METHODS: We modeled ICI response in vivo to unravel the mechanisms underlying immunotherapy efficacy, identify mechanisms of resistance in non-responsive tumors, and ascertain the therapeutic benefits of different chemotherapeutic combinations with ICI in breast cancer. We investigated the impact of ICI as monotherapy and in combination with other therapeutics in mouse models of mammary cancer, which we found robustly suppressed primary tumor growth and extended survival.
> 
> RESULTS: Interestingly, even within a single model, responses to ICI were highly variable. Resistance was not reliably retained by transplantation into syngeneic hosts, suggesting a role for systemic host immunity rather than tumor-autonomous mechanisms. Transcriptomic analysis of the primary tumor landscape by fine-needle aspiration revealed that upregulated cytotoxic T-cell response and inflammatory interferon signaling (both at baseline and post anti-programmed death-ligand 1 administration) corresponded to favorable response to ICI. Longitudinal analysis of the peripheral blood uncovered enhanced myeloid cell recruitment in resistant mice, prior to therapy initiation. Similar effects were observed through longitudinal assessment of peripheral blood in patients with ICI-treated human breast cancer. Blocking myeloid cell recruitment with navaraxin (CXCR1/2 inhibitor) improved ICI responses, further suppressing tumor growth and improving survival.
> 
> CONCLUSIONS: These findings provide insight into resistance mechanisms and suggest the potential for minimally invasive strategies (sampling of systemic immune cells from peripheral blood) to identify patients likely to respond to ICI. This approach may help inform de-escalation strategies to mitigate therapeutic toxicities and limit unnecessary treatments.

> **中文摘要：**
> 背景：免疫检查点抑制剂（ICI）已改善多种癌症的生存预后，但其在乳腺癌，尤其是三阴性乳腺癌中的疗效仍有限，受益患者不足 10%。
> 
> 方法：我们在体内构建了 ICI 应答模型，以解析免疫治疗疗效的基础机制，识别非应答肿瘤的耐药机制，并确定不同化疗药物与 ICI 联合应用在乳腺癌中的治疗效益。我们在小鼠乳腺癌模型中研究了 ICI 单药及其与其他治疗药物联合应用的影响，发现 ICI 可显著抑制原发肿瘤生长并延长生存期。
> 
> 结果：有趣的是，即便在单一模型内，ICI 应答也表现出高度差异。通过将肿瘤移植至同系宿主后，耐药性未被可靠地保留，提示系统性宿主免疫而非肿瘤自身机制在其中发挥作用。通过细针穿刺对原发肿瘤组织的转录组分析表明，上调的细胞毒性 T 细胞应答和炎性干扰素信号（无论是在基线还是接受抗 PD-L1 治疗后）与良好的 ICI 应答相关。对外周血的纵向分析显示，在开始治疗前，耐药小鼠中髓系细胞的募集增强。在接受 ICI 治疗的人类乳腺癌患者外周血的长期随访中观察到类似现象。使用 CXCR1/2 抑制剂 navaraxin 阻断髓系细胞募集可增强 ICI 应答，进一步抑制肿瘤生长并改善生存。
> 
> 结论：这些发现为理解耐药机制提供了新的见解，并提示通过微创策略（如采集外周血系统性免疫细胞）有望识别可能应答 ICI 的患者。该方法可为制定减量治疗策略、减少毒性及避免不必要治疗提供指导。

### 第二部分 AI 大师评价

本研究旨在系统解析乳腺癌接受免疫检查点抑制治疗时的宿主免疫动态与耐药机制。作者通过小鼠模型及人类样本的纵向血液分析，揭示髓系细胞募集增强与耐药相关，而细胞毒性 T 细胞与干扰素通路激活与良好疗效有关。联合使用 CXCR1/2 抑制剂可逆转耐药并增强 ICI 效果。研究的创新性在于将系统性免疫监测与肿瘤反应关联，为开发外周血免疫标志物与个体化治疗策略提供新思路，但其临床验证仍需进一步扩大样本与机制研究。

---

## 65. 免疫检查点抑制剂初次及再挑战治疗期间青少年和青年黑色素瘤患者的免疫相关不良事件模式与治疗反应特征

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41371906)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41371906
**DOI：** 10.1136/jitc-2025-012337

### 第一部分 原文与翻译

**英文原标题：** Patterns of immune-related adverse events and treatment responses in adolescents and young adults with melanoma during initial and rechallenge immune checkpoint inhibitor therapy.

> **英文摘要：**
> BACKGROUND: Immune checkpoint inhibitors (ICIs) are increasingly used in adolescents and young adults (AYAs) with cancer; however, data on treatment response, the frequency and pattern of immune-related adverse events (irAEs), and the feasibility of ICI rechallenge after irAEs are limited.
> 
> METHODS: This retrospective study included 136 AYAs (80 males and 56 females) who received ICI therapy for melanoma at our institution from 2013 to 2023. We documented the initial ICI treatment and ICI rechallenge, along with associated irAEs and treatment responses. Kaplan-Meier plots were used to analyze overall survival (OS) and progression-free survival.
> 
> RESULTS: At ICI initiation, the median age was 33 (range, 15-39) years, and most patients had stage III or IV disease (93%) and  mutations (63%). Treatment settings included adjuvant (n=70), palliative (n=50), and neoadjuvant (n=16). Compared with those receiving ICI monotherapy (n=77), patients receiving ICI combination therapy (n=59) had significantly higher rates of irAEs of any grade (53% vs 75%, p=0.011) and grade three or four irAEs (12% vs 32%, p=0.003) and higher rates of treatment delay (26% vs 51%, p=0.044), and hospitalization (8% vs 20%, p=0.032). ICI rechallenge was common (n=71), even after prior irAEs (n=48). Colitis and hepatitis were the most common irAEs following initial ICI therapy (26% and 23%, respectively) and ICI rechallenge (31% and 29%, respectively). The adjuvant, palliative, and neoadjuvant ICI therapy groups had 5-year OS rates of 86%, 77%, and 88%, respectively. In the palliative therapy group, the overall response rate and disease control rate were 38% and 42% during initial ICI therapy and 35% and 44% during ICI rechallenge. Elevated baseline lactate dehydrogenase levels were associated with worse OS (adjusted HR, 21.04, 95% CI, 1.35 to 328.29, p=0.030), and colitis and/or hepatitis were strongly associated with better OS (adjusted HR, 0.10, 95% CI 0.01 to 0.83, p=0.033).
> 
> CONCLUSIONS: AYA patients receiving ICI therapy for melanoma had high incidence of colitis and hepatitis and favorable survival. Initial and rechallenge ICI therapy had similar patterns of irAE severity and efficacy. Colitis and hepatitis were associated with improved OS.

> **中文摘要：**
> 背景：免疫检查点抑制剂（ICI）在青少年和青年（AYA）癌症患者中的应用日益增加；然而，有关治疗反应、免疫相关不良事件（irAE）的发生频率和模式，以及irAE后再挑战ICI治疗可行性的数据仍然有限。
> 
> 方法：本回顾性研究纳入了2013年至2023年间在本机构接受黑色素瘤ICI治疗的136例AYA患者（男性80例，女性56例）。我们记录了初次ICI治疗和ICI再挑战的情况，以及相关的irAE和治疗反应。采用Kaplan-Meier曲线分析总体生存期（OS）和无进展生存期。
> 
> 结果：ICI治疗开始时，患者中位年龄为33岁（范围15–39岁），多数处于III或IV期疾病状态（93%），且63%存在基因突变。治疗方案包括辅助治疗（n=70）、姑息治疗（n=50）和新辅助治疗（n=16）。与接受ICI单药治疗的患者（n=77）相比，接受ICI联合治疗的患者（n=59）任意级别irAE发生率显著更高（53% vs 75%，p=0.011），3–4级irAE更高（12% vs 32%，p=0.003），治疗延迟（26% vs 51%，p=0.044）及住院（8% vs 20%，p=0.032）比例亦升高。ICI再挑战较为常见（n=71），即使在既往发生irAE的患者中（n=48）亦如此。结肠炎和肝炎是初次ICI治疗（分别为26%和23%）及再挑战治疗（分别为31%和29%）最常见的irAE。辅助、姑息及新辅助ICI治疗组的5年OS率分别为86%、77%和88%。在姑息治疗组中，初次ICI治疗的总体反应率和疾病控制率分别为38%和42%，再挑战阶段分别为35%和44%。基线乳酸脱氢酶水平升高与较差的OS相关（调整后HR 21.04，95% CI 1.35–328.29，p=0.030）；而结肠炎和/或肝炎的出现与较好的OS显著相关（调整后HR 0.10，95% CI 0.01–0.83，p=0.033）。
> 
> 结论：接受ICI治疗的AYA黑色素瘤患者中结肠炎和肝炎发生率较高，且总体生存较好。初次和再挑战ICI治疗在irAE严重程度和疗效方面呈相似模式。结肠炎与肝炎的发生与更佳的总体生存相关。

### 第二部分 AI 大师评价

本研究系统分析了青少年与青年黑色素瘤患者在免疫检查点抑制剂初次及再挑战治疗中的不良反应模式与疗效。研究发现，结肠炎和肝炎是最常见的免疫相关不良事件，且其出现与改善的总体生存表现相关。值得注意的是，再挑战治疗的疗效与不良事件谱与初次治疗相似，提示再使用ICI具有一定可行性。该研究的创新在于聚焦AYA人群的真实世界数据，但受限于回顾性设计和样本量，仍需前瞻性研究验证。

---

## 66. 2001年至2022年美国儿童及青少年癌症发病率的趋势

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370847)
**期刊：** Cancer discovery
**PMID：** 41370847
**DOI：** 10.1158/2159-8290.CD-25-1493

### 第一部分 原文与翻译

**英文原标题：** Trends in Childhood and Adolescent Cancer Incidence Rates in the United States between 2001 and 2022.

> **英文摘要：**
> We estimated trends in age-standardized childhood and adolescent cancer rates between 2001-2022 using national data from the United States Cancer Statistics database. The incidence of cancer in 0-19-year-olds was 18.2 per 100,000 with rates increasing 0.94%/year between 2001-2016 and then decreasing 0.96%/year during 2016-2022. Lymphoma rates increased 0.49%/year during 2001-2022, while trajectories of other cancers varied over time. Leukemia rates increased by 1.03%/year during 2001-2010 and then plateaued. Rates of central nervous system tumors increased by 0.81%/year during 2001-2014 and then declined 2.10%/year during 2014-2022. Rates of other epithelial neoplasms were stable from 2001-2013, increased in 2013-2016, and were stable during 2016-2022. There were an estimated 1,040 additional childhood cancer diagnoses in 2022 compared with what would have been expected based on 2001 rates. Modifications in cancer classifications, screening practices, and diagnostic technology likely contributed to the observed changes, in addition to the potential contributions of putative risk factors.

> **中文摘要：**
> 我们利用美国癌症统计数据库的全国性数据，估算了2001年至2022年间经年龄调整的儿童和青少年癌症发病率趋势。0至19岁人群的癌症发病率为每10万人18.2例，2001年至2016年期间每年上升0.94%，而在2016年至2022年期间则每年下降0.96%。2001年至2022年间，淋巴瘤的发病率每年上升0.49%，而其他类型癌症的变化轨迹随时间不同而变化。白血病发病率在2001年至2010年期间每年上升1.03%，随后趋于平稳。中枢神经系统肿瘤发病率在2001年至2014年间每年上升0.81%，而在2014年至2022年期间每年下降2.10%。其他上皮性肿瘤在2001年至2013年间保持稳定，2013年至2016年上升，2016年至2022年期间则再次稳定。与按2001年发病率预期的情况相比，2022年约多出1,040例儿童癌症新诊断病例。癌症分类、筛查实践以及诊断技术的变更，可能与观察到的变化有关，同时潜在的风险因素也可能有所贡献。

### 第二部分 AI 大师评价

该研究系统分析了2001年至2022年美国儿童及青少年癌症的发病趋势，基于国家级癌症数据库，通过年龄标准化方法揭示了不同癌种的动态变化。结果显示整体发病率先升后降，不同癌种的时间趋势各异，尤其是白血病和中枢神经系统肿瘤表现出阶段性变化。研究提示发病率的波动可能与诊断技术提升、分类标准变化及潜在风险因素相关。该工作为理解儿童癌症流行病学演变及未来预防干预提供了重要参考，但受限于数据来源及分类变迁的影响，结果解释需谨慎。

---

## 67. 残留乳腺癌细胞通过SOX5驱动的软骨内骨化维持休眠状态

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370830)
**期刊：** Cancer discovery
**PMID：** 41370830
**DOI：** 10.1158/2159-8290.CD-25-0919

### 第一部分 原文与翻译

**英文原标题：** Residual Breast Cancer Cells Co-opt SOX5-driven Endochondral Ossification to Maintain Dormancy.

> **英文摘要：**
> Recurrent breast cancer accounts for most disease-associated mortality and can develop decades after primary tumor therapy. Recurrences arise from residual tumor cells (RTCs) that can evade therapy in a dormant state, however the mechanisms enforcing dormancy in RTCs are poorly understood. CRISPR-Cas9 screening identified the transcription factors SOX5/6 as functional regulators of tumor recurrence. Loss of SOX5 accelerated recurrence at both local and metastatic sites and promoted dormancy escape in both therapy-associated and microenvironment-induced contexts. Remarkably, SOX5 drove dormant RTCs to adopt a cartilage-dependent bone development program, termed endochondral ossification, that was confirmed by [18F]NaF-PET imaging and reversed in recurrent tumors escaping dormancy. Consistent with findings in mice, osteochondrogenic expression signatures in patients were enriched in residual disease following neoadjuvant therapy, and their enrichment in primary breast cancers predicted improved recurrence-free survival. These findings identify SOX5-dependent mesodermal transdifferentiation as an adaptive mechanism that prevents recurrence by reinforcing tumor cell dormancy.

> **中文摘要：**
> 复发性乳腺癌占据了大多数与疾病相关的死亡病例，并且可在原发肿瘤治疗后的数十年后再次发生。复发源自能够在休眠状态下逃避免疫治疗的残留肿瘤细胞（RTCs），然而维持RTCs休眠的机制尚不清楚。通过CRISPR-Cas9筛选发现，转录因子SOX5/6是肿瘤复发的功能性调控因子。SOX5的缺失可加速局部及转移部位的复发，并在治疗相关和微环境诱导的情境下促进休眠逃逸。值得注意的是，SOX5驱使休眠的RTCs进入一种依赖软骨的骨形成程序，称为软骨内骨化，该过程通过[18F]NaF-PET成像得到验证，而在逃离休眠的复发性肿瘤中则被逆转。与小鼠发现一致，患者中在新辅助治疗后残留疾病组织中检测到富集的成骨软骨分化表达特征，而这种特征在原发乳腺癌中富集时预测了更长的无复发生存期。这些发现表明，依赖SOX5的中胚层再分化是一种通过强化肿瘤细胞休眠以防止复发的适应性机制。

### 第二部分 AI 大师评价

该研究旨在揭示残留乳腺癌细胞长期休眠与复发之间的分子机制，确定SOX5作为关键调控因子在维持肿瘤细胞休眠中的作用。作者利用CRISPR-Cas9功能筛选、动物模型及影像学验证，发现SOX5通过驱动软骨内骨化样分化程序来强化休眠状态。研究创新性地提出SOX5依赖的中胚层再分化是防止肿瘤复发的适应机制，并在临床样本中得到验证。该发现为开发维持或诱导肿瘤细胞休眠的新治疗策略提供了重要理论基础，但其机制详细调控网络仍需进一步研究。

---

## 68. Disitamab Vedotin联合Toripalimab——尿路上皮癌治疗的新成员

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370803)
**期刊：** The New England journal of medicine
**PMID：** 41370803
**DOI：** 10.1056/NEJMe2514668

### 第一部分 原文与翻译

**英文原标题：** Disitamab Vedotin plus Toripalimab - New Players in Urothelial Carcinoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该篇通讯或述评聚焦于Disitamab Vedotin与Toripalimab在尿路上皮癌治疗中的潜力与临床意义。标题暗示这两种药物代表了治疗领域的新进展，可能涉及抗体偶联药物与免疫检查点抑制剂的联合应用。虽然未提供摘要，但文章预计讨论了新机制、新疗法在疗效与安全性上的初步结果。此类研究强调了个体化治疗策略在晚期尿路上皮癌管理中的重要性与挑战。

---

## 69. 弥合差距：弥散性大B细胞淋巴瘤中的嵌合抗原受体T细胞疗法——长期获益与真实世界的复杂性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370745)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41370745
**DOI：** 10.1200/JCO-25-02323

### 第一部分 原文与翻译

**英文原标题：** Bridging the Gap: Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: Long-Term Benefit, Yet Real-World Complexity.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该文旨在探讨CAR-T细胞疗法在弥散性大B细胞淋巴瘤患者中的长期疗效与现实应用挑战。标题暗示研究强调此类疗法在持久缓解方面的潜在益处，同时指出在真实世界中仍面临复杂的管理与实施问题，如患者选择、毒性管理及经济负担等。尽管缺乏具体摘要，该研究主题具有较高的临床实践意义，可为未来优化CAR-T治疗策略提供重要参考。

---

## 70. 回复：“改进 IMpower010 试验中长期效应的报告”及“早期非小细胞肺癌中辅助阿替利珠单抗治疗：信号、沉默与方法学清晰度的需求”。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370740)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41370740
**DOI：** 10.1200/JCO-25-02102

### 第一部分 原文与翻译

**英文原标题：** Reply to: "Improving the Reporting of Long-Term Effects in the IMpower010 Trial" and "Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity".

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文作为对两篇同行评论的正式回应，旨在澄清 IMpower010 试验结果报告中长期疗效与方法学解读方面的问题。虽然未提供摘要，但从标题可推测其重点在于回应外界对结果呈现及统计方法透明度的质疑。该类回应信有助于推动肿瘤免疫治疗临床研究的标准化和报告一致性。然而，其内容的深度与创新性可能受限于信件性质，主要价值在于学术交流与科学讨论的完善。

---

## 71. 用于残余HER2阳性早期乳腺癌的曲妥珠单抗德鲁斯替康研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370739)
**期刊：** The New England journal of medicine
**PMID：** 41370739
**DOI：** 10.1056/NEJMoa2514661

### 第一部分 原文与翻译

**英文原标题：** Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

> **英文摘要：**
> BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer and residual disease after neoadjuvant therapy are at high risk for recurrence.
> 
> METHODS: In a phase 3, open-label, international, randomized trial, we investigated postneoadjuvant trastuzumab deruxtecan (T-DXd; 5.4 mg per kilogram of body weight) as compared with trastuzumab emtansine (T-DM1; 3.6 mg per kilogram), the current standard treatment, in patients with HER2-positive breast cancer with residual invasive disease and node-positive disease at surgery or inoperable disease at diagnosis. The primary end point was invasive disease-free survival, and the key secondary end point was disease-free survival (including survival free from noninvasive breast cancers and second primary nonbreast cancers). Other end points included overall survival, distant recurrence-free interval, brain metastasis-free interval, and safety.
> 
> RESULTS: A total of 1635 patients were randomly assigned (in a 1:1 ratio) to receive T-DXd (818 patients) or T-DM1 (817 patients). At the data-cutoff date, the median duration of follow-up was approximately 30 months in each group. Invasive-disease events or deaths were reported in 51 patients (6.2%) in the T-DXd group and 102 patients (12.5%) in the T-DM1 group (hazard ratio, 0.47; 95% confidence interval [CI], 0.34 to 0.66; P<0.001); 3-year invasive disease-free survival was 92.4% and 83.7%, respectively. Invasive-disease events, noninvasive-disease events, or deaths were reported in 52 patients (6.4%) in the T-DXd group and 103 patients (12.6%) in the T-DM1 group (hazard ratio, 0.47; 95% CI, 0.34 to 0.66; P<0.001); 3-year disease-free survival was 92.3% and 83.5%, respectively. The most common adverse events were nausea (71.3% of patients), constipation (32.0%), decreased neutrophil count (31.6%), and vomiting (31.0%) with T-DXd and increased liver-enzyme levels (aspartate aminotransferase [50.2%] and alanine aminotransferase [45.3%]) and decreased platelet count (49.8%) with T-DM1. The incidence of adjudicated drug-related interstitial lung disease was higher with T-DXd than with T-DM1 (9.6% vs. 1.6%). Two patients with interstitial lung disease in the T-DXd group died.
> 
> CONCLUSIONS: In patients with high-risk, residual invasive HER2-positive breast cancer, postneoadjuvant T-DXd resulted in a significantly higher likelihood of invasive disease-free survival than T-DM1; toxic effects were mainly gastrointestinal and hematologic. An important identified risk of T-DXd is interstitial lung disease, which requires appropriate monitoring and management. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast05 ClinicalTrials.gov number, NCT04622319.).

> **中文摘要：**
> 背景：对于经过新辅助治疗后仍有残余病灶的人表皮生长因子受体2（HER2）阳性早期乳腺癌患者，其复发风险较高。
> 
> 方法：本研究为一项Ⅲ期、开放标签、国际、多中心、随机对照试验，比较新辅助治疗后使用曲妥珠单抗德鲁斯替康（T-DXd，5.4毫克/千克体重）与当前标准治疗曲妥珠单抗艾姆坦新（T-DM1，3.6毫克/千克）在HER2阳性乳腺癌患者中的疗效和安全性。入组对象为术后存在残余浸润性病变且淋巴结阳性者，或诊断时疾病不可手术者。主要终点为无浸润性疾病生存期（invasive disease-free survival），关键次要终点为无病生存期（disease-free survival，包括无非浸润性乳腺癌及第二原发非乳腺癌的生存）。其他终点包括总生存期、远处复发无病间期、脑转移无病间期以及安全性评估。
> 
> 结果：研究共随机分配1635例患者（按1:1比例），其中818例接受T-DXd治疗，817例接受T-DM1治疗。数据截止时，两组中位随访时间均约为30个月。T-DXd组51例（6.2%）和T-DM1组102例（12.5%）出现浸润性疾病事件或死亡（风险比0.47；95%置信区间0.34–0.66；P<0.001）；3年无浸润性疾病生存率分别为92.4%和83.7%。出现浸润性或非浸润性疾病事件或死亡的患者分别为T-DXd组52例（6.4%）与T-DM1组103例（12.6%）（风险比0.47；95%置信区间0.34–0.66；P<0.001）；3年无病生存率分别为92.3%和83.5%。最常见的不良事件为恶心（T-DXd组71.3%）、便秘（32.0%）、中性粒细胞减少（31.6%）及呕吐（31.0%）；而T-DM1组更常见的是肝酶升高（天冬氨酸转氨酶50.2%，丙氨酸转氨酶45.3%）和血小板减少（49.8%）。经判定的药物相关间质性肺疾病在T-DXd组发生率较T-DM1组高（9.6%对1.6%），其中T-DXd组有2例患者死于间质性肺疾病。
> 
> 结论：在高风险、残余浸润性HER2阳性乳腺癌患者中，新辅助治疗后应用T-DXd较T-DM1能够显著提高无浸润性疾病生存率；其主要毒性为胃肠道和血液学不良反应。T-DXd的一个重要风险是间质性肺疾病，需进行恰当的监测与管理。（由第一三共和阿斯利康资助；DESTINY-Breast05试验，ClinicalTrials.gov编号NCT04622319。）

### 第二部分 AI 大师评价

该研究旨在比较曲妥珠单抗德鲁斯替康与曲妥珠单抗艾姆坦新在新辅助治疗后残余HER2阳性乳腺癌患者中的疗效与安全性。结果显示，T-DXd显著提高了无浸润性疾病生存率，风险比为0.47，提示其在减少复发方面明显优于T-DM1。研究具有样本量大、国际多中心的优势，增强了结论的可靠性。尽管疗效突出，但T-DXd引发的药物相关间质性肺疾病风险不容忽视，提示需密切监测与干预。总体而言，该试验为HER2阳性早期乳腺癌的新辅助后治疗策略提供了新的循证依据。

---

## 72. t(11;14)阳性复发/难治性多发性骨髓瘤中维奈克拉索-地塞米松与泊马度胺-地塞米松的比较：III期随机CANOVA研究的主要结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370738)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41370738
**DOI：** 10.1200/JCO-25-00924

### 第一部分 原文与翻译

**英文原标题：** Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

> **英文摘要：**
> PURPOSE: Venetoclax, an oral BCL-2 inhibitor, has efficacy in t(11;14)-positive relapsed/refractory multiple myeloma (RRMM), which is enhanced by dexamethasone, which promotes BCL-2 dependency.
> 
> METHODS: The randomized, open-label, phase III CANOVA study (ClinicalTrials.gov identifier: NCT03539744) enrolled adults with t(11;14)-positive RRMM who had received ≥2 previous lines of therapy. Patients were randomly assigned (1:1) to venetoclax-dexamethasone or pomalidomide-dexamethasone until progression or intolerable toxicity. The primary end point was independent review committee assessed-progression-free survival (PFS) in the intention-to-treat population analyzed by stratified log-rank test (two-sided type I error rate, α = .05), with hazard ratio (HR) and 95% CI estimated by stratified Cox proportional hazard model. Secondary end points included response rates, overall survival (OS), minimal residual disease (MRD) negativity rate (<10), and safety.
> 
> RESULTS: Overall, 263 patients were randomly assigned (venetoclax-dexamethasone, n = 133; pomalidomide-dexamethasone, n = 130). Median PFS was 9.9 months (95% CI, 6.9 to 12.6) with venetoclax-dexamethasone versus 5.8 months (95% CI, 3.8 to 9.2) with pomalidomide-dexamethasone (HR, 0.823 [95% CI, 0.596 to 1.136];  = .24). Overall response and very good partial response or better rates were 62% and 39%, respectively, with venetoclax-dexamethasone versus 35% and 14% with pomalidomide-dexamethasone. MRD negativity rate was 8% with venetoclax-dexamethasone and 0% with pomalidomide-dexamethasone. Median OS was 32.4 months (95% CI, 26.4 to 40.7) with venetoclax-dexamethasone and 26.9 months (95% CI, 20.4 to 38.9) with pomalidomide-dexamethasone (HR, 0.856 [95% CI, 0.612 to 1.197]). Grade ≥3 treatment-emergent adverse event rates were 67% with venetoclax-dexamethasone versus 83% with pomalidomide-dexamethasone. There were 16 (12%) treatment-emergent deaths with venetoclax-dexamethasone versus 8 (6%) with pomalidomide-dexamethasone.
> 
> CONCLUSION: The primary end point of PFS was not met. PFS and OS were numerically longer with venetoclax-dexamethasone versus pomalidomide-dexamethasone in t(11;14)-positive RRMM. Consistent with previous studies, infections were associated with venetoclax-dexamethasone; no new safety signals were observed.

> **中文摘要：**
> 研究目的：维奈克拉索是一种口服BCL-2抑制剂，在t(11;14)阳性的复发/难治性多发性骨髓瘤（RRMM）患者中具有疗效，其疗效可通过地塞米松促进BCL-2依赖性而增强。
> 
> 研究方法：随机、开放标签的III期CANOVA研究（ClinicalTrials.gov注册号：NCT03539744）纳入了接受过≥2线既往治疗的t(11;14)阳性RRMM成年患者。患者按1:1比例随机分配至维奈克拉索-地塞米松组或泊马度胺-地塞米松组，治疗持续至疾病进展或无法耐受的毒性。主要终点为独立评审委员会评估的意向治疗人群的无进展生存期（PFS），采用分层对数秩检验分析（双侧I型错误率α=0.05），风险比（HR）和95%置信区间（CI）通过分层Cox比例风险模型估算。次要终点包括缓解率、总生存期（OS）、微小残留病灶（MRD）阴性率（<10）及安全性。
> 
> 研究结果：总体共有263例患者被随机分配（维奈克拉索-地塞米松组133例；泊马度胺-地塞米松组130例）。两组中位PFS分别为9.9个月（95% CI，6.9–12.6）和5.8个月（95% CI，3.8–9.2）（HR=0.823，95% CI，0.596–1.136；P=0.24）。维奈克拉索-地塞米松组的总体缓解率和极大部分缓解或更好反应率分别为62%和39%，而泊马度胺-地塞米松组分别为35%和14%。MRD阴性率在维奈克拉索-地塞米松组为8%，泊马度胺-地塞米松组为0%。中位OS分别为32.4个月（95% CI，26.4–40.7）和26.9个月（95% CI，20.4–38.9）（HR=0.856，95% CI，0.612–1.197）。3级及以上治疗相关不良事件发生率分别为67%（维奈克拉索-地塞米松组）与83%（泊马度胺-地塞米松组）。治疗相关死亡分别为16例（12%）和8例（6%）。
> 
> 结论：主要终点PFS未达到统计显著。尽管如此，t(11;14)阳性RRMM患者中维奈克拉索-地塞米松方案的PFS和OS在数值上均长于泊马度胺-地塞米松方案。与既往研究一致，感染为维奈克拉索-地塞米松的相关风险，但未观察到新的安全性信号。

### 第二部分 AI 大师评价

该研究为CANOVA III期随机开放研究，比较了维奈克拉索-地塞米松与泊马度胺-地塞米松在t(11;14)阳性RRMM患者中的疗效与安全性。尽管主要终点PFS未达统计显著，但维奈克拉索组显示出更高的缓解率、部分更好的PFS和OS趋势，且不良反应总体可控。研究结果支持维奈克拉索在该特定分子亚型中的潜在临床优势。其局限性包括样本量不足与PFS差异缺乏显著性，需进一步随访与机制研究验证。

---

## 73. 翻译标题未提供

**期刊：** 期刊信息缺失
**PMID：** PMID未提供

### 第一部分 原文与翻译

**英文原标题：** 原文标题未提供

> **英文摘要：**
> 原文摘要未提供

> **中文摘要：**
> 翻译摘要未提供

### 第二部分 AI 大师评价

AI评价未提供

---

## 74. 由ZAP327信号域驱动的嵌合抗原受体在小鼠模型中产生强劲且持久的抗肿瘤免疫效应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370403)
**期刊：** Science translational medicine
**PMID：** 41370403
**DOI：** 10.1126/scitranslmed.adz0529

### 第一部分 原文与翻译

**英文原标题：** ZAP327 signaling domain-driven chimeric antigen receptor generates robust and long-term antitumor immunity in mouse models.

> **英文摘要：**
> Chimeric antigen receptor (CAR) T cell therapy has shown impressive clinical responses in the treatment of blood cancers, but high percentages of disease relapse 1 year after T cell infusion and severe toxicities associated with CAR T cell therapy remain major issues. Here, we report the construction of CARs with a ZAP70-derived signaling domain (ZAP327) that enhances therapeutic antitumor activity with increasing in vivo T cell persistence. ZAP327-driven CAR T cells reduced cytokine release and expression of T cell exhaustion markers but maintained similar or better cytolytic activity against tumor cells compared with conventional CAR T cells. The costimulatory domains, such as CD28 and 4-1BB, in the ZAP327 CAR constructs are required for providing a spacer between the transmembrane domain and ZAP327 kinase domain for optimal kinase structure folding and function, as well as costimulatory signaling. Furthermore, ZAP327-driven CAR T cells outperform conventional and several recently improved CAR T cells in therapeutic antitumor immunity, particularly in an antigen-low expression tumor model, which is clinically relevant and important for immune escape and disease relapse. Mechanistically, we show that the ZAP327 domain tuned down TCR signaling, increased the pools of stem-like memory T cells, and exhibited metabolic features associated with memory T cells by using the oxidative phosphorylation pathway. These results highlight the therapeutic potential of ZAP327-driven CAR T cells to overcome the limitations of the current CAR T cell therapies and enhance the potency and persistence of antitumor T cell responses in solid tumors as well.

> **中文摘要：**
> 嵌合抗原受体（CAR）T细胞治疗在血液肿瘤的治疗中表现出令人瞩目的临床反应，但在输注T细胞后一年内疾病复发率仍然较高，且CAR T细胞疗法相关的严重毒性仍是主要问题。在此，我们报道了包含源自ZAP70的信号域（ZAP327）的CAR构建，该结构可增强体内T细胞的持续性并提高治疗性抗肿瘤活性。由ZAP327驱动的CAR T细胞可减少细胞因子释放及T细胞衰竭标志物的表达，但相比传统CAR T细胞，仍维持相似或更强的针对肿瘤细胞的细胞毒活性。ZAP327 CAR构建中的共刺激结构域（如CD28和4-1BB）对于在跨膜域与ZAP327激酶域之间提供间距、以实现激酶结构的最佳折叠与功能以及共刺激信号的传导是必需的。此外，ZAP327驱动的CAR T细胞在治疗性抗肿瘤免疫反应方面优于传统及多种近期改进的CAR T细胞，尤其在低抗原表达的肿瘤模型中表现突出，这在临床上与免疫逃逸及疾病复发密切相关。从机制上看，我们发现ZAP327结构域可调节TCR信号通路，增加干样记忆T细胞的数量，并通过利用氧化磷酸化途径表现出与记忆T细胞相关的代谢特征。这些结果凸显了ZAP327驱动的CAR T细胞在克服现有CAR T细胞疗法局限性并增强抗肿瘤T细胞反应的效力与持久性方面的治疗潜力，亦适用于实体肿瘤。

### 第二部分 AI 大师评价

本研究旨在通过引入源自ZAP70的信号域（ZAP327）设计新型CAR T细胞，以提升体内持久性和抗肿瘤功效。作者系统评估其细胞毒性、细胞因子释放、衰竭标志、代谢特征及记忆表型，发现ZAP327 CAR T在低抗原水平肿瘤模型中表现优异。其创新在于通过信号调控重塑T细胞代谢与记忆谱系，增强长期抗肿瘤免疫。研究为改善当前CAR T疗法的复发率高与毒性问题提供了结构设计新思路，但仍需进一步验证其在临床环境中的安全性与稳定性。

---

## 75. STAT3 的高活性剪接变体促进小鼠结肠炎症相关的肿瘤发生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370399)
**期刊：** Science translational medicine
**PMID：** 41370399
**DOI：** 10.1126/scitranslmed.adu8484

### 第一部分 原文与翻译

**英文原标题：** A hyperactive splice variant of STAT3 promotes colonic inflammation-associated tumorigenesis in mice.

> **英文摘要：**
> Signal transducer and activator of transcription 3 (STAT3) is essential for cell signaling in response to extracellular stimuli, and its overactivation is a hallmark of inflammation and tumorigenesis. The differential mechanisms underlying the physiological and pathological regulation of STAT3 remain elusive. Here, we demonstrated that cryptic splice sites in  generated heterogeneous isoforms with or without a single amino acid Ser701 (wS701/ΔS701), with the latter being more abundant in colon cancers. Intrinsic S701 underwent reversible phosphorylation catalyzed by mechanistic target of rapamycin complex 1 (mTORC1) and protein phosphatase 2A (PP2A). Upon inflammatory stimulation, phosphorylation at S701 (p-S701) sequestered Y705 phosphorylation (p-Y705) by interfering with the access of Janus kinase 1/2 and restricting STAT3 overactivation. In contrast, the STAT3_ΔS701 isoform was hyperactive because of the absence of this self-restricting mechanism. Deletion of S701 in mice increased susceptibility to colonic inflammation and tumorigenesis. Pharmacological inhibition of PP2A sustained p-S701 and alleviated colon inflammation in wild-type but not in ΔS701 mice. Our findings highlight the importance of STAT3 heterogeneity in colonic inflammation and colorectal cancer.

> **中文摘要：**
> 转录信号转导子3（STAT3）对于细胞响应细胞外刺激的信号转导至关重要，其过度激活是炎症和肿瘤发生的标志。STAT3在生理与病理状态下的调控差异机制仍不清楚。本研究显示，通过隐蔽的剪接位点产生了包含或不包含单一氨基酸Ser701的异质性异构体（wS701/ΔS701），其中缺失Ser701的异构体在结肠癌中更为丰富。内源性Ser701可被雷帕霉素靶蛋白复合物1（mTORC1）和蛋白磷酸酶2A（PP2A）催化发生可逆磷酸化。在炎症刺激下，Ser701位点的磷酸化（p-S701）通过干扰Janus激酶1/2的结合，抑制Tyr705位点的磷酸化（p-Y705），从而限制STAT3的过度激活。相反，由于缺乏这种自我限制机制，STAT3_ΔS701异构体表现为高活性。小鼠中删除Ser701增加了结肠炎症和肿瘤发生的易感性。药理性抑制PP2A可维持p-S701水平，并在野生型而非ΔS701小鼠中缓解结肠炎症。我们的研究揭示了STAT3异质性在结肠炎症及结直肠癌中的重要作用。

### 第二部分 AI 大师评价

本研究旨在解析STAT3在结肠炎症相关肿瘤发生中的分子异质性调控机制。作者发现一种缺失Ser701的高活性STAT3剪接变体，其通过失去自我抑制的磷酸化调控导致STAT3持续激活，从而促进炎症和肿瘤形成。实验结合分子机制研究、动物模型以及药理干预验证了Ser701磷酸化在调节STAT3活性的关键作用。该研究创新性地揭示了STAT3剪接异构体在结直肠癌发生中的功能差异，但仍需进一步探讨其在临床人群中的普遍性及潜在治疗价值。

---

## 76. 人类病原体中功能性同源基因的异常遗传机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370391)
**期刊：** Science advances
**PMID：** 41370391
**DOI：** 10.1126/sciadv.aea4905

### 第一部分 原文与翻译

**英文原标题：** Unusual inheritance of a functional  homolog in the human pathogen .

> **英文摘要：**
> Schistosomes, parasitic flatworms responsible for the neglected tropical disease schistosomiasis, are protected by a skin-like tegument, and tegument maintenance is controlled by a schistosome ortholog () of the tumor suppressor TP53. To understand  function, we characterized a schistosome cyclin-dependent kinase inhibitor homolog (). Knockdown of  resulted in hyperproliferation that, combined with  knockdown, yielded tumor-like growths, indicating that  and  are tumor suppressors in .  homologs are ubiquitous in parasitic flatworms but are absent from their free-living ancestors, suggesting that  may have come from horizontal gene transfer. This suggests that the evolution of parasitism in flatworms was aided by an unusual means of metazoan genetic inheritance.

> **中文摘要：**
> 血吸虫是一类导致被忽视的热带病——血吸虫病的寄生性扁形动物，它们通过类似皮肤的体表结构（被皮）获得保护，而被皮的维持由血吸虫中肿瘤抑制因子TP53的直系同源基因所调控。为理解该基因的功能，我们对血吸虫的另一种细胞周期依赖性激酶抑制因子同源基因进行了表征。敲低该基因导致细胞过度增殖，当其与前述基因同时敲低时，产生类似肿瘤的生长，提示两者在血吸虫中均起肿瘤抑制作用。这类同源基因在寄生性扁形动物中普遍存在，但在其自由生活的祖先中缺失，提示这些基因可能来源于水平基因转移。这进一步表明，扁形动物寄生性的进化可能受到一种非常规的多细胞动物基因遗传机制的促进。

### 第二部分 AI 大师评价

该研究旨在揭示血吸虫中与肿瘤抑制相关的同源基因及其异常遗传方式。研究者通过功能表征和基因敲低实验证实，这些基因在细胞增殖调控中起关键作用，并可能通过水平基因转移获得。其发现为寄生性扁形动物的进化机制提供了新的分子层面证据，揭示了一种不同于常规的跨物种基因继承途径。创新性在于将肿瘤抑制基因功能与寄生性演化相联系，但后续仍需更多实验验证这一遗传来源的分子机制。

---

## 77. HERVH来源的eRNA激活由超级增强子驱动的ALDH1A3/SAT1轴，促进铁死亡逃逸及胰腺癌发生。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370380)
**期刊：** Science advances
**PMID：** 41370380
**DOI：** 10.1126/sciadv.aea9074

### 第一部分 原文与翻译

**英文原标题：** HERVH-derived eRNA activates a super-enhancer-driven ALDH1A3/SAT1 axis to promote ferroptosis escape and pancreatic cancer development.

> **英文摘要：**
> Endogenous retroviruses (ERVs), widely distributed in the human genome, are usually epigenetically silenced but can be reactivated in cancer. Activated ERVs may act as regulatory elements or produce noncoding RNAs that modulate gene expression and affect tumor biology. Their role in pancreatic ductal adenocarcinoma (PDAC), particularly in ferroptosis regulation, remains unclear. Here, we identify human endogenous retrovirus-H (HERVH) derived enhancer RNAs (eRNAs) aberrantly overexpressed in PDAC by integrating gene expression and histone modification data. Silencing HERVH markedly suppresses PDAC proliferation and tumor growth. Mechanistically, HERVH transcription is driven by the super-enhancer-associated transcription factor Krüppel-like factor 5 (KLF5), and HERVH eRNAs cooperate with KLF5 to transactivate a distal super-enhancer upstream of aldehyde dehydrogenase family 1 member 3 (ALDH1A3), increasing its expression. ALDH1A3 inhibits the reactive oxygen species/specificity protein 1/spermidine/spermine N1-acetyltransferase 1 (ROS/Sp1/SAT1) cascade, reducing lipid peroxidation and ferroptosis. Disrupting this axis induces ferroptotic death and impairs PDAC development. Our study reveals a previously unrecognized mechanism in which HERVH-derived eRNAs regulate ferroptosis via super-enhancer-mediated transcriptional reprogramming and highlights the KLF5/HERVH/ALDH1A3 pathway as a potential therapeutic target in PDAC.

> **中文摘要：**
> 内源性逆转录病毒（ERVs）广泛分布于人类基因组中，通常受到表观遗传沉默，但在癌症中可能被重新激活。被激活的ERVs既可作为调控元件，也可产生调控基因表达并影响肿瘤生物学的非编码RNA。它们在胰腺导管腺癌（PDAC）中的作用，尤其是在铁死亡调控方面，仍不清楚。在本研究中，我们通过整合基因表达和组蛋白修饰数据，鉴定出在人PDAC中异常高表达的人内源性逆转录病毒H（HERVH）来源的增强子RNA（eRNAs）。沉默HERVH显著抑制PDAC的增殖和肿瘤生长。从机制上看，HERVH的转录受到超级增强子相关转录因子Krüppel样因子5（KLF5）的驱动，且HERVH eRNA与KLF5协作，转激活位于醛脱氢酶家族1成员3（ALDH1A3）上游的一个远端超级增强子，从而提高其表达。ALDH1A3抑制活性氧/特异性蛋白1/精胺/亚精胺N1-乙酰转移酶1（ROS/Sp1/SAT1）级联反应，减少脂质过氧化和铁死亡。破坏这一轴可诱导铁死亡并抑制PDAC的发生与发展。本研究揭示了一个先前未被认识的机制，即HERVH来源的eRNA通过超级增强子介导的转录重编程调控铁死亡，并强调了KLF5/HERVH/ALDH1A3通路作为PDAC潜在治疗靶点的价值。

### 第二部分 AI 大师评价

该研究揭示了HERVH来源的增强子RNA在胰腺导管腺癌中的关键致癌作用。研究者通过整合转录组与表观遗传数据发现，HERVH eRNA由KLF5驱动并激活ALDH1A3超级增强子，从而通过ALDH1A3/SAT1轴抑制铁死亡、促进肿瘤进展。这一发现不仅阐明了ERVs在铁死亡调控中的新角色，也为KLF5/HERVH/ALDH1A3通路靶向治疗提供了潜在方向。尽管机制清晰，但未来仍需探讨其在临床中的可操作性与安全性。

---

## 78. 在外观正常的白癜风皮肤中对功能性记忆性CD8 T细胞的免疫调控

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370369)
**期刊：** Science advances
**PMID：** 41370369
**DOI：** 10.1126/sciadv.adu9360

### 第一部分 原文与翻译

**英文原标题：** Immune control of functional memory CD8 T cells in normal-appearing vitiligo skin.

> **英文摘要：**
> Emerging evidence demonstrates that self-reactive CD8 T resident memory cells (T cells) may already populate the never-lesional (NL) skin of patients with chronic inflammatory conditions, including vitiligo. However, their functional activity and regulation remain unknown. By combining cellular and transcriptomic approaches, we show that common CD8 T cell clusters with a similar transcriptional profile infiltrate NL and peri-lesional (PL) skin of patients with vitiligo. Pathways related to immune activation were more active in T cells from PL skin, while those related to immune regulation were enriched in NL skin T cells, also evidenced by the stronger infiltration of regulatory T cells and the higher expression of programmed cell death protein 1 (PD-1) by CD8 T cells in NL skin. Treatment of patients with baricitinib led to an increase in regulatory T cells and CD8 T cells expressing PD-1 in repigmented skin. These findings suggest that functional T cells populate pigmented skin in vitiligo and highlight the importance of regulatory mechanisms to restrain their activation and prevent depigmentation.

> **中文摘要：**
> 新兴证据表明，包括白癜风在内的慢性炎症性疾病患者，其从未出现病变的（NL）皮肤中可能已存在自反应性CD8 T常驻记忆细胞（T细胞）。然而，它们的功能活性和调控机制仍不清楚。通过结合细胞学与转录组学方法，我们显示出具有相似转录特征的共同CD8 T细胞簇可浸润白癜风患者的NL皮肤及病变周围（PL）皮肤。与免疫激活相关的通路在PL皮肤来源的T细胞中更加活跃，而与免疫调节相关的通路则在NL皮肤的T细胞中富集，这一现象还体现在调节性T细胞的更强浸润以及NL皮肤中CD8 T细胞程序性细胞死亡蛋白1（PD‑1）表达的更高水平。给予患者巴瑞替尼治疗后，可促使再色素皮肤中调节性T细胞及表达PD‑1的CD8 T细胞数量增加。这些发现提示，白癜风的有色皮肤中存在功能性T细胞，并凸显调节机制对限制其活化、避免脱色具有关键作用。

### 第二部分 AI 大师评价

该研究旨在阐明在外观正常的白癜风皮肤中功能性CD8记忆T细胞的免疫控制机制。研究者结合细胞学和转录组学分析，揭示了NL与病变周围皮肤中T细胞功能状态的差异，并发现免疫调节在防止脱色中具有重要作用。巴瑞替尼治疗后调节性T细胞与PD‑1阳性CD8 T细胞增加，进一步支持免疫耐受机制的重要性。整体上工作揭示了白癜风皮肤免疫微环境的精细平衡，但尚需更多机制研究以明确关键调控因子。

---

## 79. SxIP配体的“锚定-锁定”结合机制是实现稳定且选择性EB1相互作用的必要条件

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370336)
**期刊：** eLife
**PMID：** 41370336
**DOI：** 10.7554/eLife.98063

### 第一部分 原文与翻译

**英文原标题：** Dock-and-lock binding of SxIP ligands is required for stable and selective EB1 interactions.

> **英文摘要：**
> End binding protein 1 (EB1) is a key component of the signalling networks at microtubule plus ends. It contains an N-terminal microtubule-binding CH domain and a C-terminal EBH domain interacting with SxIP-containing sequences of other microtubule plus end tracking proteins (+TIPs). Using a series of SxIP-containing peptides derived from the microtubule-actin cross-linking factor (MACF), we demonstrate that the SxIP motif itself binds to EBH with low affinity, and that the full interaction requires contribution of residues following the SxIP motif. Based on the solution structure and dynamics of the EBH/MACF complex, we propose a two-step 'dock-and-lock' model for the EBH interaction with targets, where the SxIP motif initially binds to a partially formed EBH pocket. This subsequently induces folding of the unstructured C-terminus and transition to a stable complex. We dissect contributions into the binding and design MACF mutations of the post-SxIP region that enhance the affinity by two orders of magnitude, leading to a nanomolar interaction. We verify the enhanced recruitment of the mutated peptide to the dynamic plus ends of MTs in a live-cell experiment. Our model explains EB1's interaction with the SxIP-containing ligands and can be used to design small-molecule inhibitors blocking SxIP interaction with EB1.

> **中文摘要：**
> 末端结合蛋白1（EB1）是微管正端信号网络中的关键组成部分。它包含一个N端的微管结合CH结构域，以及一个C端的EBH结构域，该结构域可与其他微管正端跟踪蛋白（+TIPs）中含有SxIP序列的片段相互作用。利用来源于微管-肌动蛋白交联因子（MACF）的多种含SxIP序列的肽段，我们发现SxIP基序本身与EBH结合的亲和力较低，而完整的相互作用需要SxIP基序之后残基的参与。基于EBH/MACF复合物的溶液结构与动态特征，我们提出了一个两步式的“锚定-锁定”模型，解释EBH与其靶标的结合过程。在该模型中，SxIP基序首先与部分成形的EBH口袋结合，随后诱导无结构C端的折叠，形成稳定的复合物。我们进一步剖析了结合所需的关键贡献，并设计了位于SxIP之后区域的MACF突变，这些突变将结合亲和力提高了两个数量级，达到纳摩尔级相互作用。在活细胞实验中，我们验证了该突变肽段在动态微管正端的增强募集。我们的模型阐明了EB1与含SxIP配体之间的相互作用机制，并可用于设计阻断EB1-SxIP相互作用的小分子抑制剂。

### 第二部分 AI 大师评价

本研究聚焦于EB1蛋白与SxIP配体的特异性结合机制，通过结构生物学与定量动力学分析提出了创新性的“锚定-锁定”模型。研究过程利用溶液结构、肽段突变与活细胞实验相结合，揭示SxIP后续残基在EB1结合稳定性中的关键作用。结果表明，优化后的序列可大幅提高结合亲和力至纳摩尔水平，具有潜在的药物研发价值。该研究为理解+TIPs复合体动态调控提供了新的结构基础，但仍需进一步验证该机制在细胞内复杂环境中的广泛适用性。

---

## 80. 萌芽酵母中参与DNA损伤修复通路的着丝粒组蛋白H3伴侣的证据

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370334)
**期刊：** eLife
**PMID：** 41370334
**DOI：** 10.7554/eLife.104431

### 第一部分 原文与翻译

**英文原标题：** Evidence of centromeric histone 3 chaperone involved in DNA damage repair pathway in budding yeast.

> **英文摘要：**
> The centromeric protein-A (CENP-A) is an evolutionarily conserved histone H3 variant that marks the identity of the centromeres. Several mechanisms regulate the centromeric deposition of CENP-A as its mislocalization causes erroneous chromosome segregation, leading to aneuploidy-based diseases, including cancers. The most crucial deposition factor is a CENP-A specific chaperone, HJURP (Scm3 in budding yeast), which specifically binds to CENP-A. However, the discovery of HJURP as a DDR (DNA damage repair) protein and evidence of its binding to Holliday junctions in vitro indicate a CENP-A-deposition-independent role of these chaperones. In this study, using budding yeast, we demonstrate that Scm3 is crucial for the DDR pathway as Scm3-depleted cells are sensitive to DNA damage. We further observe that Scm3 depletion genetically interacts with the  DDR mutant and is compromised in activating DDR-mediated arrest. We demonstrate that Scm3 associates with DNA damage sites and undergoes posttranslational modifications upon DNA damage. Overall, from this report and earlier studies on HJURP, we conclude that DDR functions of CENP-A chaperones are conserved across eukaryotes. The revelation that these chaperones promote genome stability in more than one pathway has clinical significance.

> **中文摘要：**
> 着丝粒蛋白A（CENP-A）是一种在进化上高度保守的组蛋白H3变体，用于标识着丝粒的特异性。CENP-A在着丝粒处的沉积受到多种机制调控，其错误定位会导致染色体分离异常，引发以非整倍体为基础的疾病，包括癌症。最关键的沉积因子是一种CENP-A特异性伴侣蛋白HJURP（在萌芽酵母中称为Scm3），该蛋白可特异性结合CENP-A。然而，HJURP被发现是一种DNA损伤修复（DDR）相关蛋白，并且其在体外可与Holliday交叉结构结合的证据，表明这些伴侣还具有独立于CENP-A沉积的功能。在本研究中，我们以萌芽酵母为模型，证明Scm3对DDR通路至关重要，因为缺失Scm3的细胞对DNA损伤高度敏感。进一步观察发现，Scm3缺失与DDR突变体在遗传上发生相互作用，且其激活DDR介导的细胞阻滞的能力受损。我们还证明Scm3能够与DNA损伤位点结合，并在DNA损伤后发生翻译后修饰。总体而言，结合本研究和先前关于HJURP的研究结果，我们得出结论，CENP-A伴侣在DDR中的功能在真核生物中具有保守性。揭示这些伴侣在多条通路中促进基因组稳定性的作用具有重要的临床意义。

### 第二部分 AI 大师评价

该研究探索了萌芽酵母中着丝粒组蛋白H3伴侣Scm3在DNA损伤修复通路中的功能，利用基因缺失和DDR突变体相互作用等实验方法，揭示Scm3在DNA损伤响应及基因组稳定性维持中的关键作用。作者进一步发现Scm3可定位至DNA损伤位点并发生翻译后修饰，从而揭示其在CENP-A沉积以外的生物学功能。该发现拓展了着丝粒组蛋白伴侣的功能范围，表明其DDR活性在真核生物中具有保守性。尽管研究深度有限于酵母模型，但为理解组蛋白伴侣在维持基因组稳定性中的多重作用提供了新视角。

---

## 81. 单细胞水平上肝内胆管癌肝转移的时空图谱

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370247)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41370247
**DOI：** 10.1097/HEP.0000000000001641

### 第一部分 原文与翻译

**英文原标题：** Spatiotemporal landscape of intrahepatic cholangiocarcinoma liver metastasis at the single-cell level.

> **英文摘要：**
> BACKGROUND AND AIMS: Intrahepatic cholangiocarcinoma (iCCA) is a highly metastatic tumor type, and iCCA with intrahepatic metastasis is associated with poor prognosis. Previous studies have confirmed that the tumor microenvironment (TME) is closely related to tumor metastasis. However, the state of the TME during iCCA liver metastasis remains unknown.
> 
> APPROACH AND RESULTS: We profiled 28 specimens from 16 patients with iCCA (with and without intrahepatic metastasis) using integrated single-cell and spatial transcriptomics, bulk RNA sequencing, whole-exome sequencing, and in vivo and in vitro functional experiments to characterize the specific TME changes during iCCA liver metastasis. we identified the metastatic tumor cells, COL3A1+ epithelial cells, and revealed that COL3A1+ epithelial cells-endothelial-to-mesenchymal transition cells crosstalk promoted tumor invasion by inducing mesenchymal transformation of endothelial cells, while COL3A1+ epithelial cells-VEGFA+ CCL4+ neutrophils crosstalk promoted tumor colonization by forming neutrophil extracellular traps.
> 
> CONCLUSIONS: We revealed the key biological mechanisms involved in the invasion and colonization phases of iCCA liver metastasis. Moreover, we provide valuable data for understanding iCCA liver metastasis and a possible avenue for the treatment of advanced iCCA.

> **中文摘要：**
> 背景与目的：肝内胆管癌（iCCA）是一种高度转移性的肿瘤类型，伴有肝内转移的 iCCA 患者预后较差。既往研究已证实肿瘤微环境（TME）与肿瘤转移密切相关。然而，在 iCCA 肝转移过程中 TME 的状态仍不清楚。
> 
> 方法与结果：我们对来自 16 例肝内胆管癌患者（包括有肝内转移和无肝内转移）共 28 个样本进行了整合性分析，结合单细胞与空间转录组学、整体 RNA 测序、全外显子测序，以及体内外功能实验，以描绘 iCCA 肝转移过程中 TME 的特征性变化。研究鉴定出了转移性肿瘤细胞及 COL3A1+ 上皮细胞，并发现 COL3A1+ 上皮细胞与内皮—间质转化细胞之间的相互作用可通过诱导内皮细胞的间质化转变促进肿瘤侵袭；而 COL3A1+ 上皮细胞与 VEGFA+ CCL4+ 中性粒细胞之间的互作通过形成中性粒细胞胞外诱捕网促进肿瘤定植。
> 
> 结论：本研究揭示了 iCCA 肝转移过程中侵袭和定植阶段涉及的关键生物学机制。同时，我们提供了理解 iCCA 肝转移的重要数据，并为晚期 iCCA 的治疗提供了新的潜在方向。

### 第二部分 AI 大师评价

该研究旨在系统解析肝内胆管癌肝转移过程中肿瘤微环境的动态变化，基于单细胞与空间转录组综合分析，结合基因组与功能实验，揭示了转移相关的关键细胞互作机制。研究发现 COL3A1+ 上皮细胞通过影响内皮细胞转分化和中性粒细胞诱捕网形成促进肿瘤侵袭和定植，构建了 iCCA 转移的时空分子图谱。该工作在机制层面具有创新性，数据深度和方法学完备，但仍需更多临床样本验证其转化潜力。

---

## 82. Disitamab Vedotin联合Toripalimab治疗HER2表达的晚期尿路上皮癌

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41124210)
**期刊：** The New England journal of medicine
**PMID：** 41124210
**DOI：** 10.1056/NEJMoa2511648

### 第一部分 原文与翻译

**英文原标题：** Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.

> **英文摘要：**
> BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate monotherapy has shown preliminary clinical efficacy in patients with chemotherapy-refractory HER2-positive locally advanced or metastatic urothelial cancer. Previous data showed promising antitumor activity and safety of HER2-specific disitamab vedotin as monotherapy and when combined with programmed cell death protein 1 (PD-1)-directed immunotherapy in this cancer.
> 
> METHODS: In this phase 3, multicenter, open-label, randomized trial, we assigned patients with previously untreated HER2-expressing (immunohistochemical score of 1+, 2+, or 3+) locally advanced or metastatic urothelial cancer in a 1:1 ratio to receive either disitamab vedotin plus PD-1-specific toripalimab every 2 weeks or chemotherapy (gemcitabine plus cisplatin or carboplatin) every 3 weeks. The dual primary end points were progression-free survival (assessed by blinded independent review) and overall survival. Secondary end points included objective response and safety. Here we report the prespecified progression-free survival analysis and interim overall survival analysis.
> 
> RESULTS: A total of 484 patients underwent randomization. The median follow-up was 18.2 months. Progression-free survival was significantly longer in the disitamab vedotin-toripalimab group than in the chemotherapy group (median, 13.1 vs. 6.5 months; hazard ratio for progression or death, 0.36; 95% confidence interval [CI], 0.28 to 0.46; P<0.001). Overall survival was also significantly longer in the disitamab vedotin-toripalimab group than in the chemotherapy group (median, 31.5 vs. 16.9 months; hazard ratio for death, 0.54; 95% CI, 0.41 to 0.73; P<0.001). The percentage of patients with an objective response was 76.1% (95% CI, 70.3 to 81.3) in the disitamab vedotin-toripalimab group and 50.2% (95% CI, 43.7 to 56.7) in the chemotherapy group. The safety profile of disitamab vedotin plus toripalimab was more favorable than that of chemotherapy; grade 3 or higher treatment-related adverse events occurred in 55.1% of patients who received disitamab vedotin plus toripalimab and 86.9% of those who received chemotherapy.
> 
> CONCLUSIONS: Disitamab vedotin-toripalimab led to a significantly greater improvement in outcomes than chemotherapy among patients with untreated HER2-expressing locally advanced or metastatic urothelial cancer. (Funded by RemeGen and others; RC48-C016 ClinicalTrials.gov number, NCT05302284; ChinaDrugTrials.org.cn number, CTR20220348.).

> **中文摘要：**
> 背景：针对人表皮生长因子受体2（HER2）的抗体-药物偶联物单药治疗已在化疗耐药的HER2阳性局部晚期或转移性尿路上皮癌患者中显示出初步的临床疗效。既往数据显示，HER2特异性药物Disitamab Vedotin无论单药使用还是与程序性细胞死亡蛋白1（PD-1）靶向免疫治疗联合使用，均展现出有希望的抗肿瘤活性和安全性。
> 
> 方法：在这项多中心、开放标签、随机的Ⅲ期临床试验中，我们按1:1的比例将既往未接受治疗的HER2表达（免疫组化评分为1+、2+或3+）的局部晚期或转移性尿路上皮癌患者随机分配至两组，一组每2周接受Disitamab Vedotin联合PD-1特异性抗体Toripalimab治疗，另一组每3周接受化疗（吉西他滨联合顺铂或卡铂）。双主要终点为无进展生存期（经盲法独立评审）和总生存期。次要终点包括客观缓解率和安全性。本报告提供了预先设定的无进展生存分析和期中总生存分析结果。
> 
> 结果：共有484例患者随机入组，中位随访时间为18.2个月。Disitamab Vedotin-Toripalimab组的无进展生存期显著长于化疗组（中位数13.1个月 vs. 6.5个月；疾病进展或死亡的风险比为0.36；95%置信区间[CI]，0.28至0.46；P<0.001）。总生存期在联合治疗组亦显著延长（中位数31.5个月 vs. 16.9个月；死亡风险比为0.54；95% CI，0.41至0.73；P<0.001）。联合治疗组的客观缓解率为76.1%（95% CI，70.3至81.3），而化疗组为50.2%（95% CI，43.7至56.7）。联合治疗的安全性优于化疗组，3级及以上治疗相关不良事件发生率分别为55.1%和86.9%。
> 
> 结论：与化疗相比，Disitamab Vedotin-Toripalimab在未经治疗的HER2表达局部晚期或转移性尿路上皮癌患者中显著改善了疗效和生存结局。（由荣昌生物及其他机构资助；注册号RC48-C016；ClinicalTrials.gov编号NCT05302284；ChinaDrugTrials.org.cn编号CTR20220348。）

### 第二部分 AI 大师评价

本研究是一项Ⅲ期随机对照试验，评估Disitamab Vedotin联合Toripalimab在HER2表达的晚期尿路上皮癌患者中的疗效与安全性。结果显示，该联合治疗在无进展生存期、总生存期及客观缓解率方面均显著优于标准化疗，且安全性更佳。该研究首次在大样本随机试验中验证了HER2靶向抗体偶联药物与免疫检查点抑制剂联合的临床价值，具有重要创新意义。其局限在于随访时间相对较短及化疗对照方案的异质性，仍需长期随访以验证持久疗效。

---

## 83. 融合基因耗竭消除干性并诱导急性髓系白血病的双向分化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40991849)
**期刊：** Blood
**PMID：** 40991849
**DOI：** 10.1182/blood.2025028988

### 第一部分 原文与翻译

**英文原标题：** Fusion gene depletion eliminates stemness and induces bidirectional differentiation of acute myeloid leukemia.

> **英文摘要：**
> Chromosomal rearrangements that generate novel fusion genes are a hallmark of acute myeloid leukemia (AML). Depletion experiments in cell line models have suggested that their continued expression is required for maintaining their leukemic phenotype and that fusion genes therefore represent ideal cancer-specific therapeutic targets. However, the extent to which this result holds true for the different stages of hematopoietic development in primary cells and whether therapeutic agents can be efficiently delivered to those cells is still unclear. In this study, we demonstrate that primary AML cells harboring the chromosomal translocation t(8;21) are critically dependent on the corresponding fusion gene, RUNX1::RUNX1T1, to suppress differentiation and maintain stemness. Silencing RUNX1::RUNX1T1 expression using small interfering RNA (siRNA)-loaded lipid nanoparticles induces substantial changes in chromatin accessibility, thereby redirecting the leukemia-associated transcriptional network toward a myeloid differentiation program. Single-cell analyses reveal that this transcriptional reprogramming is associated with the depletion of immature stem and progenitor-like cell populations, accompanied by an expansion of granulocytic and eosinophilic/mast cell-like populations with impaired self-renewal capacity. These findings underscore the essential role of RUNX1::RUNX1T1 in sustaining AML and highlight the therapeutic potential of targeting fusion gene expression in primary AML cells.

> **中文摘要：**
> 染色体重排产生新型融合基因是急性髓系白血病（AML）的标志。细胞系模型中的耗竭实验表明，其持续表达对于维持白血病表型是必要的，因此融合基因被认为是理想的肿瘤特异性治疗靶点。然而，这一结果在原代细胞造血发育不同阶段中是否适用，以及治疗药物能否有效递送至这些细胞，仍不清楚。在本研究中，我们证明携带染色体易位 t(8;21) 的原代 AML 细胞，严重依赖相应的融合基因 RUNX1::RUNX1T1 以抑制分化并维持干细胞特性。利用负载小干扰 RNA（siRNA）的脂质纳米颗粒沉默 RUNX1::RUNX1T1 的表达，会引起染色质可及性的显著变化，从而将白血病相关转录网络重新导向髓系分化程序。单细胞分析显示，这种转录重编程与未成熟干细胞和祖细胞样群体的耗竭相关，同时伴随粒细胞及嗜酸性/肥大细胞样群体的扩增，但这些群体具有受损的自我更新能力。这些发现凸显了 RUNX1::RUNX1T1 在维持 AML 中的关键作用，并强调了在原代 AML 细胞中靶向融合基因表达的治疗潜力。

### 第二部分 AI 大师评价

本研究旨在探讨融合基因 RUNX1::RUNX1T1 在急性髓系白血病维持及分化过程中的功能。研究者通过 siRNA 纳米颗粒沉默该基因，揭示其在抑制分化与维持干性中的关键作用，并通过单细胞分析证实其耗竭可导致细胞谱系向粒细胞和嗜酸/肥大细胞方向分化。该工作创新性地在原代 AML 细胞中验证了融合基因依赖性，为治疗策略提供了新的靶点思路。其局限在于递送体系和体内验证仍需进一步完善。

---

## 84. CUX1通过抑制干细胞固有的炎症通路限制潜在造血干细胞的可塑性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40920873)
**期刊：** Blood
**PMID：** 40920873
**DOI：** 10.1182/blood.2024026815

### 第一部分 原文与翻译

**英文原标题：** CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell-intrinsic inflammatory pathways.

> **英文摘要：**
> Long-term maintenance of somatic stem cells relies on precise regulation of self-renewal and differentiation. Understanding the molecular framework for these homeostatic processes is essential for improved cellular therapies and treatment of myeloid neoplasms. CUX1 is a widely expressed, dosage-sensitive transcription factor crucial for development and frequently deleted in myeloid neoplasia in the context of -7/(del7q). Here, using novel mouse models and single-cell approaches, we report that dynamic and distinct CUX1 levels are integral to hematopoietic stem cell (HSC) activity. Knockdown of CUX1 reverses HSC differentiation and strikingly reendows progenitors with stem cell function, accompanied by restoration of the HSC transcriptome and DNA accessibility landscape. CUX1 mediates these activities, in part, via suppressing endogenous retroelements (EREs) and the ensuing interferon-stimulated gene expression program. Both EREs and the interferon response are upregulated in CUX1-deficient acute myeloid leukemia, suggesting a conserved role of CUX1 in regulating these elements. These data establish an unexpected entwinement between stem cell-intrinsic innate immune activation and the transcriptional programs of stem cell identity. Furthermore, we reveal the profound effects of transcription factor levels in cell fate.

> **中文摘要：**
> 体细胞干细胞的长期维持依赖于自我更新和分化的精确调控。理解这些稳态过程的分子框架对于改进细胞治疗和治疗髓系肿瘤至关重要。CUX1是一种广泛表达、剂量敏感的转录因子，在发育过程中至关重要，并且在伴随-7/(del7q)的髓系肿瘤中经常发生缺失。在此，我们利用新型小鼠模型和单细胞分析方法，报道了动态且差异化的CUX1水平是造血干细胞（HSC）活性的重要组成部分。CUX1的敲低可逆转HSC的分化，且显著地使祖细胞重新获得干细胞功能，同时伴随着HSC转录组及DNA可及性景观的恢复。CUX1通过抑制内源性反转录元件（EREs）及随之激活的干扰素刺激基因表达程序部分介导这些作用。在CUX1缺陷的急性髓系白血病中，EREs和干扰素反应均上调，提示CUX1在调控这些元件中具有保守作用。这些数据揭示了干细胞固有的先天免疫激活与干细胞身份的转录程序之间意料之外的缠结。此外，我们揭示了转录因子水平对细胞命运的深远影响。

### 第二部分 AI 大师评价

该研究旨在阐明转录因子CUX1在造血干细胞可塑性调控中的作用。作者通过新型小鼠模型及单细胞技术揭示CUX1水平的动态变化对于维持干细胞活性及分化平衡至关重要。CUX1缺失会激活内源性反转录元件和干扰素信号通路，从而重塑干细胞基因表达谱。该研究创新性地揭示了干细胞固有免疫与干细胞命运决定间的分子联系，但仍需进一步探讨其在人类疾病中的功能机制及治疗潜力。

---

## 85. 在蛋白酶体抑制治疗下，核呼吸因子1促进多发性骨髓瘤细胞存活

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40920573)
**期刊：** Blood
**PMID：** 40920573
**DOI：** 10.1182/blood.2025028441

### 第一部分 原文与翻译

**英文原标题：** Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy.

> **英文摘要：**
> Multiple myeloma (MM) continues to be an incurable malignancy, even with recent therapeutic advancements. Although epigenetic dysregulation at cis-regulatory elements is known to drive disease progression, the complete molecular mechanisms underlying these alterations are poorly understood. Using Assay for Transposase-Accessible Chromatin with high-throughput sequencing analysis combined with the computational footprinting of CD138+ cells from 55 patients with MM, we depicted the dynamic changes in chromatin accessibility during disease progression and identified nuclear respiratory factor 1 (NRF1) as a master regulator of vital MM survival pathways. We demonstrated that NRF1 maintains proteasome homeostasis by orchestrating the ubiquitination pathway, which is essential for MM cell survival. We discovered a novel enhancer element that physically interacts with the NRF1 promoter, sustaining its expression. Targeting this enhancer RNA reduced NRF1 levels and increased tumor cell sensitivity to bortezomib (BTZ), suggesting therapeutic potential. In xenograft models, we showed that antisense oligonucleotides targeting the NRF1 enhancer, either alone or combined with BTZ, significantly decreased tumor burden and improved survival. Our findings reveal a previously unknown NRF1-dependent mechanism regulating MM cell survival and present a promising therapeutic approach through the manipulation of its regulatory network.

> **中文摘要：**
> 尽管近年来治疗方法取得了进展，多发性骨髓瘤（MM）仍然是一种不可治愈的恶性肿瘤。虽然顺式调控元件的表观遗传失调已知可推动疾病进展，但这些改变的完整分子机制仍不清楚。通过结合高通量测序的转座酶可及染色质分析（ATAC-seq）与来自55例MM患者CD138+细胞的计算足迹分析，我们描绘了疾病进展过程中染色质可及性的动态变化，并鉴定出核呼吸因子1（NRF1）是调控关键MM存活通路的主调控因子。我们证明，NRF1通过协调泛素化通路维持蛋白酶体稳态，这一过程对MM细胞的生存至关重要。我们发现了一个新型增强子元件，它可与NRF1启动子发生物理相互作用，从而维持其表达。靶向该增强子RNA可降低NRF1水平并增强肿瘤细胞对硼替佐米（BTZ）的敏感性，提示其具有治疗潜力。在异种移植模型中，我们发现靶向NRF1增强子的反义寡核苷酸，无论单独使用或与BTZ联合使用，均可显著减少肿瘤负荷并改善生存率。我们的研究揭示了一个此前未知的NRF1依赖机制在调控MM细胞生存中的作用，并通过调控其基因调控网络提出了一种具有前景的治疗策略。

### 第二部分 AI 大师评价

该研究以多发性骨髓瘤为对象，通过整合ATAC-seq和计算足迹分析，揭示了NRF1作为关键转录调控因子维持蛋白酶体稳态与细胞存活的作用。研究发现NRF1与其增强子之间的调控环路对MM耐药性具有重要影响，靶向该增强子可增强药物敏感性并改善动物模型的生存。研究在机制层面填补了MM表观遗传调控的空白，并提供了潜在的反义核酸治疗方向。其创新性在于解析了NRF1依赖的调控网络，但仍需进一步研究临床转化的可行性。

---

## 86. Layilin 抑制整合素激活，其缺失通过 Rac1 导致炎症性肠病中血小板的过度活化。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40829161)
**期刊：** Blood
**PMID：** 40829161
**DOI：** 10.1182/blood.2025028477

### 第一部分 原文与翻译

**英文原标题：** Layilin inhibits integrin activation, and its loss results in platelet hyperactivation via Rac1 in inflammatory bowel disease.

> **英文摘要：**
> Platelets are specialized cells for hemostasis which circulate in close contact to the glycocalyx, an extracellular layer of interwoven glycoproteins, proteoglycans, and glycosaminoglycans that maintain vascular homeostasis. Platelets survey their circulating environment, balancing inhibitory signals that prevent inappropriate activation with activating signals that initiate thrombus formation. Disease can disrupt this delicate balance of endogenous inhibitory signaling, leading to an increased risk of thrombosis as in patients with inflammatory bowel disease (IBD). In this study, we demonstrate that physiological concentrations of hyaluronan (HA), an essential component of the glycocalyx, acts as an inhibitor of activation and aggregation in human platelets. Using a combination of affinity chromatography and functional assays of platelets from humans and genetically modified mice, we identify layilin as the receptor for HA and an endogenous inhibitor of platelet activation. Platelets from layilin knockout mice display agonist-induced hyperactivation of αIIbβ3 and increased adhesion to fibrinogen under venous shear. Loss of layilin results in dysregulation of Rho guanosine triphosphatase (GTPase) family members (RAC1, Cdc42, RhoA, and Ras-like Rap1) via layilin's binding partner, merlin, and downstream p21-activated kinase 1. Furthermore, platelets of patients with IBD contain reduced layilin protein levels correlating with heightened basal Rac1-guanosine triphosphate levels and increased reactivity. Finally, although IBD platelets have enhanced sensitivity to activation, pharmacologic inhibition of RAC1 effectively reduces platelet hyperactivity in platelet of patients with IBD. These findings highlight a novel role for layilin and HA in the maintenance of platelet homeostasis that becomes disrupted in patients with IBD.

> **中文摘要：**
> 血小板是专门负责止血的细胞，它们在循环中与糖萼紧密接触。糖萼是一种由交织的糖蛋白、蛋白聚糖和糖胺聚糖构成的细胞外层结构，维持血管稳态。血小板监测其循环环境，在防止不恰当激活的抑制信号与启动血栓形成的激活信号之间保持平衡。疾病可扰乱这种内源性抑制信号的微妙平衡，从而导致血栓风险增加，如在炎症性肠病（IBD）患者中所见。在本研究中，我们证明了糖萼的重要成分透明质酸（HA）在生理浓度下可作为人血小板活化和聚集的抑制因子。通过结合亲和层析以及来自人类和基因修饰小鼠的血小板功能实验，我们鉴定出 layilin 是 HA 的受体，同时也是血小板活化的内源性抑制因子。来自 layilin 基因敲除小鼠的血小板表现出受体激动剂诱导的 αIIbβ3 过度激活，并在静脉剪切条件下对纤维蛋白原的黏附增强。Layilin 的缺失通过其结合伙伴 merlin 及下游 p21 激酶 1，导致 Rho GTP 酶家族成员（RAC1、Cdc42、RhoA 和 Ras 样蛋白 Rap1）的失调。此外，IBD 患者的血小板中 layilin 蛋白水平降低，与基础 Rac1-GTP 水平升高及反应性增强相关。最后，尽管 IBD 血小板对激活更为敏感，药理性抑制 RAC1 可有效减少 IBD 患者血小板的过度活化。这些发现揭示了 layilin 和 HA 在维持血小板稳态中的新作用，而这种机制在 IBD 患者中被破坏。

### 第二部分 AI 大师评价

本研究旨在揭示 layilin 与透明质酸在血小板稳态调控中的作用及其在炎症性肠病中的异常表现。作者利用人类与基因修饰小鼠血小板模型，结合分子互作与功能实验，确定 layilin 是透明质酸受体且为血小板活化的内源性抑制因子。研究发现，layilin 缺失导致血小板整合素 αIIbβ3 过度激活，并通过 Rac1 及下游信号通路介导的机制促进血小板高反应性。该研究创新性地揭示了血小板糖萼信号调控的新机制，为 IBD 相关血栓风险的干预提供潜在靶点，但仍需在临床验证其可转化性及治疗价值。

---

速递结束，祝您工作愉快！